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Abstract 
 
Chronic lymphocytic leukaemia (CLL) is the most common leukaemia in the 
western world, and continues to have very low cure rates.  The bulk of the tumour 
cells are non-cycling peripheral cells that accumulate from a minority of dividing 
cells within proliferation centres (PCs), located in the lymph nodes (LN) and 
spleen.  The PCs are rich in primed T helper (TH) cells that express CD40L and 
secrete IL-4.  Like normal B cells, CLL cells interact with TH via their expression of 
CD40 and receive signals from IL4.  This stimulation provides the signal for B cells 
to divide, as well as protecting them from apoptotic stimuli.  Consequently, many 
current therapies are unable to sufficiently target the cells in the PC, resulting in 
therapy resistance, residual disease (RD) and relapse.  In addition, most therapies 
have associated toxicities, restricting their use to younger, fitter patients.  Thus, 
there is an urgent need for new therapies with low toxicity, especially for older 
patients.  New drug discovery is time consuming and expensive.  Redeployment of 
existing drugs is one way to potentially combat this issue.  The lipid lowering drug 
bezafibrate (BEZ) and the sex steroid, medroyprogesterone acetate (MPA) have 
been shown to have anti-leukaemic properties in other settings.  In this study the in 
vitro efficacy of BEZ and MPA on resting CLL cells (representing resting cells in the 
periphery) and when stimulated to proliferate by CD40L (representing cells in the 
PCs) have been investigated.  Both BEZ and MPA exerted pro-apoptotic actions 
against resting CLL cells and reduced CD40L stimulated proliferation.  These 
actions were increased when both agents were combined and demonstrated 
selectivity against CLL cells compared to normal peripheral blood mononuclear 
cells.  Combined BEZ+MPA, was as effective as the commonly used 
chemotherapeutic chlorambucil, with the combination of all 3 agents exerting the 
greatest effects.  However none of the combinations induced apoptosis of CLL cells 
protected by CD40L.  Investigations into the possible mechanisms of drug action 
revealed that MPA was unlikely to be working either by steroid receptors or by 
inhibition of the enzyme AKR1C3 and the mechanism remains unknown.   BEZ 
alone and in the presence of MPA induced the production of prostaglandin D2 
(PGD2) and exogenously applied PGD2 was found to exert apoptosis in a similar 
manner to BEZ.  Both BEZ and MPA generated reactive oxygen species (ROS) in 
both culture settings and the combination was more effective than either drug 
alone.  In the absence of CD40L, mitochondrial superoxide (MSO) was also 
produced but not in CD40L stimulated cells.  This finding suggested that CD40L is 
able to prevent or protect against MSO production and, consequently, apoptosis.  
Attempts at overcoming this effect revealed that the plant derived compound 
lycorine exerted minimal effects alone but, when combined with BEZ+MPA, 
reinstated the induction of MSO and recapitulated BEZ+MPA induced apoptosis 
despite the continual presence of CD40L.  In contrast, the reported ability of 
dasatinib to overcome CD40L mediated fluadaribine resistance was discovered to be 
unfounded.  
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1.1. The leukaemias. 
The term leukaemia refers to a group of malignancies that involve the progressive clonal 
proliferation of abnormal leukocytes in the bone marrow (BM), which can then be 
observed in the peripheral blood and other organs.  Leukaemia can be of myeloid or 
lymphoid origin and either acute or chronic.  Therefore, there are broadly 4 types of 
leukaemia commonly termed: acute myeloid (AML), acute lymphoid (ALL), chronic 
myeloid (CML) and chronic lymphocytic (CLL).  The first three of these types arise from 
haemopoietic progenitor cells whilst CLL is derived from mature B lymphocytes. 
1.2. Chronic lymphocytic leukaemia.  
CLL is always a disease of neoplastic B cells (Binet et al., 2006) and, although diagnosed 
by a panel of phenotypic markers, is characterised by the relentless accumulation of CD5+ 
B lymphocytes in the peripheral blood, BM and secondary lymphoid organs (lymph 
nodes and spleen) (Ghia et al., 2007a, Chiorazzi et al., 2005, Rozman and Montserrat, 
1995).  Until recent times CLL was often ignored by researchers being categorised as a less 
interesting disease (Delgado et al., 2009a), although the renowned haematologist 
Dameshek noted the disease as being of great interest in 1967 (Dameshek, 1967). 
1.2.1. Incidence of CLL. 
In the Western world, CLL is the most common form of adult leukaemia, accounting for 
25-30% of all leukaemias in 1995 (Rozman and Montserrat, 1995), with 22-30/100,000 new 
cases worldwide (Eichhorst et al., 2009a).  Statistics reveal: that only 25-30% of patients 
diagnosed with CLL are under 55 years of age, that the median age at diagnosis is 72 
years (Delgado et al., 2009a), and that patients over the age of 65 represent the largest 
group of CLL sufferers.  CLL has a male bias, with the ratio of female to male sufferers 
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being around 1:2 (www.LRF.org.uk).  It is rare in Asia and this is most notable in Japan 
and China (Boggs et al., 1987) and it remains rare in immigrants from these countries.  
There is also increasing evidence of familial predispositions to CLL (Houlston et al., 2003, 
Jonsson et al., 2005, Yuille et al., 1998) with 5-10% of CLL occurring in the offspring of 
CLL sufferers tending to manifest at a younger age.  This, together with the low incidence 
in Asia, indicates that genetic factors are likely to play a role in the pathogenesis of CLL.  
1.2.2. Presentation of CLL. 
The majority of CLL patients are diagnosed as a consequence of routine blood tests.  
When patients do present with lymphocytosis and symptoms (such as anaemia (due to 
infiltration of the BM), fever without infection, night sweats and fatigue), they could be 
attributable to other lymphoproliferative diseases such as mantle cell lymphoma (MCL), 
follicular lymphoma, splenic lymphoma with villous lymphocytes, marginal zone 
lymphoma, or hairy cell leukaemia (Ghia et al., 2007a).  To distinguish CLL for these other 
malignancies at least 2 different examinations should be performed to diagnose CLL; one 
on blood count and blood films and, immunophenotyping for the type of leukaemic cells 
present (Cheson et al., 1996).   
The phenotype of CLL is highly distinctive.  All mature B cells, normal and malignant, 
express the specialised adaptor protein CD19; therefore, immunostaining will reveal that 
the cells are CD19+ve.  CLL cells can be distinguished from other B cells by their expression 
of low levels of CD20 and CD79b and the prevalence of high levels of dual 
CD5+ve/CD23+ve.  The latter population allows CLL to be distinguished from other CD5+ve 
diseases, such MCL (Ghia et al., 2007b).  CLL cells are also mono-typic with either kappa 
or lambda light chain restriction and are negative for the glycoprotein FMC7 (Matutes et 
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al., 1994, Delgado et al., 2003), which is found on other B cell malignancies.  It is also 
characteristic for CLL B cells to have weak surface (S) immunoglobulin (Ig), usually IgM 
± IgD but occasionally IgG or IgA (Ghia et al., 2007b).  The Matutes scoring system of CLL 
diagnosis is based on the five parameters of CD23, CD5, FMC7, CD79b and weak SIg 
status (Matutes et al., 1994).  
Thus, a diagnosis of CLL would be on the basis of an increase in the number of 
lymphocytes, in excess of 5x109/L for more than one month, together with the above 
morphologic and immunophenotypic characteristics of CD19+/CD5+ and with 
demonstration of clonality by light chain restriction (Binet et al., 2006).  This is in 
accordance with the National Cancer Institute-Working group (NCI-WG) (Cheson et al., 
1996).  According to the CLL working group, for a blood count less than 5x109/L, 
examination of the BM for infiltration of B lymphocytes is necessary, in which there must 
be an excess of 30% lymphocytes (Cheson et al., 1996).  Examination of the BM is also a 
pre-requisite for patients to be considered in complete remission (CR) (Ghia et al., 2007b).  
However, the fourth and most recent edition of the world health organisation (WHO) 
guidelines are different and less specific.  These guidelines state that, in the absence of 
‘extramedullary infiltration’(Ott et al., 2009), monoclonal B-lymphocytes must be present 
in the peripheral blood, in an excess of 5x109/L  (Ott et al., 2009).  No WHO guidelines are 
provided for a diagnosis in the event of a lymphocyte count less than 5x109/L (Ott et al., 
2009), this is likely to be due to this status being classified as monoclonal B cell 
lymphocytosis (MBL).   
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1.3. MBL. 
Advancements in flow cytometry (FC) and the inclusion of CLL like-MBL in the NCI-WG 
(Dagklis et al., 2009, Landgren et al., 2009), have led to an increase in research into MBL.  
MBL is characterised as the occurrence of a low number of monoclonal B-cell clones, i.e. 
less than 5x109/L in the peripheral blood of otherwise healthy subjects (Dagklis et al., 2009, 
Landgren et al., 2009).  Based on FC analysis, MBL can be subcategorised into CD5-ve MBL, 
CD5+ve /CD20bright atypical CLL-like and CD5+ve /CD20low CLL-like MBL, which also express 
CD23, CD79 and low SIg (Dagklis et al., 2009).  Considering the similarities between CLL 
and CLL-like MBL, the likelihood of MBL to progress to CLL is a consideration.  In light 
of this, two recent studies into MBL have contrasting views on the likelihood of MBL 
preceding CLL.  Langdren et al (2009) studied stored, pre-diagnostic samples from 49 
patients with CLL and discovered that 93% of the pre-diagnostic bloods had an abnormal 
kappa/lambda ratio and 96% immunoglobulin heavy chain variable (IgHV) 
rearrangements.  In addition, 42% of the patients had the same light-chain restrictions at 
diagnosis of CLL as found in the pre-diagnostic sample (Landgren et al., 2009).  
Notwithstanding the stage of CLL, in almost all cases a pre-diagnostic clone was detected.  
Based on these findings the authors concluded that the majority of patients with CLL will 
have had a detectable precursor state of MBL from six months to six years prior to CLL 
diagnosis (Landgren et al., 2009).  Conversely, Dagklis et al (2009) investigated a cohort of 
1,725 healthy individuals, with no history of CLL, all from an isolated valley.  In 89 
participants (5.2% of the cohort) CLL-like MBL was detected, in which 93% showed 
abnormal kappa/lambda ratios and IgHV rearrangements.  Like CLL, these CLL-like MBL 
cases were found to occur with increasing age and could be clustered in families.  
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However, the inter-family IgHV rearrangements were not the same (Dagklis et al., 2009).  
Additionally, the IgHV mutations found were different to those typically found in CLL 
patients.  Therefore, the authors concluded that the development of CLL from MBL is 
extremely unlikely (Dagklis et al., 2009). 
1.4. Staging systems for CLL. 
There are two systems currently used for the staging of CLL: Rai and Binet.   The systems 
are similar in their diagnostic criteria with the main difference being emphasis on the 
occurrence of lymphocytosis and lymphadenopathy in the Rai system and the number of 
sites involved in the Binet system.  In the UK and Europe only the Binet system, 
developed in 1981, is used.  It categorises CLL into 3 stages, and is summarised in table 1. 
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Group Hb count Platelet count Number of sites 
involved 
Cases within 
whole 
population of 
disease (%) 
Expected 
survival (y) 
A Normal Normal <3 55 In line with 
population of 
same age and 
distribution 
B Normal Normal >3 30 Median 7 
C <10g/dL <100,000/mm3 Not considered <15 Median 2 
 
Table 1.  Binet staging of CLL.  Adapted from (Binet et al., 1981) 
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1.5.  Genetic abnormalities in CLL. 
As highlighted in table 1, for decades the variable progression of CLL has indicated it to 
be a heterogeneous disease (Galton, 1966).  Recent developments in the field, with 
particular regard to genetic alterations, have begun to describe potential mechanisms 
behind this heterogeneity (Hamblin, 2002).    The most frequent alterations are the 
presence of mutated IgHV gene(s) as discussed for MBL, deletions in chromosome 13q14 
and/or 17p13, trisomy of chromosome 12 (Coll-Mulet and Gil, 2009) and deletions in 
11q22-q23.  The ataxia telangectasia mutated (ATM) tumour suppressor gene is located in 
11q22-q23 (Stankovic et al., 1998), mutations of which are observed in around 15% of CLL 
patients.  Although not always concurrent with 11q deletions (Dal-Bo et al., 2009), ATM is 
more common in patients with this deletion.  At presentation, the tumour protein 53 
(TP53) is mutated in around 10% of patients and is linked in many cases with a 17p 
deletion (Dal-Bo et al., 2009).  A mutated TP53 status is currently considered to be the 
worst chromosomal prognostic indicator.  
Any chromosomal alterations can be apparent at diagnosis or, in particular for 17p13, can 
be acquired following treatment.  These chromosomal abnormalities can lead to the loss of 
sequences encoding short/micro RNA (miRNA).  In particular, a cluster of miRNAs (mir-
15a and mir-16-1) were discovered to be deleted in patients harbouring the 13q14 deletion 
(Ghia et al., 2007a).  These miRNA deletions have been suggested to be relevant to the 
onset of CLL and more recently have been found to be down regulated in most CLL cases, 
with or without the 13q14 deletion (Calin et al., 2008).  Additionally, mouse studies have 
revealed that reinstating the mir-15a and mir-16 deletions in New Zealand black (NZB) 
mice, re-sensitises CLL cells to chemotherapeutics (Salerno et al., 2009) and that inducing 
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a knock out of the DLEU2/miR-15a/16-1 cluster induces the CLL phenotype in mice 
observed in humans (Klein et al.).   
1.5.1. Prediction of CLL Prognosis. 
Prognosis of disease is assessed by classical factors, including lymphocyte count, β-2 
microglobulin (B2M), which has currently fallen out of favour (Delgado et al., 2009b), and 
lymphocyte doubling time (LDT), as well as modern biological factors.  CLLU1, the first 
gene reported to be specific in CLL is encoded in 12q22, and high CLLU1 levels have been 
associated with poor prognosis, although mainly in younger patients (Dal-Bo et al., 2009).  
The T cell specific zeta associated protein-70 (ZAP70) was first discovered in T cells as 
critical in tyrosine kinase signalling (Chu et al., 1998).  More recently, ZAP70 has been 
linked with IgHV mutational status (Dal-Bo et al., 2009) but most currently has been 
shown to be an independent prognostic indicator, with high expression indicating poor 
prognosis (Ghia et al., 2007a).  The 45kDa type II membrane glycoprotein CD38 is 
expressed by many haemopoietic tissues and its engagement signals cell activation and 
differentiation (Dal-Bo et al., 2009).  High expression of CD38 is associated with poor 
patient prognosis (Ghia et al., 2003).  Recently, studies into the significance of CD38 have 
increased with studies showing a correlation between CD38 and BCL2 proteins as poor 
prognostic indicators (Pepper et al., 2008).  These factors, along with those in section 1.5, 
provide indications of the likelihood for disease progression, as summarised in table 2.  
These factors can change over time, i.e. progression through the Binet staging.  Currently 
only the deletion of TP53 is used to direct therapy and, as yet, there is no clear role for 
other prognostic factors in directing therapy.   
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Factor Output Indication 
Binet staging A Good  
 B Average-good 
 C Poor 
LDT <6 months Disease stable 
 >6 months Disease progression 
IgHV genes mutation ≥98% similarity to 
germ line (unmutated) 
sequence  
Aggressive disease. median 
survival 8 y 
 <98% homology Milder disease: median 
survival 24 y 
CD38 expression Positive Less time to progression 
Lower survival 
 Negative Good prognosis 
CLLU.1 High Poor prognosis 
 Low Good prognosis 
Intracellular ZAP70 >20% positive 
leukaemic cells 
Poor prognosis 
 <19% positive Good prognosis 
Chromosomal deletions 17p Poor prognosis mean survival 
32 months 
 TP53 Poor prognosis 
 11q Poor prognosis mean survival 
79 months 
 Trisomy of 
chromosome 12 
No effect on outcome of 
disease 
 
Table 2.  Prognostic indicators for CLL.  Modified from Ghia et al 2007 and Dal-Bo et al 
2009. 
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1.6. The ontogeny of B lymphocytes. 
Before discussing the biology that underpins the in vivo survival and accumulation of CLL 
cells it is useful to consider the ontogeny of normal B cell development.  There are two 
types of recirculating B cell.  The first are B1 cells, which are produced in the foetal liver 
and in the BM until the age of five, and are self-sustaining beyond that age.  B1 cells are 
able to mount T cell independent immune response.  The second type are conventional B 
cells, which are derived from haemopoietic stem cells (HSCs) in the BM (pro-T cells can 
be developed from the same HSC depending on the perceived stimulus).  Unlike T cells 
that travel to the thymus to continue development, B cells remain in the BM, where the 
BM stromal cells provide the microenvironment for the pro-B cell to proliferate and 
differentiate into precursor (pre-) B cells (Hess et al., 1998).  Cell adhesion molecules 
(CAM) (for example, integrins x4ß1; VLA-4) on the B cells bind to ligands, (in this example 
V (vascular) CAM-1) on the stromal cell (Barreiro et al., 2002).  The stromal cells 
additionally express stem cell factor (SCF) on the outer membrane.  The initial binding of 
CAMs, assists in binding of the pro-B cell c-Kit receptor to the stem cell factor (SCF) 
ligand of the stromal cell.  This activation of c-Kit receptor drives the B cell into 
proliferation and differentiation, by heavy (H) chain gene rearrangement, into pre-B cells.  
The progeny then bind Interleukin-7 (IL-7), which is secreted from the stromal cells that 
further drives the maturation of the B cell (Hentges, 1994).  The B cells are then detached 
from the stroma, following down-regulation of CAMs in the maturation process.   
The pre-B cells must undergo further light chain rearrangement to develop into an 
immature B cell.  The light chain rearrangement will commit an immature B cell to a 
particular antigenic specificity, related to the heavy chain VDJ and light chain VJ 
 Chapter One - General Introduction 
 12 
 
sequences.  The immature B cell will also express membrane (m) bound IgM (mIgM), 
together with Ig-α and Ig−β.  Collectively, the expression of these Igs form the B cell 
receptor (BCR) (MacLennan, 2005). 
The immature B cell in the BM is not fully functional and engagement of the BCR at this 
stage should lead to anergy or cell death.  Changes in the transcription of the heavy chain 
RNA, leads to full expression of IgD on the cell membrane.  Thus the co-expression of IgM 
and IgD leads to the cell being fully mature.  It was considered for many years that CLL 
cells were immature B cells (Dameshek, 1967).  However, it is now accepted that these 
cells are of a more mature phenotype and are capable of some antibody secretion and B 
cell function (Ranheim and Kipps, 1993, Jurlander, 1998). 
1.7. The lymph node. 
Further stimulation of conventional B cells occur antigenically, once the cell is released 
from the BM.  Although normal B cells are found in interstitial spaces as well as in the 
peripheral blood, the engagement of antigenically stimulated B-cells occurs in critical 
niches within secondary lymphoid organs such as lymph nodes (LN), which traps 
particles of antigen (Clark and Ledbetter, 1994, Natkunam, 2007).  The LN can be divided 
into two zones: light (LZ) and dark (DZ).  The LZ contains T cell zones and B cells cross 
the high endothelial venules (HEVs) and migrate to the edge of the T zone.  If they 
encounter antigen here it is internalised by the B cell and the resulting peptides presented 
on the cell surface.  This presentation of antigen and the BCR makes interaction with 
primed (alternatively termed activated/helper/CD4+/TH) T cells highly efficient (Benson et 
al., 1997).  This interaction induces rapid proliferation and clonal expansion of the B cell, 
isotype switching and production of both plasma cells, that secrete low affinity antibody 
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or immunologic memory B cells (Natkunam, 2007).  Cells that are released from the T 
zone will only have had fleeting interaction with primed TH cells (Stewart et al., 2007).  
However, if they do not differentiate into antibody secreting plasma cells, they can be re-
recruited into proliferation if they re-enter the T-cell zone within the LN (MacLennan, 
2005).  If no antigen is encountered in the T zone they migrate to the cortex of the LN to 
the LZ and encounter primary B cell follicles (PBCF). 
1.7.1. The role of the PBCF and the Germinal Centre.  
In relation to the underlying biology of CLL, the PCBF is probably the most significant LN 
area to consider.  PBCFs are formed within the LN following the first expansion of B cells 
(Natkunam, 2007, Clark and Ledbetter, 1994).  T cells that have been activated in the 
T zone, migrate to the PBCFs.  These cells drive a burst of the follicular B cell proliferation 
after which the central collection of follicular B cells differentiates into the germinal centre 
(GC) and the remaining blasts differentiate into centroblasts (reviewed in Maclennan., 
1994).  Hypermutation targeted Ig variable regions is switched on in the centroblasts, 
generating thousands of mutant IgHVs, with very little expression of protein Ig receptor.  
The centroblasts next exit cell cycle and migrate to the germinal centre area that is rich in 
follicular dendritic cells (FDCs) that have antigen trapped on their surface (Nossal et al., 
1964).  The centroblasts can take up antigen from the FDC and present to TH cells located 
in the FDC region.  GC TH cells select only the B cells that will secrete antibodies of high 
affinity.  The high rate of IgHV mutation within the GC allows the generation of specific 
antibodies and a high rate of B clonal cell ‘production’.    
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1.7.2. The biology of the B cell- T cell/ CD40-CD40L interaction. 
The cognate interactions between B cells and TH cells, inducing proliferation and survival, 
include signalling via CD40 expressed on the membrane of the B cell, which interacts with 
CD40L (also termed CD154) expressed on TH cells (Willimott et al., 2007a) and IL-4.  CD40L 
is a member of the tumour necrosis factor receptor (TNFR) family; with CD40 reciprocally 
belonging to the tumour necrosis factor (TNF) family.  The cross linking that occurs when 
CD40 interacts with CD40L is critical to induce and sustain B-cell response, (Grdisa, 2003) 
and works by activation of protein kinases, phospholipase C and the activation and 
transcription of NFκB.  The activation of the B cell also causes increased expression of 
cytokine receptors including IL-5 and IL-7 and, importantly, IL-4.  
1.8. The mechanisms underlying the accumulation of CLL cells. 
For some time it was widely considered that G0/G1 peripheral CLL cells were resistant to 
apoptotic stimuli and that this contributes to the accumulation of the malignant clone 
(Kitada et al., 1999).  However, since CLL cells have been reported to rapidly undergo 
apoptosis in vitro, if not provided with cytokine support, (Burger et al., 2000, Willimott et 
al., 2007b, Lanham et al., 2003) it has also been suggested that their apoptotic machinery 
must be intact.  The peripheral accumulation of CLL cells was also thought to be due to an 
exceedingly slow proliferation rate of cells within the periphery, coupled with a defect in 
(or lack of) apoptosis (Chiorazzi, 2007, Dameshek, 1967).  However, it is now widely 
recognised that CLL cells have undergone several rounds of proliferation compared to 
their normal counterparts, demonstrated by shortened telomeres and an appearance of 
being metabolically active (Chiorazzi, 2007, Dal-Bo et al., 2009).  The in vivo measurement 
of the proliferation rate of CLL clones demonstrated clonal expansion to be between 0.1-
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1.75% per day (Messmer et al., 2005) or 1% and 10% per week (Chiorazzi, 2007, Messmer 
et al., 2005).  Messmer et al calculated that these values translate to between 109 and 1012 
cells produced per day.  However, the circulating lymphocyte count did not increase by 
the same degree (Chiorazzi, 2007, Messmer et al., 2005).  This led Messemer et al to 
conclude that CLL cells must also be undergoing apoptosis and they calculated death rate 
to be up to 2% per day.  
The observations that most CLL cells are out of cell cycle but have undergone significant 
numbers of divisions and that apoptosis rates are significant in the peripheral pool of 
cells, progressively suggests that CLL has two compartments: a circulating non-
proliferative compartment and a tissue resident proliferating component.  A review by 
Dameshek in 1967 supported the theory proposed by Gorman and Marmount that CLL 
cells occupy B cell niches in lymphoid tissues (Dameshek, 1967).   Indeed, it has been 
suggested more recently that CLL cells may have a competitive advantage in proliferation 
and survival over normal B cells, allowing their occupation in the BM and LN and 
consequent accumulation in the periphery (Keating et al., 2003).  This competitive 
advantage could be dependent on factors perceived in the microenvironments, in 
particular the LN (Ghia et al., 2008).   
1.9. The role of the LN in CLL. 
Considering the proliferation of B cells within the LN and the evidence of a proliferative 
compartment in CLL, it is certain the LNs play a vital role in the microenvironment of 
propagating CLL.  Histological studies support the in vivo interaction between T cells and 
CLL cells.  CLL cells have been found to accumulate in the LN and, additionally, high 
numbers of primed T cells have been found intermingled with the B cells in the same 
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CLL  involved tissues (Granziero et al., 2001, Patten et al., 2008).  A histopathology study 
conducted in 1994 has confirmed the existence of B cell follicle like proliferative centres 
(PC) of CLL cells within the LN that contain higher numbers of T cells than in the 
surrounding tissue and a higher proliferative fraction of cells (Schmid and Isaacson, 1994).  
More recent histochemistry has demonstrated that within the PC CLL cells are 
proliferating, demonstrating a blast-like morphology, and that this is driven by CD40L 
signals (Luqman et al., 2008, Burger et al., 2009, Ghia et al., 2008).  It is interesting to note, 
in light of prognostic indicators, that clonal expansion studies (similar to those discussed 
above) have postulated that, from within the proliferative tissue compartments, CD38+ve 
CLL cells generate approximately two-fold higher percentage of new CLL cells compared 
to their CD38-ve counterparts (Calissano et al., 2009).  In support of the Pepper et al study 
(2008) the CD38+ve cells were also found to have a reciprocal expression of the cell cycle 
protein Ki67 (Calissano et al., 2009) although Ki67 was also detected on the CD38- ve 
fraction and telomere length in both groups was found to be the same (Calissano et al., 
2009, Pepper et al., 2007).  Therefore, it is possible that within the PC, CLL cells are 
CD38+ve and this plays a role in proliferation of CLL cells following engagement with 
CD40L but that on release of the cells from the PC into the periphery CD38 positivity is 
downregulated.   
Evidently, CLL cells will perceive other stimuli, such as IL-2, IL-13, IL-7 and IL-15, all of 
which have been shown to increase DNA synthesis of CLL cells (reviewed in (Jurlander, 
1998) and CD80-CD28 (another B-cell-T-cell interaction) (Clark and Ledbetter, 1994, 
Natkunam, 2007).  However, no interaction has been shown to be as critically involved in 
CLL cell survival and proliferation as CD40-CD40L (Clark and Ledbetter, 1994), nor have 
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any been as well investigated.  This mix of proliferating CLL cells in the presence of 
T cells has several terms: microenvironment, simply the LN, GC or the PC.  It should be 
noted, however, that the BM also plays a role in the maintenance of CLL, and is likely to 
harbour different cell-cell interactions and provide divergent cell survival signals.  Studies 
by Burger’s group in Austria have addressed the likelihood of nurse cells and stromal 
support networks within the BM providing survival signals to CLL cells.  They, and 
others have identified the important role of stromal cell derived factor -1 (SDF-1) (Burger 
et al., 2000).  SDF-1 is constitutively expressed by BM stromal cells. with its chemokine 
receptor CXCR4 (or CD184) widely expressed on both normal and tumour B cells (Meads 
et al., 2008).   The expression of SDF-1 on the BM cells and the expression of CXCR4 on the 
B cells is thought to allow the more mature malignant CLL cells to home to the BM, where 
other factors such as interleukin-6 (IL-6) are thought to promote cell survival and reduce 
cell sensitivity to treatment (Meads et al., 2008).  In vitro studies by the Burger group have 
identified that BM stromal cells from many sources can successfully promote cell survival 
and drug resistance of CLL cells, including the lines M210B4 (Kurtova et al., 2009, Burger 
et al., 2000), KUM4, ST-2 and KUSA H1, and that cell-cell interaction was essential to 
mediate this (Kurtova et al., 2009).  Interestingly, however, primary stromal cells derived 
from human samples were less protective than any cell line or primary stromal BM cells 
derived from mice (Kurtova et al., 2009).   Additionally others, using deutriated water in 
nine stable CLL patients, found that only the LN and not the BM contributed to CLL 
proliferation (van Gent et al., 2008).  Thus, the microenvironment of CLL cells is 
potentially diverse and includes many involved tissues.  The work presented in this thesis 
will focus upon the PCs within the LN microenvironment and not that of the less 
involved BM.  
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1.9.1. In vitro recapitulation of the LN.  
Attempts to recapitulate the PCs in vitro have identified that CLL cells can be  protected 
from spontaneous in vitro apoptosis by co-culture with autologous T cells (Ranheim and 
Kipps, 1993).  In 1993 Crawford et al demonstrated that use of a co-culture system of Fc 
gamma RII+ (CD32) L-cells together with an anti-CD40L antibody induced rapid 
proliferation of CLL cells taken from peripheral blood (Crawford and Catovsky, 1993).  In 
addition they showed that whilst IL-4 induced very little DNA synthesis alone, when CLL 
cells were co-cultured in the same way, but with the addition of IL-4, proliferation was 
further enhanced (Crawford and Catovsky, 1993).  Jacob et al also observed that combined 
IL-4 and CD40L induced greater CLL cell proliferation than CD40L alone. However, their 
study additionally identified that CD32 used in Crawford and Catovsky’s original study 
was not required to stimulate proliferation (Jacob et al., 1998).   The significantly increased 
cell viability and proliferation upon culturing with both CD40L and IL-4 was proposed by 
Gridsa to indicate that each molecule induced alternative and complimentary pathways of 
signalling (Grdisa, 2003).  It is interesting to note, however, that neither Gricks nor Gridsa 
reported an upregulation of cell cycle proteins (Grdisa, 2003) or genes (Gricks et al., 2004) 
but they did report a significant increase in protection from apoptotic signals.  
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Figure 1.  Schematic of culture conditions mimicking the culture conditions used for 
CLL in vitro experiments.  Top shows the proliferative centre cells cultured with CD40L  
and bottom shows the peripheral CLL cells cultured with stroma without CD40L.   Both 
systems have the addition of IL-4.  This culture condition is based on that discussed by 
Willimot et al., 2007. 
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In this regard, in vitro cultures of CLL with CD40L delivered by stable stromal 
transfectants and IL-4 has been shown to reproduce the in vivo anti-apoptotic effect of TH-
B cell interaction as depicted in figure 1.   This interaction has also been demonstrated to 
induce an increase in anti-apoptotic proteins such as myeloid cell leukaemia-1 (MCL-1) 
and B-cell lymphoma-2 (BCL-2), further indicating the highly protective role of this 
cellular interaction (Willimott et al., 2007c) and these anti-apoptotic proteins are regarded 
as therapeutic targets in CLL (Pepper et al., 2008, Hallaert et al., 2007, Gandhi et al., 2008). 
1.10. The importance of the PC in CLL. 
Without evidence of a leukaemic stem cell, the occurrence of PCs in CLL is unique to this 
B cell malignancy.  Only other chronic immune disorders such as rheumatoid arthritis 
have shown similar proliferative arrangements.  Thus CLL can be regarded as a disease of 
constant immune stimulation (Burger et al., 2009, Ghia et al., 2008), with the PCs 
continually harbouring dividing leukaemic cells and has been considered an autoimmune 
disease by many since the 1960s (Dameshek, 1967).  The interaction of CLL cells with 
CD40L provides the cells with both a pro-proliferative (Grdisa, 2003, Crawford and 
Catovsky, 1993, Luqman et al., 2008) and a pro-survival signal (Grdisa, 2003) that is 
presumably part-way responsible for engendering the reduced apoptotic index of the 
peripheral CLL cells.  Although the microenvironment needs to be fully characterised for 
the disease to be fully understood (Motta et al., 2009) it is clear that the treatment and 
ultimately cure of CLL will require not only the removal of the peripheral B-cells but also 
more focus on the PC where the residing CLL clone can result in minimal residual disease 
(MRD).   
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1.10.1. Targeting MRD within the PC.  
Treatment of CLL has for many years been based on alkylating agents and purine 
analogues but many patients are refractory to these treatments or relapse over time (Byrd 
et al., 2007).  In addition, improved technology such as multi-colour flow cytometry, 
allows a more precise measure of CLL tumour load (Moreton et al., 2005).  Therefore, 
therapies that may have appeared to achieve CR in the 1960s, would now possibly be 
classified as achieving partial response (PRS) owing to the more sensitive techniques 
employed (Moreton et al., 2005), that would detect MRD (even at exceedingly low levels).  
It is becoming increasingly apparent that achieving CR, together with MRD negativity, 
can result in improved survival but at a cost of increasing toxicity (Moreton et al., 2005, 
Hillmen et al., 2007, Motta et al., 2009, Chanan-Khan et al., 2006).   Recent studies have 
addressed this, utilising modern therapies including ofatumumab (Coiffier et al., 2008), 
lenalidomide (Chanan-Khan et al., 2006) and most notably alemtuzumab (Moreton et al., 
2005, Hillmen et al., 2007).  A comparison of alemtuzumab against the alkylating agent  
chlorambucil in 2007 concluded that alemtuzumab achieved a superior CR (Hillmen et al., 
2007).  This was an encouraging result, especially considering the claims that an MRD 
negative state is achievable with alemtuzumab  therapy (Moreton et al., 2005).  However, 
this was only achieved in patients with low (or no) enlarged LN.  In patients with LNs in 
excess of 5cm, patients remained MRD positive (Moreton et al., 2005).  This status was 
improved on the administration of additional therapies including fludarabine (F-ara-A) 
and autologous/allogeneic stem cell transplant, but this is unlikely to be available to the 
majority of elderly CLL sufferers.  Together with the infection rate following 
alemtuzumab administration, the overall clinical benefit for the average patient remains 
to be determined.  
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An alternative way to tackle MRD is to eradicate the CD40-CD40L interaction or interfere 
with its downstream consequences, and many believe that a better understanding of this 
interaction and disruption of it would be a great step to curing CLL (Luqman et al., 2008, 
Jurlander, 1998, Willimott et al., 2007c).   Treatment of CLL by targeting the CD40L 
stimulus has recently been investigated in many ways.  A recent study utilised an anti-
CD40 antibody, HCD122, to inhibit CD40-CD40 L interactions and showed the ability of 
this antibody to do this and to induce cell lysis (Luqman et al., 2008).  However, the 
number of patients studied was small (n=8), with most data shown for only one patient.  
Therefore, it remains to be proven whether this therapy would be clinically useful.   Other 
approaches are the use of agents to sensitise cells within the PC to chemotherapeutics.  An 
in vitro study, carried out by Hallaert et al (2008) utilised dasatinib (DSN) with 
chemotherapeutics such as F-ara-A and concluded that DSN increased cell death in 
response to chemotherapeutics (Hallaert et al., 2008).  However, in these studies CD40L 
was not continually available to the CLL cells, therefore, it remains questionable as to 
whether this would truly translate in vivo within the PC (Hallaert et al., 2008).  In chapter 
5 experiments will be presented that address this possibility.  
1.11. The decision to treat and current treatment strategies. 
The treatment of CLL initially relies on the stage of disease at diagnosis.  Patients in Binet 
stage A are left with a ‘wait and watch’ approach and are not currently treated until the 
disease progresses (Ghia et al., 2007b).  This is due to the majority of patients (85% of stage 
A) having a good quality of life, unaffected by CLL, and dying of unrelated disorders.  In 
addition, current common therapies are unable to halt the natural course or cure the 
disease (Dighiero et al., 1998) and a number of studies have failed to show any benefit for 
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treating early stage disease.  Binet stage B will often be treated once the disease has started 
to progress, with stage C patients being given early treatment (Ghia et al., 2007b).   
1.11.1. Established current therapies.  
There are many established CLL therapies, many of which are covered in the following 
sections.  
1.11.1.1. Alkylating agents. 
Alkylating agents such as cyclophosphamide and chlorambucil were considered the ‘gold 
standard’ of therapy until the 1980s, with chlorambucil being the first line of therapy 
(Oscier et al., 2004).  Alkylating agents have three described mechanisms of action: 1) to 
add alkyl groups to DNA bases causing the DNA to be fragmented during the repair 
processes, thus preventing DNA synthesis and RNA transcription; 2) cross linking DNA, 
thereby inhibiting transcription and 3) inducing DNA mutations by causing alkylated G 
nucleotides to pair with T nucleotides.  Chlorambucil has a 10% CR rate and virtually all 
patients will be expected to relapse (Ghia et al., 2007b).  The UK Medical clinical Research 
Council reported in 1988 that chlorambucil does not improve overall survival (OS) and 
that continuous administration is not beneficial (Catovsky et al., 1988).  Additionally, to 
date, combining chlorambucil with other agents such as prednisolone (PRD) has no 
additional long term benefit (Jaksic and Brugiatelli, 1988).  Recent studies are examining 
whether there is benefit in combining chlorambucil with rituximab or ofatumumab (Kay 
et al., 2006). Chlorambucil is well tolerated with manageable toxicities, although 
myelosuppression is common and related to duration of use.     
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1.11.1.2. Purine analogues. 
Purine analogues such as cladribine and pentostatin overtook chlorambucil as first line 
therapy in the mid 1980s with F-ara-A becoming the most used in the developed world.  
These agents exert their activities by interfering with the function of multiple DNA 
polymerases, DNA primase, DNA ligase I and are therefore S phase-targeted.  F-ara-A has 
a 38% CR rate and is considered to have a superior remission rate to chlorambucil (Rai et 
al., 2000).  Nevertheless, studies continue to show that, as a single agent, use of F-ara-A 
does not improve OS (Leporrier et al., 2001, Abrisqueta et al., 2009, Eichhorst et al., 2009b).  
Attempts at combination therapy with agents such as cyclophosphamide have also 
showed that the OS rate is not improved (Eichhorst et al., 2006) but response rates are 
considerably better than with F-ara-A or chlorambucil alone (Catovsky et al., 2007).  The 
new gold standard regimen for induction in CLL is a combination of F-ara-A, 
cyclophosphamide and rituximab (FCR) based on German studies (Michael Hallek ASH 
2009) and MD Anderson data (Tam et al., 2008).  The FCR regimen is associated with 
higher response rates but again there is a lack of clarity as to whether this leads to 
improved OS.  Future studies are exploring whether the addition of an anthracyclin 
(mitozantrone) is beneficial and addressing the optimal dosing of rituximab (Dr Guy 
Pratt, personal communication). 
1.11.1.3. CAP, COP, CHOP. 
In the late 1980s and early 1990s new combination therapies were investigated including 
CAP (cyclophosphamide, doxorubicin and prednisone) (Keating et al., 1998), COP 
(cyclophosphamide, vincristine and prednisone) and Binet’s modified CHOP 
(cyclophosphamide, doxorubicin, vincristine, and prednisone) regimen (Binet, 1993).  
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However results showed that overall survival rates using these therapies are not 
improved.   
In addition to the lack of prolonged survival of CLL patients undertaking the above 
chemotherapeutic based therapies, they all have associated toxicities (Oscier et al., 2004) 
and have complications such as high rate of infections and anaemia (Steurer et al., 2006).  
Combining multiple chemotherapeutics together serves to increase the toxicity and 
reduce the benefits to older patients.  This has led to studies advocating that, in the 
elderly, high dose chlorambucil maintains better patient benefit. (Jaksic and Brugiatelli, 
1988, Jaksic et al., 1997). 
1.11.1.4. Methyl-prednisolone. 
Studies using a high dose of the glucocorticoid receptor (GR) antagonists, PRD and 
methyl-prednisolone (ML-PRD) in the late 1990s have shown that these agents can induce 
remission.  Prednisolone is a useful agent with anti-tumour activity, particularly in the 
setting of CLL related marrow failure and is used as a palliative treatment.  ML-PRD was 
more likely to be used in refractory patients, in whom other therapies had failed.   ML-
PRD combination therapy has recently gained renewed interest as a combination therapy 
with monoclonal antibodies (Castro et al., 2009).  The combination of ML-PRD with 
rituximab (discussed in 1.12.1.1), has been shown to induce 19-50% CR (depending on the 
dose of rituximab used) with a 16.7% MRD negative state in the higher CR group. The 
associated rate of toxicity of this regimen was high, although most (80%) were classified 
as low grade toxicities (Eichhorst et al., 2009a).  
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1.12. Newly established approaches.  
The therapies described in 1.11.1. are largely based on agents that were first established 
decades ago.  The following sections will consider more recent approaches to treating 
CLL.  
1.12.1. Monoclonal antibodies.  
Studies using monoclonal antibody therapy have been ongoing since the late 1980s (Press 
et al., 1987) and include those raised against CD20 and CD52.  Importantly, unlike 
chemotherapeutics, these novel agents do not rely on the ATM-p53 apoptotic pathway, 
which is often defective in relapsed and refractory CLL and is a major mechanism for 
chemoresistance (Austen et al., 2005).  These agents can potentially overcome 
chemoresistant and poor risk disease states (Luqman et al., 2008).   
1.12.1.1. CD20. 
The most successful monoclonal antibody to date has been the use of CD20 antibody 
therapy. CD20 is a calcium channel that interacts with the B-cell Ig receptor complex on 
the surface of both normal and malignant B-cells.  The first antibody therapy targeted 
against this phosphoprotein in B-cell malignancies was rituximab.  The benefit of CD20 
antibody therapy is that whilst normal mature B cells will also be affected; precursor B 
cells will remain untouched as they do not express CD20 (Reff et al., 1994).  However, as B 
CLL cells express relatively little CD20, therapy using it alone has been disappointing and 
ineffective compared to F-ara-A (Hainsworth et al., 2003).  Combination therapy using F-
ara-A /cyclophosphamide/rituximab (FCR) has been shown to be much more effective  
(Wierda et al., 2005). 
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However, rituximab has its own associated side effects (Hainsworth et al., 2003) due it 
stimulating the release of cytokines.  Combined with the toxicity of FC therapy, this 
means that this treatment is not well tolerated, especially in patients over the age of 70.  
The MD Anderson Cancer Centre, University of Texas reported FCR as first-line therapy 
in patients < 70 years of age and showed that 75% of patients experienced grade 3-4 
myelosuppression, 11% experienced grade 3-4 infection and fewer than half were able to 
complete the six cycles of induction (Keating et al., 2005, Wierda et al., 2005). 
Ofatumumab is a newly developed, alternative anti-CD20 antibody with a higher affinity 
for CLL cells, when tested in vitro (Coiffier et al., 2008) and an ability to activate 
complement.  A phase I/II study of this agent did not produce any CRs, but lower 
lymphocyte numbers were reported in the BM following treatment and significant 
responses were seen (Coiffier et al., 2008).  However, the trial additionally reported a 30% 
incidence of immunosupression and a 57.6% rate of infection (Coiffier et al., 2008).  
Further studies are examining ofatumumab in combination with chlorambucil and F-ara-
A /cyclophosphamide combinations.  Whilst these combinations may improve responses, 
it is likely that the immunosupression would be worse. 
1.12.1.2. CD52. 
Mature B cells, T cells, NK cells, macrophages all express CD52.  Also, in contrast to CD20, 
all CLL cells also express this heavily glycosylated, membrane-anchored glycoprotein.  
Alemtuzumab is an antibody raised against CD52 and trial results from the use of this 
antibody used alone, (Rai et al., 2002) have shown that it is more effective than rituximab, 
especially in patients with more progressive CLL (Osterborg et al., 1997).  Combination 
therapy of this antibody with rituximab with and without F-ara-A are currently underway 
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(O'Brien, 2008).  However, as previously discussed, there are known associated toxicities 
of alemtuzumab (Thursky et al., 2006) and on its own it is unlikely to treat MRD.  
Additional research and trials are currently underway, investigating the use of other 
monoclonal antibody therapies such as CD23, CD70 and different epitopes of CD20.  
1.12.2. Flavopiridol. 
Flavopiridol is a cyclin dependent kinase inhibitor that clearly has activity in CLL (Lin et 
al., 2009).  Like antibody therapies, it does not rely on the ATM-p53 apoptotic pathway 
(Pepper et al., 2003).  Trials into flavopiridol demonstrated that it can have activity in 
relapsed high risk disease (Byrd et al., 2007) but only in younger patients.  As it is difficult 
to deliver and it has associated significant toxicity (Lin et al., 2009) its therapeutic use, 
especially in the over 65s, is questionable.   
Thus, although there have been improvements in responses in CLL, it remains incurable 
for the vast majority of patients and there is a need for novel treatments with acceptable 
toxicity. Also, given the heterogeneity of disease progression, eradicating MRD may be a 
reasonable aim for fitter patients or patients with high risk disease (Nabhan et al., 2007) 
whereas palliation may be the best approach for a significant proportion of CLL patients .  
It is clear that new treatment strategies for CLL are desirable.  In order to achieve these 
different strategies should be applied - such as drug redeployment.  
1.13. History of drug redeployment. 
The theory of utilising existing drugs in new settings is a research area that has recently 
gained interest (Chong and Sullivan, 2007).  It is well known that therapeutic agents 
designed many years ago probably have targets other than those for which they have 
been prescribed (Keiser et al., 2009).  In the acute leukaemia setting this has led to the 
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successful use of retinoic acid (RA) (Fenaux et al., 2007) and arsenic trioxide (Chen et al., 
2007) in APL, valproic acid in AML (Kuendgen and Gattermann, 2007) and thalidomide in 
multiple myeloma (MM) (Prince et al., 2007, Breitkreutz and Anderson, 2008, Breitkreutz 
et al., 2007) as individual agents.  In the case of B cell malignancies, bendamustine, a 
cytostatic alkylating agent, has been redeployed for the treatment of Hodgkin’s 
lymphoma and CLL (Cheson and Rummel, 2009, Kalaycio, 2009, Kath et al., 2001, Knauf 
et al., 2009), although not without associated toxicities (Kath et al., 2001, Knauf et al., 2009) 
including tumour lysis syndrome (Hummel et al., 2005).  Investigations have also 
highlighted the potential use of medroxyprogesterone acetate (MPA), a female sex steroid, 
in canine CLL (Florio et al., 2003).  
In 2003, this group published a study on the use of ‘old drugs’ in a new setting of Burkitt’s 
Lymphoma (BL) (Fenton et al., 2003).  The agents utilised in this study were members of 
the fibrate family, clofibric acid (CA) or bezafibrate (BEZ), and MPA.  This study showed 
that combining these 2 classes of agents, induced apoptosis, reduced proliferation and 
caused mitochondrial damage to BL cells and cell lines.  
1.14. The Fibrates’ function.  
Fibric acid derivatives, including Bezafibrate (BEZ), are lipid regulating agents that 
reduce triglycerides by 30-50% and moderately reduce (by 15-20%) low-density 
lipoprotein cholesterol (LDL-C) (Goldenberg et al., 2008b).  They are synthetic peroxisome 
proliferator–activated receptor (PPAR) ligands with highest specificity for 
PPARα (Tenenbaum et al., 2003), with BEZ being a pan-PPAR ligand.  The 
PPARα mediated effects are both lipid and non-lipid related.  These include increased 
gene expression for lipoprotein lipase (LpL), a fatty acid binding protein, and a decrease 
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in expression for cyclooxygenase 2 (COX-2), VCAM-I and interleukin-6 (IL-6) 
(Goldenberg et al., 2008b).  In addition to its regulation of triglycerides, BEZ has also been 
shown to have beneficial cardio-protective effects that are long-lived after therapy has 
ceased (Goldenberg et al., 2008a) and significantly reduce the incidence of new onset type 
2 diabetes in patients with impaired fasting glucose (Tenenbaum et al., 2004).  
BEZ has also been demonstrated to induce oxidative stress.  It has been shown that, when 
used against AML cell lines, it induces differentiation in a dose dependant manner that 
was reduced in the presence of anti-oxidants (Scatena et al., 1999).  Additionally, BEZ is 
known to induce mitochondrial depolarisation and mitochondrial specific ROS in rodent 
hepatocytes (Qu et al., 2001).  Scatena et al (2003) have also shown that BEZ inhibits 
mitochondrial respiratory chain at the level of NADH cytochrome C reductase activity in 
AML cell lines.  Both Qu et al (2001) and Scatena et al (2003) have suggested that, whilst 
the generation of ROS and the mitochondrial effects may be due to PPARα mediated 
effects, it is most likely that these are independent of PPAR. 
1.15. MPA and steroidal activity. 
The synthetic progesterone family of progestins is large with all members having effects 
against the progesterone receptor (PR).   MPA belongs to the medrogestone class and 
unlike some of the other progestins, is not metabolised by the liver and therefore does not 
have a first pass effect (Schindler et al., 2003).  As the family of progestins is large and 
structurally diverse all progestin members are known to exert additional activities.  An 
example of this is the binding capacity of MPA to other steroid receptors.  Relative to their 
known natural ligands the binding affinity of MPA to the PR is 115%, with affinities of 
29% for the glucocorticoid receptor (GR), 5% for androgen receptor (AR) and 160% for 
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mineralocorticoid receptor (MR).  It is thought that MPA has no binding affinity for 
oestrogen receptor (ER) (Schindler et al., 2003).   
1.15.1. Non-steroidal activities of MPA. 
Whilst Fenton et al (2003) did not investigate the mechanisms of action of MPA in BL cells, 
a recent study from this group has also investigated the mechanism of MPA against AML 
cell lines (Khanim et al., 2009).  It was demonstrated that, in AML cells, MPA inhibits the 
enzyme aldoketoreductase (AKR) 1C3 (AKR1C3).  AKR1C3 is a member of the AKR1 
enzyme superfamily.  In humans, four members  of the AKR1 family have been detected: 
AKR1C1, AKR1C2, AKR1C3 and AKR1C4 (Mindnich and Penning, 2009).   In vitro the 
enzymes have high substrate promiscuity.  Penning et al demonstrated that all of the 
AKR1C1 family members are capable of reducing 5α-dihydrotestosterone (5α-DHT), 
oestrone and progesterone.  However, AKR1C3 is thought to be unique in its metabolism 
of prostaglandin (PG) D2 (PGD2), described as 11β-PGD2 ketoreductase activity.  It has 
been shown in vitro that AKR1C3 will reduce PGD2 to 9α, 11β-prostaglandin F2 (11-epi 
PGF2α) (Suzuki-Yamamoto et al., 1999).  The metabolism of PGD2 with and without 
AKR1C3 is shown in figure 2. 
In the AML study from this group (Khanim et al., 2009) it was demonstrated that the anti-
leukaemic activity of MPA was mediated, at least in part, via the inhibition of the 11β-
PGD2 ketoreductase activity of AKR1C3 leading to accumulation of PGD2 and its bioactive 
metabolite 15d∆12,14PGJ2.   
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Figure 2.  Schematic of the conversion of PGD2 via both the non-enzymatic pathway to 
15d∆12,14PGJ2 and AKR1C3 pathway to 11β-PGF2α.  AKR1C3 is shown as its crystal 
structure as determined by Lovering et al (2004). 
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1.16. The generation and signalling of PGD2. 
PGs are naturally occurring cyclic 20 carbon fatty acids, synthesised mainly from 
arachidonic acid (AA) (Straus and Glass, 2001).  The synthesis of most PGs is COX 
dependent.  In the first step, AA is transformed to an unstable endoperoxide by COX, 
which is converted to several related PGs, including PGD2, by their specific PG synthases.  
PGD2 has a cyclopentane ring (Straus and Glass, 2001) that undergoes dehydration to 
produce the J series PGs.   
Although relatively unstable, PGD2 is found in bodily fluids in the nanomolar range, 
increasing to micromolar during highly allergenic responses (Offenbacher et al., 1986).  It 
has been shown to exert wide ranging biological activities including regulation of body 
temperature, regulation of the sleep cycle, inhibition of platelet aggregation, relaxation of 
smooth muscle and chemotactic recruitment of inflammatory cells (Herlong and Scott, 
2006).  Its best known activity is pro-inflammatory, although it has also been 
demonstrated that it has the potential to inhibit inflammation as it can induce T cell 
apoptosis (Nencioni et al., 2003).  
PGD2 has two known mechanisms of signalling by two distinct seven transmembrane G-
protein coupled receptors.  The role of these receptors in leucocytes has been reviewed by 
Sandig et al in 2006.  The first receptor, DP1, was discovered first in mice and then in 
humans by Boie et al in 1995.  This receptor has been reported to be expressed by 
T lymphocytes (Tanaka et al., 2004) cells in the immune system as well as other cells.  DP1 
has been suggested to mainly have a pro-inflammatory role, although some reports have 
been published of the anti-inflammatory response mediated by DP1 (reviewed in (Sandig 
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et al., 2007)).  The second receptor for PGD2, is chemoattractant-receptor homologous 
molecule expressed on TH (CRTH2)/DP2 that was independently discovered by three 
different groups in the years 1999-2001 (reviewed in (Sandig et al., 2007)).   
The DP1 receptor is widely regarded to be the classical PG receptor as it shares similarity 
to other PG receptors.  The reported Ki value for PGD2 to this receptor is 1.7nM, whereas 
the Ki for PGD2 to DP2 receptor is 2.4nM (Herlong and Scott, 2006).  In addition, DP2 is 
known to bind many other agonists with high affinity.  These include 15d∆12,14PGJ2 , the 
nonsteroidal anti-inflammatory drug (NSAID) indomethacin (IDM) and metabolites of 
thromboxane (Herlong and Scott, 2006).  Reviews on PGD2 and its signalling also concede 
that the precise action of PGD2 and its metabolites are not fully understood and there 
remains the possibility that they act on many other receptors (Herlong and Scott, 2006, 
Sandig et al., 2007) 
1.16.1. The anticancer activities of 15d∆12,14PGJ2.  
As mentioned in 1.6, PGD2 is short lived and either is metabolised by AKR1C3 to produce 
11-epi PGF2α or spontaneously dehydrates to form prostaglandin J2 (PGJ2). In turn PGJ2 
undergoes a series of non-enzymatic reductions until it becomes the terminal derivative 
15d∆12,14PGJ2 that has a cyclopentenone structure with unsaturated α,β ketone moieties 
(Piva et al., 2005). This, in particular of all the J series prostanoids, has been reported to 
have wide ranging anticancer activities, including inhibition of proliferation and 
induction of apoptosis (Piva et al., 2005).  Pertinently, 15d∆12,14PGJ2 has also been shown to 
have antineoplastic properties against haematological malignancies (Laurora et al., 2003), 
including lymphoid (Padilla et al., 2002, Nencioni et al., 2003).  Some of the activity of 
15d∆12,14PGJ2 is exerted through it being a ligand for PPARγ, which was demonstrated by 
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Kleiver et al in 1995 by the use of 15d∆12,14PGJ2 to induce adipocyte differentiation.  Whilst 
the evidence that 15d∆12,14PGJ2  acts as a ligand for PPARγ was demonstrated, this is likely 
to be cell type specific.  In haematological malignancies 15d∆12,14PGJ2  has been 
demonstrated to reduce proliferation and induce apoptosis independently of PPARγ 
(Laurora et al., 2003, Piva et al., 2005).   
1.17. The Isoprostane pathway. 
In addition to the synthesis of PGs by the COX pathway, in the 1990s the formation of PGs 
was shown to occur in vivo via the isoprostane pathway (IoPP).  Subsequently, the 
Morrow and Roberts’s group have demonstrated that PGD2 is formed non-enzymatically 
from the free-radical-catalysed peroxidation of AA (Gao et al., 2003).  Briefly, after AA 
peroxidation, three arachidonyl radicals are produced and undergo endocyclisation to 
form four PGH2-like bicyclic endoperoxide intermediate regioisomers.  These then 
undergo a reduction reaction to form, four F-ring regioisomers, each consisting of eight 
racemic diastereoisomers.  Isoprostanes (IoPs) are initially formed esterified on 
phospholipids (PL) and are then released in free form by phospholipase(s) (Morrow et al., 
1992b, Morrow et al., 1992a).  However, the IoP endoperoxides may undergo 
rearrangement in vivo to form an E- or D-ring and thromboxane-ring compounds 
(Morrow and Roberts, 1997).  Subsequently, E2- and D2-IoPs can form reactive 
cyclopentenone A2 and J2-IoPs after undergoing dehydration reactions.   
Therefore, in vivo, PGD2 can still be formed independently of COX, the inhibition of which 
would not stop the PGD2 being formed via the IoPP.  This has been shown by the Morrow 
group to occur significantly in vivo when cells are subjected to oxidative stress (Morrow et 
al., 1992a, Morrow et al., 1992b, Morrow and Roberts, 1997).   
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1.17.1. Oxidative stress and Reactive oxygen species.  
Free radicals are mainly derived from oxygen and are commonly termed reactive oxygen 
species (ROS).  They can be generated from various sources including, environmental 
toxins.  The ROS family includes superoxide (O2-), hydrogen peroxide (H2O2), hydroxyl 
radicals (-HO) and peroxynitrite (ONOO–).  ROS are continually found within cells but 
they can cause direct damage to DNA, lipids and proteins.  Antioxidants, including 
glutathione, vitamins C and E and antioxidant enzymes such as superoxide dismutases 
(SOD) and catalase, actively scavenge free radicals and are able to attenuate their effects 
(Gutteridge and Mitchell, 1999).  However, if an imbalance arises between the generation 
and scavenging of ROS or there is an excessive production in ROS, this can lead to 
oxidative stress.   
1.17.2. The link between ROS and lipid peroxidation. 
The effects of oxidative stress and lipid peroxidation (LPO) have been comprehensively 
reviewed by Montushi et al (Montuschi et al., 2007, Montuschi et al., 2004).  Free radical 
attack on lipids is known to lead to LPO.  This, in turn, is damaging to the cells by a chain 
of events.  First, the biophysical properties of the membrane are altered leading to 
inactivation of membrane bound receptors and/or enzymes.  Finally, this may impair 
normal cellular function.  
Whilst IoPs are not a major product of LPO, the fact they are chemically stable and readily 
detectable in all major tissues and fluids (Morrow and Roberts, 1997, Morrow et al., 1992b, 
Pratico et al., 2001) means that they are currently considered to be the best measure of 
oxidative stress-mediated-LPO (Montuschi et al., 2004). 
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PGD2- like IoPs have been shown to readily react with thiols forming glutathione and 
protein adducts in the same way as PGD2 (Chen et al., 1999).  However, the receptors by 
which IoPs exert their effects are currently unknown.  It has been demonstrated that they 
can activate prostanoid receptors (Montuschi et al., 2007) and a novel IoP receptor has 
been reported to exist in vascular smooth muscle of the rat (Morrow and Roberts, 1997). 
As well as effects on LP, ROS also have a role in signalling.  This so called ‘redox cell 
signalling’ has been demonstrated to be important at many levels of cell processes and 
can lead to the activation of pathways that control cell differentiation and apoptosis 
(Droge, 2002). 
1.18. The significance of ROS in CLL. 
The total levels of ROS and concentration gradients within a cell have been reported to be 
critical for basic cell signalling processes and not all ROS will be produced in equal 
amounts.  Therefore, the presence of ROS within cells may not be detrimental to their 
survival.  Indeed, a study on ROS generation in CLL cells showed that, post-
chemotherapy, the surviving CLL cells showed mutations in mitochondrial DNA 
(mtDNA) associated with increased ROS (Carew et al., 2003), perhaps indicating a 
survival advantage in these cells.  However, a sudden and sustained increase in ROS has 
been hypothesised to lead to apoptosis in the lymphoma cell line Ramos (Ryan et al., 
2008).  Additionally, it has been proposed that the treatment of CLL with 2-
Methoxyestradiol (2-ME) is successful at inducing apoptosis in vitro due to its induction of 
ROS (Zhou et al., 2003).   As well as finding ROS within the cytoplasm of the cell, it is 
found compartmentalised within organelles.  This compartmentalisation of ROS, 
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especially in the mitochondria, has been suggested to play a major role in the redox state 
of the cell (Droge, 2002) 
1.19. Mitochondrially mediated ROS. 
Mitochondria are key organelles in conversion of energy, regulation of cellular signalling 
and amplification of programmed cell death.  Synthesis of ATP by mitochondria depends 
on energy derived from the flow of electrons from metabolic intermediates through the 
electron transport chain to molecular oxygen.  Although the electron transport chain 
converts about 85%–90% of the oxygen utilized by cells to water, 1%–2% of the oxygen is 
converted to ROS (Richter et al., 1995).  A review conducted in 1995 concluded that 
mitochondria are strongly linked to apoptosis, either as endpoint organelles of cell death 
or as an environmental sensor, but highlighted that the mechanisms by which this 
occurred were unclear (Cavalli and Liang, 1998). 
Mitochondrial ROS including superoxide (MSO) can cause damage to mitochondrial 
proteins, lipids and DNA, thereby disrupting mitochondrial function.  It is thought that 
mtDNA is particularly susceptible to MSO owing to it being located in close proximity to 
the site of MSO production.  Mitochondrial damage owing to MSO has been reported in 
clinically relevant situations such as cardio vascular disease (Victor and Rocha, 2007), 
although the importance of MSO in vivo is not currently understood.   
Normally mitochondrial ROS causes little oxidative damage because mitochondria 
possess an efficient antioxidant defence system composed of manganese superoxide 
dismutase (MnSOD/SODII), glutathione peroxidase, NADPH transhydrogenase, reduced 
glutathione, NADPH, and vitamins E and C (Raymond and Johnson, 2004).   It has also 
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been hypothesised that there is a range of mnSOD activity: high enough to remove excess 
MSO and low enough to allow the controlled release of H2O2 (Kim et al., 2004). 
MnSOD is the key free radical scavenger in the mitochondria.  It converts MSO to O2 and 
H2O2, which is either enzymatically detoxified within the mitochondria or diffuses into the 
cytoplasm (Victor and Rocha, 2007).  However, MnSOD has also been shown to have pro-
oxidant activity by the production of H2O2.  These anti- and pro-oxidant activities of 
mnSOD are thought to be a key regulator of the redox state of the cell (Kim et al., 2004).  
The described evidence of mitochondrial redox states in cell death suggests this could be 
an exploitable target for the induction of apoptosis in malignant cells, including CLL.  
Indeed, many agents, including plant derivatives, have been shown to be anti-leukaemic 
by causing mitochondrial damage.   
1.20. The history of the potential use of plant derived compounds in leukaemia 
therapy. 
Plants have been used medicinally by mankind for centuries.  Indeed, extracts from the 
Narcissus genus of Amaryllidaceae plants were documented to have been used as cancer 
therapy by Hippocrates in the 4th century BC (Evidente et al., 2009).  In recent decades, the 
therapeutic use of many plant derived compounds has been investigated by the scientific 
community.  From such studies many plant derived compounds have been implicated for 
their use as anti-leukaemia therapies.  These include: PEP005, derived from the plant 
Euphorbia peplus in AML (Hampson et al., 2005); jasmonates, found in all plants, in AML, 
CLL and B cell lymphoma (Davies et al., 2009, Flescher, 2005, Flescher, 2007, Heyfets and 
Flescher, 2007, Rotem et al., 2005); and pancratistatin and lycorine from the Amaryllidaceae 
plant family in AML and APL (Liu et al., 2004, Liu et al., 2007, Liu et al., 2009).    
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1.20.1. Investigations into the use of Jasmonates. 
The small hydrophobic plant stress hormones, jasmonates, have been investigated for 
their anti-neoplastic therapy in recent years.   Jasmonate family members include jasmonic 
acid (JA) and methyl jasmonate (MeJ).  MeJ in particular has been found to be selectively 
toxic towards leukaemic cells in the ALL cell line MOLT-4 (Flescher, 2005).  The jasmonate 
family have been proven in animal models to prolong survival (Fingrut and Flescher, 
2002) and in human B cell lymphoma line, carrying the p53 mutation, to be pro-apoptotic.   
Jasmonates have additionally been investigated in non-proliferating CLL cells (Rotem et 
al., 2005).  In this setting, MeJ induced high levels of Δψm depolarisation and, therefore, 
Rotem et al (2005) have postulated that this direct damage to the mitochondria is the 
target of MeJ.  Rotem et al have investigated this further with analysis of hexokinase, an 
enzyme bound to the external mitochondrial membrane, essential for the ATP-dependant 
phosphoylation of glucose to glucose-6-phosphate in glycolysis.  Hexokinase is typically 
overexpressed in cancer cells and it has been shown that MeJ is able to detach 
mitochondrial bound hexokinase, thereby dramatically reducing the glycolytic rate of the 
cell.  This was demonstrated in primary murine colon cancer, melanoma and B cell 
lymphoma and human Molt-4 cell lines (Goldin et al., 2008).  However, JA was unable to 
exert the same activity and, therefore, it has been suggested that the jasmonate family 
exert their actives using another, yet unknown, mitochondrial mechanism (Goldin et al., 
2008). 
1.20.2. The induction of apoptosis by lycorine. 
Lycorine is the most abundant alkaloid of the Amaryllidaceae family and has wide ranging 
biological activities.  Studies this century have indicated that lycorine interferes with 
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replication of the polio, small pox and SARS viruses (Hwang et al., 2008, Deng et al., 2007, 
Li et al., 2005), has anti-fungal (Mackey et al., 2006) and anti-parasitic activities, including 
against malaria (Sener et al., 2003).  In the last decade research has begun to investigate 
the potential use of this compound to treat leukaemia (Evidente et al., 2009, Li et al., 2005, 
Liu et al., 2004, Liu et al., 2007, Liu et al., 2009) although, to date, no studies have 
investigated its use in the treatment of CLL.  
In vitro studies of lycorine against APL and AML cells have shown it to induce apoptosis.  
This has been shown to be attributable to the rapid down regulation of the anti-apoptotic 
protein MCL-1 (Liu et al., 2009) and subsequent caspase activation and cell cycle arrest (Li 
et al., 2007).  Additionally, lycorine has been shown to be specifically targeted to 
malignant cells.  In an HL-60 xenograft model (Liu et al., 2007) lycorine successfully 
reduced the tumour load without exerting any reported adverse effects.  It should be 
noted, however, that published results of this study only just reach significance.   
1.20.3.  Structural significance of Lycorine. 
A recent publication in 2009 has shown that for lycorine to induce apoptosis, the free ring-
C 1,2-diol is required (McNulty et al., 2009); selective mono-silylation of the C-2 hydroxyl 
group, rendered lycorine biologically inactive.  It has been hypothesised that owing to the 
structural similarity of lycorine (shown in section 2.7; table 6) to pancratistatin, another 
Amaryllidaceae alkaloid, they may exert their activities via the same receptor (McNulty et 
al., 2009).  Certainly studies have shown that both alkaloids destabilise mitochondria 
(McLachlan et al., 2005, Evidente et al., 2009).  Nevertheless, further studies are required 
to firmly establish the mechanism of action of lycorine.   
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1.20.4. Lycorine and the mitochondria. 
Investigations in saccharomyces cerevisiae have demonstrated that cells lacking mtDNA 
(Davey et al., 1998) are unaffected by lycorine, whilst wild type (WT) cells are sensitive to 
the compound.  S. cerevisiae are able to survive in the absence of mtDNA by retrograde 
(RTG) signalling, in which some nuclear genes are altered to allow the cells to compensate 
for the resultant deficiency in respiration.  This signalling is mediated via RTG genes.  In 
2005 it was shown that S. Cerevisiae, expressing null alleles of RTG genes, recapitulated the 
inhibition of growth observed in the lycorine treated WT cells.   It is possible that, as 
mtDNA is easily damaged by ROS, which in turn renders the Krebs cycle inoperable 
(Skulachev, 2009), this is a mechanism of lycorine that would explain its lack of activity in 
cells without mtDNA.  In order to establish the mechanism of lycorine signalling, 
eukaryotic models should be investigated further.  
Despite the mechanistic action of lycorine being unknown, interest is growing in the use 
of this compound as therapy.  In 2009, Evidente et al (2009) identified lycorine as a novel 
lead for anticancer drug design and Jones et al (2009) have published the first successful 
study of its synthesis.  
1.21. Aims of this study. 
The central concept of this study was to determine whether the anti-tumour activities of 
BEZ and MPA observed by this group against BL (Fenton et al., 2003) can be successfully 
recapitulated in CLL cells.  In addition to investigating the effects of BEZ and MPA 
against peripheral CLL cells, the study also investigated their ability to overcome the 
protective effects of CD40L on CLL cells.   In the studies of these agents against BL, 
apoptosis was readily observed.  In addition to investigating BEZ and MPA, this study 
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also examined the anti-tumour activities of other promising agents in vitro and focused on 
DSN (based on recent publications) and lycorine.  
A central component of the studies herein has been the assessment of variable apoptosis 
between patient samples in response to the drugs alone, in combination and in the 
presence of current and potential therapeutics.  Apoptosis can be measured in vitro by 
several techniques such as the Δψm marker 5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1), fragmented DNA and the binding of 
annexin V (AV).  Since the measurement of apoptosis by AV has been met with some 
controversy it is worth considering here.  AV is a PL binding protein that has a high 
affinity for phosphatidyl serine (PS) that becomes exposed on the outer membrane during 
the early stages of apoptosis.   However, it has been noted that B cells that bind AV do not 
always go on to die (Holder et al., 2006).  Despite this, a study by Pepper et al into flow 
cytometric analysis of CLL cell apoptosis identified that, providing events are gated with 
caution, AV could sensitively distinguish between live and apoptotic cells (Pepper et al., 
1998).  In accord with this, many studies of CLL apoptosis utilise AV binding.  In this 
thesis, AV binding together with the uptake of propidium iodide (PI) has been extensively 
used, although the other markers were also used to confirm whether AV binding 
correlated with cell death. 
In the studies herein it is also demonstrated that CLL cells engaged with CD40L, using an 
in vitro system, undergo proliferation and protection.  The ability of BEZ and MPA to 
induce apoptosis in this system and reduce proliferation, by measuring the incorporation 
of tritiated (3H) thymidine (3H- thymidine) is investigated.   Further, the claims that DSN 
can overcome CD40L promoted survival are investigated and compared with treatment of 
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cells with BEZ+MPA+lycorine.  It is shown that the induced apoptotic cell death of BEZ 
and MPA of non-CD40L treated CLL cells is associated with the generation of MSO. In 
contrast, the failure of these drugs to induce apoptosis in CD40L-protected cells was 
reciprocally associated with a failure to induce MSO accumulation.  The ability of lycorine 
to reinstate this MSO response is investigated.  
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Unless stated otherwise, all chemicals were purchased from Sigma (Poole, U.K.) and all 
FC analyses were conducted using a FACSCalibur and Cell QuestPro software (BD, 
Oxford, U.K.). 
2.1. Patients’ and donors’ cells.  
Unselected patients with B-cell CLL attending the outpatient clinic at Birmingham 
Heartlands Hospital were recruited to the study.  The patients had been diagnosed 
according to standard morphologic, immunophenotypic and clinical criteria (Oscier et al., 
2004) and had provided informed written consent for the study which had received local 
ethical approval.  Normal donors were recruited following informed consent. 
2.1.1. Primary Cell purification. 
Blood samples were diluted 1 to 1 in RPMI (Invitrogen Gibco, Paisley, U.K.) 
supplemented 100U/ml penicillin, 100µg/ml streptomycin (Invitrogen Gibco).  Leucosep 
tubes (Greiner Bio-one, Gloucester, U.K), which have an inbuilt filter, were loaded with 
15ml ficoll paque plus (G.E Healthcare, Amersham, U.K.) and centrifuged at 1000xg for 1 
minute, to force the liquid below the filter.  The diluted blood was poured onto the 
leucosep filter prior to centrifugation at 1000xg for 10 minutes without the brake.  The 
mononuclear cells (MNCs) were visible as a band above the filter and were carefully 
pipetted, diluted 1:3 in RPMI (as above) and centrifuged at 374 x g for 10 minutes. The 
MNCs were subsequently washed twice more in RPMI prior to counting using a 
haemocytometer. 
2.1.2. Isolation of CD19+ve cells. 
For experiments using CD19+ve cells, MNCs were isolated as above (section 2.1.2) and 
washed three times in RPMI medium.  2x107 cells were washed in cold MACS buffer (see 
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buffers and recipes appendix) by centrifugation at 374 x g for 5 minutes.  The cell pellet 
was resuspended in 320µl cold MACS buffer and 80µl anti-CD19 MACS beads (Miltenyi 
Biotec, Surrey, U.K), prior to incubation for 15 minutes at 4ºC.  The cell suspension was 
then centrifuged as previous and the pellet resuspended in 0.5ml MACS buffer.  The cells 
were positively selected using a MACS column LS (Miltenyi Biotec) that was placed in the 
magnetic field of a MACS separator magnet (Miltenyi Biotec) and washed using 2ml 
MACS buffer.  The cell suspension was then added to the column and the negative 
fraction discarded.  The column was washed three times with 1ml MACS buffer, prior to 
removal from the magnet.  5ml MACS buffer was added to the column, the plunger firmly 
applied and the positive fraction collected in a 15ml tube.  The positive fraction was 
counted and the purity assessed by staining an aliquot with anti-CD19 antibodies and 
analysis using flow cytometry (see section 2.2.).  The remaining cells were pelleted, prior 
to resuspension at an appropriate density for experimentation.   
2.2. Analysis of cell phenotype using flow cytometry (FC)  
Following positive selection of CD19 cells, or where noted in the text, cell expression of 
phenotypic markers was carried out, using individual markers or a panel of markers from 
shown in table 3.  In each case, appropriate fluorophore isotypes were used to account for 
non-specific binding (BD, Oxford, U.K.).  
Staining was carried out on 3x105 cells made up to 200 µl final volume in phosphate 
buffered saline (PBS) (Invitrogen Gibco) and incubation with 2µl the appropriate 
antibodies at room temperature (RT) in the dark.  Cells were subsequently washed in 2ml 
PBS by centrifugation at 374 x g for 5 minutes, the supernatant was removed and the cells 
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resuspended in 300µl FACS fix (see buffers and recipes appendix).  This staining was 
analysed within two weeks. 
 
 
 
 
Antibody  Flurophore  Manufacturer 
Anti-CD19 PerCP BD 
Anti-CD7 FITC BD 
Anti-CD5 PE BD 
Anti-CD40 FITC BD 
Anti-CD154 PE BD 
Anti-CD11b FITC AbD SeroTec, Oxford, U.K.  
Anti-CD34 APC BD  
 
Table 3.  Details of antibodies used for phenotyping. 
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2.3. Maintenance of leukaemia cell lines. 
The ALL cell lines REH and Nalm6 were a kind gift from Dr Pamela Kearns (University of 
Birmingham).  The AML cell lines HL-60, KG1a and K562 were obtained from the Health 
Protection Agency cell bank.  All the cell lines were maintained in: RPMI 1640 (Invitrogen, 
Gibco) supplemented with 100U/ml penicillin, 100µg/ml streptomycin and 10% v/v foetal 
bovine serum (FBS)(all Invitrogen Gibco), from this point termed compete medium.  
Cultures were maintained at 37ººC with 5% CO2.  Cells were diluted 1 part in 3 parts when 
appropriate to 2.54x105 cells/ml, to maintain cells in exponential growth. 
2.4. L3-L-cells (stromal cells). 
2.4.1. Maintenance of L3-L cells.  
Murine L3- L cells, stably transfected with plasmids encoding CD40L (CD40 L -L cells), 
(Gagro et al., 2000)  as well as non-transfected L cells were a kind gift from Prof. John 
Gordon (University of Birmingham, U.K.) and were maintained at 37ºC with 5% CO2 in 
complete medium.  When 80-90% confluent, as assessed by microscopy, the media was 
removed, the cell monolayer washed with 10ml warm PBS and 2ml Trypsin EDTA added 
(Invitrogen Gibco).  Following incubation for 5 minutes, the now detached cells were 
repeatedly pipetted to produce a single cell suspension and 8 ml of media added.  1ml of 
this cell suspension was left behind with the addition of 10ml fresh RPMI.  The cells were 
routinely analysed for the expression of CD40L, according to section 2.2.  A representative 
plot of non-transfected L-cells and CD40L-transfected L cells is shown in figure 3. 
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Figure 3.  Example of analysis of expression of CD40L by L-control and CD40L 
transfected stromal cells.  3X105 cells were incubated with 2µL anti-CD40L (PE) and anti-
CD40 (FITC) for 15 minutes in the dark, prior to analysis by FC.  Plots shown are 
representative.  a) dot plots for L-control (right) and L-40 (left) stroma, CD40L is shown in 
FL-2 and CD40 in FL-1.  b) histogram overlay of expression of CD40L by L-control (purple) 
and L-40 (pink) stroma.    
 
Chapter Two - Materials & Methods 
 
 51 
 
 
2.4.2. Storage and recovery of cell lines in liquid nitrogen. 
Unless described differently in the text, 1x107 cells were harvested by centrifugation at 374 
x g for 5 minutes.  The supernatant was discarded, the cell pellet resuspended in 1ml 
freezing mix (see buffers and recipes appendix) and the mix transferred to a cryovial. 
Cells were slowly frozen by placing the vials in a sealed polystyrene container and 
incubating this at - 20ºC for 60 minutes and -80ºC overnight and stored in liquid nitrogen 
thereafter.  
To re-establish a culture, a frozen vial was thawed rapidly in hot water for 2-3 minutes.  
Cells were transferred to a 25ml universal and 0.5ml of cold complete medium added 
drop wise.  The cell suspension was allowed to stand for 1 minute before repeating this 
with 1, 2, 5 and 10ml.  This method gradually dilutes the freezing mix and prevents 
cellular apoptotic shock.  Subsequently, the cell suspension was centrifuged at 374 x g for 
5 minutes and the supernatant discarded.  The cell pellet was resuspended as described 
above for L-cells or for leukaemia cell lines in 2ml cold media, transferred to a 24 well 
plate and incubated at  37ºC with 5% CO2 until the cells had recovered sufficiently to be 
transferred into a 25cm2 flask and maintained as before.  
2.4.3. Mitomyocin C treatment of L-cells. 
Complete medium, containing 0.02M Mitomycin C (MC) (Sigma, Poole, U.K.) was 
prepared.  When L cells were 100% confluent, assessed by microscopy, the media was 
removed and replaced with the 0.02M MC media.  Cells were incubated for 3 hours, the 
monolayer washed 3 times in warm PBS (as before), trypsinised (as before) as above and 
counted.  Aliquots of 5x106 cells were frozen as described in section 2.4.2, to ensure that 
any remaining MC was destroyed. 
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2.5. Co-culture of primary cells. 
2.5.1. Co-culture of L-cells with CLL cells or CD19 sorted cells.  
L-cells either with or without CD40L were thawed from -80ºC as described previously.  
Cells were counted and resuspended at 1x105 cells/ml in complete medium.  L-cells were 
seeded in plates according to table 4.  For 96 well plates, only the inner wells were used, 
leaving the outer edges empty.  These wells were filled with 200µl PBS as a humidity 
barrier.  Cells were allowed to attach over night at 37ºC with 5% CO2. 
MNC, CLL cells or CD19+ve cells were diluted to 1x106cells/ml  in complete medium with 
the addition of 4x1ng/ml IL-4 (R&D systems, Oxford, U.K.) and seeded onto the stromal 
L-cells, according to table 5 and were allowed to settle over night at 37ºC with 5% CO2 
 
Number of wells/plate Cell volume (ml) Cell number 
96 0.1 1x104 
12 1 1x105 
6 2 2x105 
 
Table 4.  Seeding density of L-cells in different plate sizes. 
Number of wells/plate Cell volume (ml) Cell number 
96 0.05 1x105 
12 0.5 1x106 
6 1 2x106 
 
Table 5.   Seeding density of CLL cells in different plate sizes  
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2.5.2. Removal of cells from stromal support. 
Prior to analysis, the cells were removed from the stromal cells by repeated pipetting, 
creating a vortex using a P200 for 96 wells and a P5000 for larger wells.  To ensure that all 
the patient cells had been recovered, that the stroma was still intact, and that no CLL cells 
were under the stromal surface, all plates were assessed using phase-contrast microscopy.   
2.6. Cell line seeding for treatments.  
REH, Nalm6, HL-60, KG1a and K562 were maintained as in section 2.5).  For 
experimentation, cells were counted and REH and Nalm6 cells diluted to 1x106/ml, HL-60, 
KG1a and K562 diluted to 2.5x105/ml, in supplemented RPMI.  REH and Nalm6 were and 
seeded at 100µl (1x105) cells/well.  HL-60, KG1a and K562 were seeded in flasks at a 
minimum of 4ml/flask for Fe cylinder experiments and 10ml/flask for 3H-PGD2 
experiments.  Cells were treated as described below (section 2.7) and were analysed as 
denoted in the text.  
2.7. Treatments. 
2.7.1. Agent stocks.  
Concentrated stocks of each agent were made according to table 6 and stored at -20ºC. 
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Agent Stock concentration Solvent Structure 
BEZ 0.5M (1000X) DMSO 
 
MPA 5mM (1000X) Ethanol 
 
Chlorambucil 10mM (10000X) Ethanol 
 
15dΔ12,14PGJ2 35mM (1000X) DMSO 
 
PGD2 50mM (1000X) DMSO 
 
GW 9662 (Cayman 
Chemicals, Michigan, 
U.S.A) 
1mM (1000X) DMSO N/A- 
BW 868C (Cayman, 
Chemicals) 
21.8mM Ethanol  N/A- 
MFE 1mM Ethanol 
 
PRD 20mM (1000X) Ethanol 
 
ML-PRD 20mM (1000X) Ethanol 
 
SPN 4mM DMSO 
 
Hydrocortisone 4mM Ethanol 
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IDM 20mM(1000x) DMSO 
 
FLA 20mM (1000x) Ethanol 
 
Fe Cylinder 
(University of 
Birmingham) 
25mM  RPMI 
 
JA 1M (1000x) Ethanol 
 
MeJ 1M (1000x) Ethanol 
 
lycorine 10mM (10000X) Ethanol 
 
zVADfmk 
(Southampton, U.K.) 
50mM DMSO N/A- 
 
Table 6.  Compounds used experimentally to treat CLL cells.  Table shows concentration 
of stock, carrier solvent and chemical structure where appropriate.  
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2.7.2. Cell treatments. 
For 96-well plate experiments stocks were diluted to a working concentration of 4x in 
complete medium for CLL and purified CD19 cultures and 2 x for ALL cell lines.  The 
working stocks were added to the wells in 50µL and 100µl volumes for CLL/purified 
CD19 cultures and CLL/ALL cell lines respectively.  Following this final addition to CLL 
cell cultures, the IL-4 concentration was now 1ng/ml.  For larger plate or flask 
experiments, the appropriate drug treatments were added directly.  For PGD2 receptor 
antagonist experiments, cells were pre-treated overnight with 100nM BW 868C.  All 
treatments were set in triplicate.  Controls in every case were set up and denotes solvent 
control, containing the highest volume of carrier solvent used in the corresponding 
treatments. 
2.8. Assessment of cell proliferation and viability. 
2.8.1. Thymidine incorporation assay. 
3H-thymidine (G.E. Healthcare) was diluted to 20µCi/ml in RPMI supplemented as above 
and stored at 4oC.  Cells were incubated in 96-well plates with treatments for 60 hours 
prior to the addition of 20µl (0.4µCi ) and culture for a final 12-16 hours.  Subsequently, 
the plate was stored at -20ºC.  Samples were harvested to a filter mat (Wallac, 
Massachusetts, USA) using a Skatron cell harvester (Skatron Instruments, Bath, U.K.) and 
readings taken using a Beta-Plate scintillation counter (Skatron Instruments).  The mean 
thymidine incorporation of three treatments and the standard error of the mean (s.e.m.) 
calculated.   
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2.8.2. Cellularity/cell titre blue assay. 
At day 5, 20 µL cell titre blue cell viability assay reagent (Promega) was added to each 
well of a 96-well plate.  Following mixing, the plate was incubated for 4 hours at 37ºC, and 
subsequently, fluorescence was measured at an excitation of 530/25 nm and emission of 
595/35 nm on a KC4 fluorometer.  Fluorescence bears a direct relationship to cell viability 
in cultured cells. Background readings were assessed using wells containing medium 
alone, and these measurements were subtracted from readings obtained for samples. To 
account for differences in readings due to the different feeding regimens on days 2 and/or 
4, results were adjusted accordingly, to account for cells that were removed from the 
cultures. 
2.8.3. Cell cycle analysis. 
An aliquot of 3x105 cells were removed from the cell culture and made up to 1 ml in PBS 
(as before).  Following centrifugation at 374 x g for 5 minutes the supernatant was 
removed and 500µL cell cycle buffer (see buffers and recipes appendix) added.  Cell 
suspension was vortexed and stored, in the dark at 4ºC for 24 hours prior to analysis.  
2.9. Analysis of cell death. 
2.9.1. AV/PI staining. 
Single AV and co-AV/PI positivity was assessed by FC following staining using an AV 
FITC kit (BD) on pooled triplicate wells, according to manufacturer’s instructions.  Briefly, 
the cells were harvested and pooled in a FACS tube and 1ml cold PBS, containing Mg and 
Ca (Invitrogen, Gibco) added.  Cells were centrifuged for 5 minutes at 374 x g. The 
supernatant was removed and cells resuspended in 100µl 1x AV binding buffer and 5µl 
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each of AV FITC antibody and PI stain, prior to incubation at RT in the dark for 15 
minutes.  Staining was analysed within one hour.  
2.9.2. Assessment of Δψm and Apoptosis by JC-1. 
The Δψm was measured by JC-1 (Sigma) and FC.  The JC-1 was dissolved at 1mg/ml in 
DMSO (Sigma) and stored at -20ºC.  Following treatment, CLL cells from triplicate wells 
were transferred from the stroma, pooled and washed in 1ml warm PBS.  Cells were 
centrifuged, supernatant removed and the cell pellet resuspended in 500 µl warm PBS 
containing 2.5µg/ml JC-1 and incubated for 30 minutes at RT.  Staining was analysed 
within 1 hour.  
2.9.3. Assessment of Caspase cleavage. 
As a positive control, 1µM staurosporin (Sigma) treatment was carried out for 12 hours for 
each patient sample.  Caspase cleavage was analysed using CaspaTag assay Kit 
(Millipore, Watford, U.K.), a pan-caspase in situ assay kit on pooled wells according to 
manufacturer’s instructions.  Briefly, the methodology is based on cell permeable and 
non-cytotoxic, fluorochrome inhibitors of caspases (FLICA) and a sulforhodamine-
labelled fluoromethyl ketone peptide inhibitor of caspase (SR-VAD-FMK), which 
produces a red fluorescence.  On entering the cell, the FLICA binds covalently to the 
active caspase.  The SR-VAD-FMK probe is then added and covalently binds to a reactive 
cysteine residue that resides on the large subunit of the active caspase heterodimer, 
thereby inhibiting further enzymatic activity.  The bound labelled reagent is retained 
within the cell, while any unbound reagent will diffuse out of the cell and is washed 
away.  The red fluorescent signal measured by FC is a measure of the amount of active 
caspase present in the cell at the time the reagent was added. 
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2.10. Investigations into oxidative stress.  
2.10.1. Assessment of accumulation of Reactive Oxygen Species (ROS).  
Carboxy-H2DCFDA (H2DCFDA) (Invitrogen Molecular Probes, Paisley, U.K) binds to all 
ROS and was dissolved in DMSO to yield a 2000x stock, of 10µM.  This was aliquoted into 
10µl volumes and was stored under nitrogen at -20oC.  Immediately prior to use, a 5µM 
working dilution was made in warm PBS (Invitrogen Gibco). The media in each well was 
carefully removed, without disturbing the cells and was replaced with 200µl of the 
working stock and incubated at 37oC for 40 minutes. Following incubation, appropriate 
wells were pooled into FACS tubes and immediately analysed.  
2.10.2. Assessment of accumulation of Mitochondrial Superoxide (MSO). 
MitoSOX Red (Invitrogen Molecular Probes, Paisley, U.K) was used to assess the presence 
of MSO on pooled triplicate wells, according to manufacturer’s instructions.  Briefly, 
triplicate wells were pooled, 1ml of warm PBS added and centrifuged at 374 x g for 5 
minutes.  The supernatant was removed and a vial of MitoSOX Red was diluted in 13µl of 
DMSO to yield a 10mM stock.  A working stock of 10µl MitoSOX Red was prepared in 
warm PBS (Invitrogen Gibco) and this was added to the cells, prior to incubation at 37OC 
for 10 minutes.   
2.11. mRNA analysis: Quantitative real-time polymerase chain reaction (QRT-PCR). 
2.11.1. RNA extraction. 
RNA was extracted from a pellet of 1x106 cells using a Qiagen RNeasy mini kit (Qiagen, 
Crawley, U.K.) according to the manufacturer’s instructions.  Briefly, cells were 
resuspended in 350µl buffer RLT (plus β-mercaptoethanol; Sigma). The sample was then 
homogenised using a QIAshredder spin column.   One volume of 70% ethanol (Fischer 
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Loughborough, U.K.) was added to the homogenised sample and 700µl of this mixture 
added to an RNeasy mini column.  The column was centrifuged for 15 seconds at 
14,000 rpm in a microfuge.  Further DNA removal was carried out using the RNase-free 
DNase set.  350µl buffer RW1 was added to the column and the column centrifuged for 
15 seconds at 14,000 rpm in a microfuge.  The DNase I stock solution was added to buffer 
RDD according to manufacturer’s instructions and 80µl of this mix added to the column 
and incubated for 15 minutes at room temperature. 350µl buffer RW1 was added to the 
column and the column centrifuged for 15 seconds at 14,000 rpm in a microfuge.  Buffer 
RPE (500µl) was added to the column and centrifuged for 15 seconds at 14,000 rpm in a 
microfuge.  Another 500µl RPE was applied to the column prior to centrifugation for 
2 minutes at 14,000 rpm in a microfuge.  The RNeasy column was transferred to a 1.5ml 
collection tube, RNA eluted with the addition of 30µl RNase-free water and centrifugation 
for 1 minute at 14,000 rpm in a microfuge, and the RNA stored at - 20ºC.  
2.11.2. RNA quantification. 
RNA samples were diluted 1 part to 50 parts RNase-free water (Invitrogen Gibco) in a 
total volume of 100µl.  The absorbance at 260nm was measured at OD 260 and the RNA 
concentration calculated using the following equation: 
RNA concentration (µg/µl) = (OD260 x 40 x dilution factor)/1000. 
2.11.3. Reverse transcription. 
cDNA was produced from 100ng RNA using reverse transcription.  Unless stated 
otherwise, all constituents were obtained from Invitrogen (Paisley, U.K.) and the 
procedure carried out as follows: 1µl of both random primers (Promega) and dNTPs 
(Bioline, London, U.K.) were added to 100ng RNA, the volume made up to 12µl with 
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DNase RNase-free water (Invitrogen Gibco), and the mix heated to 65oC for 5mins, 
transferred to ice and centrifuged for 15 seconds at 14,000rpm in a microfuge.  A master 
mix was made as 1 x mix of the following: 1x buffer, 0.1M DTT, RNase Out (Promega) and 
Superscript:  After centrifugation, 8µl of master mix was added to the RNA, primer, 
dNTP mix.  The mix was incubated at 25ºC for 10 minutes, 42ºC for 90 minutes and 70ºC 
for 15 minutes in a thermocycler.  
2.11.4. β-actin PCR. 
To assess that the RT reaction had worked, PCR reactions for β-actin were performed.  
The sequence of these primers is as follows: 
Forward 5’ GTCACCAACTGGGACGACA  3' 
Reverse 5’ TGGCCATCTCTTGCTCGAA  3' 
The 1x reaction mix was set up as follows: Taq buffer, primers (33µM), dNTP's (10mM), 
MgCl2 (50mM), Taq polymerase, cDNA and DNase RNase-free water to 50µL.  The PCR 
cycle included an initial denaturation step (95ºC for 2 minutes) followed by 38 cycles of 
94ºC for 20 seconds, 55ºC for 30 seconds and 72ºC for 60 seconds, followed by a final 
incubation at 72ºC for 5 minutes.  Subsequently, 6µl was mixed with 2µl 10x DNA gel 
loading buffer (Bioline), loaded onto a 1% agarose gel and electrophoresed in 1xTBE (see 
Appendix A1) at 60V for 45 minutes.   β-actin products were visualised under UV 
transillumination. 
2.11.5. Real-time PCR.  
2.11.5.1. Measurement of AKR1C gene expression. 
Reactions were performed using an ABI Prism 7700 sequence detector (Applied 
Biosystems) using an 18S ribosomal RNA internal standard kit.  Gene specific primers 
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were synthesized by Alta Bioscience (University of Birmingham) for AKR1C3 or Sigma 
Genosys (Sigma, Dorset, U.K.) for AKR1C1, 1C2 and 1C4, and all probes were synthesised 
by Eurogentec (Southampton, U.K.).  Thermocycler conditions were 50ºC for 2 minutes, 
95ºC for 10 minutes, followed by 44 cycles of 95ºC for 15 seconds and 60ºC for 1 minute. 
Each AKR1C reaction contained 900 nM gene specific 5’ and 3’ primers, 1X MasterMix 
(containing pre-optimized dNTPs, MgCl2 and buffer concentrations; (Applied Biosystems, 
Warrington, U.K.), 125nM gene specific probe (5’-6-FAM, 3’-TAMRA labelled) and cDNA 
(1 µl) in a total volume of 20 µl with dH2O.  
Control 18 S reactions contained 50nM 18S 5’ and 3’ primers, 200nM 18S probe (5’-VIC, 3’-
TAMRA labelled) (Applied Biosystems) and cDNA in a total volume of 20 µl. Reactions 
were performed in triplicate.  
AKR1C3 primers and probes were designed and optimised for use by Dr. Farhat  Khanim 
and are shown in table 7.
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AKR1C Forward sequence 5’ Reverse sequence 5’ 
 
Probe. 5’6’-FAM Product 
(base 
pairs) 
1 CCTAAAAGTAAAG
CTTTAGAGGCCAC
C 
GAAAATGAATAA
GGTAGAGGTCAA
CATAAT 
CGGAAGCCAGCTT
CAATTGCC-TAMRA 
 
268 
2 CCTAAAAGTAAAG
CTCTAGAGGCCGT 
GAAAATGAATAA
GATAGAGGTCAA
CATAG; 
GGCAATAGAAGCC
GGGTTCCAC-
TAMRA 
258 
3 GGGATCTCAACGA
GACAAACG 
AAAGGACTGGGT
CCTCCAAGA 
TGGACCCGAACTC
CCCCGGTG-TAMRA 
268 
4 CGAGGAACAGAGC
TGTAGAGGTCAC 
GAGAGCCATTGG
GAAATGAAGA 
CGGAAGCCAGCTT
CTATTGCTAATTTG-
TAMRA 
 
277 
 
Table 7.  Sequences of primers and probes used for QRT-PCR. 
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2.11.5.2. Q-PCR data analysis. 
Q-PCR data was first analysed using ABI Prism 7000 software (Applied Biosystems) 
according to manufacturer’s guidelines. Briefly, cycle threshold (CT) values were 
determined for both 18S internal control and gene of interest in each sample by placing a 
threshold line over the exponential phase of the PCR cycle profiles. The average CT values 
were calculated from the duplicates. The 18S internal control value was then subtracted 
from the value for the gene of interest to give ΔCT values.  K562 was analysed in parallel 
as a positive control.  The K562 ΔCT value was subtracted from sample ΔCT values to 
give ΔΔCT values. This value was converted to fold change in gene expression relative to 
control using the equation: fold change=2-ΔΔCT, and fold change converted to percentage 
expression relative to control via multiplication by 100. The average and standard error of 
the mean of samples was calculated. 
2.12. Prostaglandin D2 Enzyme-linked immunosorbent assay (ELISA).  
Cells were cultured as described in section 2.5. and treated in 6 well plates as described in 
section 2.7. for 6 hours.  Subsequently, cells were harvested along with 1ml of supernatant 
removed prior to centrifugation. Cell pellets were resuspended in appropriate retained 
medium followed by homogenisation using a Precellys 24 ceramic bead based 
homogenisation system (Omni International). Cell homogenates were incubated on ice for 
5 minutes with 1ml ice cold acetone prior to centrifugation at 3000xg for 20 minutes. 
Supernatant was removed and kept on ice. A further 0.5ml ice cold acetone was added to 
homogenised pellet followed by further centrifugation. The subsequent supernatant was 
pooled with that from the first centrifugation step and kept at - 80ºC until use. PGs were 
extracted using C18 reverse phase extraction columns (Chromabond) and all assay 
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specific reagents for PG D2-MOX EIA kit (Cayman Chemicals) were prepared and PG 
levels determined according to manufacturer’s instructions. 
2.13. Analysis of PGD2 and DHT metabolism by thin layer chromatography (TLC). 
2.13.1. Cell incubation with tritiated (3H)-PGD2. 
If pre-treatment was required, as denoted in the text, cells were seeded as described in 
section 2.5. and treated as described in section 2.7. overnight.  Subsequently, cells were 
cultured as 200µl cultures in 96 well plates at 2x106 cells/well (1x107 for experiments 
analysing cells only) in PBS (Invitrogen Gibco), with 0.2µCi of 3H-PGD2 (Amersham) for 9-
18 hours.  Following incubation, the suspension was centrifuged at 14,000 rpm using a 
microfuge.  The cell pellet and supernatant were stored separately at -20ºC.   
2.13.2. Extraction and visualisation of prostanoids. 
Prostanoids were extracted from the supernatant by: the addition of 0.5ml methanol 
(Fischer) and 2.5µL 10%(v/v) formic acid (Sigma) and vortexing, before the addition of 
1ml of chloroform and 50µl 4.2% (w/v) KCL (Sigma) and from cell pellets by: 
resuspension in 1 ml 50% methanol and vigorous vortexing prior to the addition of 2.5µL 
10%(v/v) and vortexing for a further 2 minutes.  The cell suspension was pelleted at 14,000 
rpm in a microfuge, for 2 minutes and the supernatant transferred to borosilicate glass 
culture tubes.  To either the supernatant or the cellular extract mix, 2ml dichloromethane 
(Fischer) and 100µl 4.2% (v/v) KCL (Sigma) was added and vortexed for 3 minutes.  The 
mixed suspensions were then centrifuged at 374xg for 15 minutes.  The proteinaceous and 
aqueous layers were removed by aspiration and discarded.  The remaining sterol-
containing fraction was evaporated to dryness under a stream of nitrogen prior to being 
re-dissolved in 70µl methanol and applied to Silica gel TLC plates (Fluka).  A solvent 
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mixture of 90:8:1:0.8 chloroform, methanol, glacial acetic acid (all Sigma) and distilled 
water was prepared and left to equilibrate in TLC tanks.  The prostanoids were separated 
by incubation in the tank for 3 hours and, once dry, were read on a Bioscan AR-2000 plate 
reader. The migration of prostanoids was identified by their co-migration with known 
standards as revealed by incubation in iodine vapour. 
2.13.3. Cell incubation with 3H-5α-DHT.  
To measure steroid activity, cells were seeded in 24 well plates, according to table 5 with 
the addition of 1µCi 3H- 5α-DHT (Amersham) and incubation of 18 hours.  Following 
incubation, cell supernatants were harvested and stored at - 20 ºC.   
2.13.4. Extraction and visualisation of sterols. 
To extract sterols, the supernatants were thawed, transferred to borosilicate glass culture 
tubes and 5ml of dichloromethane (Fisher Scientific) added.  The mixture was vortexed 
for 5 minutes prior to centrifugation at 374g for 15 minutes.  The resulting aqueous and 
proteinaceous layers were removed by aspiration and discarded.  The remaining, sterol 
containing chloroform fraction was evaporated to dryness under a stream of air at 55ºC.  
The sterols were re-dissolved in 80µl of dichloromethane and applied to Silica gel TLC 
plates (Fluka).  A solvent mixture of 1:4, n-hezane:hexanol (both Fischer) was prepared 
and left to equilibrate in sealed TLC tanks.  The sterols were separated by incubation in 
the tank for 3 hours, prior to being read on a Bioscan AR-2000 plate reader. 
2.14. Protein analysis: western blotting. 
2.14.1. Protein extraction and quantification. 
For protein extraction, 1x106 cells were resuspended in 50 µl RIPA buffer (see Appendix 
A1), supplemented with 1X protease inhibitor (Sigma), and incubated for 30 minutes on 
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ice prior to centrifugation at 14,000rpm at 4oC for 10 minutes in a microfuge.  The 
supernatant was transferred to a 1.5ml centrifuge tube and frozen at -20ºC. 
For protein quantification, the Dc protein assay protocol (Bio-Rad, Hemel Hempstead, 
U.K.). was followed according to manufacturer’s instructions.  Briefly, 5µl BSA standards 
(0, 0.625, 1.25, 2.5, 5 and 10mg/ml) were added to duplicate wells of a 96 well plate and 
2µl of each protein sample was added to 3µl distilled water in replicate wells. 20µl 
reagent S was added to each ml of reagent A required to make solution ‘A’, and 25µl A’ 
added to each well. 200µl reagent B was then added to each well, the wells mixed, and the 
reaction allowed to develop for 15 minutes before the optical density was measured at 
645nm using a plate reader.  
2.14.2. Sample preparation and protein separation by sodium doecyl sulphate –
polyacrylamide gel electrophoresis (SDS PAGE). 
Protein samples (20-40µg) were mixed in a 3:1 ratio with 4x SDS gel loading buffer (see 
buffer and recipes appendix), heated to 100ºC for 10 minutes in boiling water.  A 10% 
resolving gel mix was prepared (see Appendix A1) and allowed to fully polymerise at RT 
for 40 minutes prior to the addition of the stacking gel; prepared according to the 
Appendix A1. 
Protein samples, and 5µl pre-stained precision dual stained markers (Bio-Rad) were 
loaded onto the gel and electrophoresed at 150V with 1x SDS gel running buffer for 90 
minutes.   
2.14.3. Protein transfer. 
PVDF membrane (Millipore, Watford, U.K.) was soaked in methanol (Fischer) for 15 
seconds, dH2O for 2 minutes and equilibrated in transfer buffer (see Appendix A1) for 10 
minutes.  Semi-dry transfer was carried out using four layers of pre-transfer buffer-soaked 
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3mm paper (Fischer) on the cathode and anode and the transfer was carried out using a 
Mini-Protean transfer tank (Bio-Rad) at 25V for 1 hour. 
2.14.4. Immunodetection of proteins. 
The membrane was rinsed in TBS-T (see buffer and recipes appendix) and then blocked 
for 45 minutes in 5% blocking solution (see Appendix A1).  Primary mouse anti-human 
AKR1C3 antibody (Sigma) was diluted 1 in 1000 in 5% blocking solution and the 
membrane incubated overnight at 4ºC with rocking.  The membrane was washed three 
times for 5 minutes in TBS-T, the secondary antibody (horseradish peroxidase (HRP)) 
conjugated rabbit anti-mouse, (Sigma) diluted 1 in 1000 in 5% blocking solution and the 
membrane incubated for 45 minutes in this solution at RT, with rocking.  The membrane 
was washed as above and signal developed using Supersignal West Pico 
Chemiluminescent substrate (Pierce, Northumberland, U.K.) and signal detected by 
exposure to Xomat scientific imaging film (Kodak, Sigma) for 5 minutes. Films were 
developed using an AGFA CURIX 60 (Agfa, Mortsel, Belgium).  Equal loading was 
checked using mouse anti-human β-actin antibody (Sigma) and secondary rabbit anti-
mouse following the same protocol (dilutions 1 in 10,000 for each).  
2.15. Statistical analysis. 
Data are reported as mean values and their standard deviation (s.d.) or standard error of 
the mean (s.e.m.) as stated. 
2.15.1. Statistical analysis of patients’ drug responses. 
These statistics were carried out by Dr J Delgado at the University of Barcelona. Briefly, 
one-factor within subjects’ analysis of variance was used to assess drug responses. 
Homogeneity of variance was assessed by the Mauchly sphericity test. When data sets 
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significantly violated this requirement, the Greenhouse-Geissler test was used to calculate 
a more conservative P value for each F ratio. Partial eta-squared (ηp2) was used to measure 
the size of the statistical association, and pair-wise comparisons were adjusted according 
to the Bonferroni method. 
Several CLL prognostic factors were analysed for their association with in vitro drug 
responses using the Mann-Whitney test. Drug responses were measured as drug/control 
ratios. CLL prognostic factors included Binet stage (A vs B/C), lymphocyte doubling time 
(< vs > 12 months), ZAP-70 expression (negative vs positive), CD38 expression (negative 
vs positive), IgVH mutation status (mutated vs unmutated) and cytogenetics (normal vs 
abnormal). Statistical analyses were performed using SPSS, version 14. 
2.15.2. Statistical analysis of experiments. 
Unless stated otherwise in the text, statistical analyses shown were calculated using the 
McNemar and Wilcoxon tests in SPSS, version 14.  
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3.1. Introduction  
This chapter describes the effects of BEZ, MPA and BEZ+MPA on both the quiescent 
peripheral and the proliferating CLL cells.  The proliferative signal was generated using a 
stroma of L-cells stably transfected with CD40L, to mimic the PCs.   For the quiescent 
counterparts, the CLL cells were also co-cultured with stromal L-cells but without 
expression of CD40L, providing a support but not driving proliferation.  In both systems 
IL-4 was added (to a concentration of 1ng/ml).  A schematic of this system was shown in 
figure 1. 
The effects of BEZ and MPA, both individually and in combination, were assessed for the 
induction of apoptosis in both the absence and presence of CD40L, and for anti-
proliferative activity when CD40L was present.  Having established the effectiveness of 
these agents against unpurified CLL cells, their ability to target malignant B cells, their 
effects on normal B-cells and their use, compared to the commonly used 
chemotherapeutic, chlorambucil, was investigated (Oscier et al., 2004). 
All of the work presented in this chapter was published in 2009 by Macmillan Publishers 
Ltd.  The full details of this manuscript can be found in Appendix A2. 
 
Chapter Three - Effects of BEZ & MPA on Peripheral and ‘PC’ CLL Cells 
 
 72 
 
3.2. The assessment of BEZ and MPA on quiescent CLL cells 
3.2.1.  BEZ and MPA induce apoptosis in non-proliferating CLL cells.  
The previous study using BEZ and MPA, against BL cells (Fenton et al 2003) utilised doses 
of 0.5mM BEZ and 5µM MPA.  Therefore, these doses were chosen for initial experiments 
to test their effectiveness against CLL cells.  Single agents and the combination of 
BEZ+MPA were used against CLL cells on non-CD40L expressing stroma and 
subsequently tested for the induction of apoptosis at 24 hours as measured by AV and PI 
co-incubation.  Cells in the early stages of apoptosis will lose membrane asymmetry, 
which causes PS to be exposed on the cell surface to which AV can then bind (Koopman et 
al., 1994).  In vivo this process signals for macrophages to remove the apoptosing cell.  At 
later stages of cell death, the cells lose plasma membrane integrity, allowing dyes such as 
PI to accumulate (Ormerod et al., 1992).  Although this would not normally occur in vivo 
until the cell has been phagocytised by a macrophage, in vitro cells incur membrane 
damage causing the accumulation of PI (Pepper et al., 1998).  The response of a single CLL 
sample to BEZ, MPA and the combination, of BEZ+MPA, as measured by this assay are 
shown in figure 4.  Both BEZ and MPA induced apoptosis but the combination generated 
greater apoptosis than either agent alone (figure 4).  This data is commensurate with that 
of the BL study (Fento et al., 2002).   
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Figure 4.  BEZ, MPA and BEZ+MPA treated cells have reduced viability, bind AV and 
accumulate PI in the absence of CD40L.  CLL cells were cultured on non-CD40L 
expressing stroma in a ratio of 10:1 in 96 well plates.  Treatments of either solvent control, 
0.5mM BEZ, 5µM MPA or BEZ+MPA were performed in triplicate for 24 hours, prior to 
harvesting and staining with AV and PI and analysis by FC.  a) Lower left (LL) quadrant 
shows viable cells, lower right (LR) indicates cells in early stages of apoptosis, upper right 
(UR) is indicative of late apoptosis. Total AV staining was calculated by adding the events 
in the LR with those in the UR in further experiments.  b) FSC/SSC analysis: gate indicates 
viable events.  The plots are representative of n=>50 experiments. 
a b 
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However, as it has been reported that AV positive B cells do not always go on to die 
(Holder et al., 2006) further measures of apoptosis were employed.  As cells become 
apoptotic they reduce in size and increase in granularity.  This change can be detected by 
FC, by a shift from right to left in forward scatter (FSC) and bottom to top in side scatter 
(SSC).  Such a shift is shown in figure 4; as the cells lose viability with treatment, the 
number of events visible in the viable drawn gate decrease.  As a further measure, the 
Δψm marker, JC-1, was used as an additional marker of apoptosis in a subset of patients.  
Viable cells have high Δψm, in the presence of which JC-1 spontaneously forms 
aggregates detected by red fluorescence.  In apoptotic cells, Δψm lowers; and the JC-1, 
stays as a monomer which is detected by green fluorescence (Green and Reed, 1998).  
Figure 5 shows a clear induction of apoptosis by either agent but overall the combination 
of BEZ+MPA gives greater Δψm depolarisation.  This data is in accordance with the PI 
and AV positivity and the remaining cell viability by FSC/SSC shown in figure 4, 
therefore, it was concluded that AV positivity reflects true apoptosis.  Consequently, this 
assay was chosen as the main measure of apoptosis for further experiments.  Total 
percentage of AV positivity was calculated by the addition of the AV positive PI negative 
events in the LR to those with dual AV and PI positivity in the UR (figure 4).  This 
analysis portrays cells in both early and late stages of apoptosis. 
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Figure 5.  Cells treated with BEZ, MPA and BEZ+MPA show Δψm depolarisation in the 
absence of CD40L.  CLL cells were cultured on non-CD40L expressing stroma in a ratio of 
10:1 in 96 well plates.  Treatments of either solvent control, 0.5mM BEZ, 5µM MPA or 
BEZ+MPA, were performed in triplicate for 24 hours, prior to harvesting and staining 
with JC-1 and analysis by FC.  Plots were gated on FSC and SSC to show viable (R1) and 
non-viable (R2) regions.  The regions are translated onto the FL-1/FL-2 plots.   Events 
captured in the FL-2 region (red dots) indicate Δψm is preserved whereas those captured 
in the FL-1 channel (green dots) highlight aggregation of JC-1, indicative of a loss of ∆ψm.  
The plots shown are representative of n=10 patients. 
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3.2.2. BEZ and MPA exert pro-apoptotic effects in a dose dependent manner.  
Whilst the doses shown in figures 4 and 5 show similarity with those of the BL study, a 
two-fold dose titration of the single agents was carried out to establish their effectiveness 
at lower and higher concentrations.  Total AV positivity measured at 24 hours (figure 6) 
showed similar results to those observed in BL; apoptosis induced by MPA essentially 
plateaued beyond 5µM and a similar level of apoptosis was observed in response to 
0.5mM BEZ.  Subsequent experiments used 5µM MPA and 0.5mM BEZ either as single 
agents or in combination.  The pertinence of these doses for potential in vivo treatment of 
CLL is addressed in chapter 6.  
3.2.3. Induction of CLL cell apoptosis by BEZ and MPA is time-dependent. 
The experiments described to this point were all analysed at 24 hours.  To determine the 
time dependency of drug induced apoptosis, CLL cells from 4 patients were treated with 
solvent control or BEZ+MPA and analysed for total AV positivity and Δψm 
depolarisation at 7, 24, 48 and 72 hours (figure 7).  It is important to note that this set of 
experiments was conducted using CLL cells that had previously been frozen and stored at 
-80ºC.  Upon thawing, the cells were plated immediately on to stroma and allowed to 
settle for a few hours before treatment.  Analysis at 7 hours, showed a high level of 
apparent apoptosis in the solvent control treated cells, as measured by AV (figure 7, top 
graph, black circles).  This level of apoptosis was not observed with the JC-1 staining.  
Furthermore, at 24 hours the levels of total AV positivity was reduced from a mean of 
60% to 22%.  
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Figure 6.  Dose titration of BEZ and MPA as single agents show induction of apoptosis 
at doses commensurate with those seen against BL cell lines.  CLL cells were cultured 
on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates and were treated with 
solvent control and either MPA (top) or BEZ (bottom) in a 2-fold dose escalation (1.25µM-
10 µM MPA and 0.125-1 mM BEZ) for 24 hours.  Samples were analysed for the binding of 
AV and uptake of PI using FC.  Data are the mean ± s.e.m. of n=7 patients. 
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Figure 7.  The BEZ+MPA effect peaks at 24-48 hours.  CLL cells thawed from - 80ºC were 
cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates. Treatments of 
either solvent control or BEZ+MPA were performed in triplicate and were harvested and 
pooled at 7, 24, 48 and 72 hours and assessed for a) the binding of AV and uptake of PI 
and b) Δψm depolarisation using JC-1, and analysis by FC.  Plots shown are the mean ± 
s.e.m. from n=4 patients.  
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Overall, this suggests that, at seven hours, the majority of freshly thawed CLL cells had PS 
exposed on the surface membrane but that they recovered and did not go on to die.  The 
24 hour time point, with the reduced total AV positivity, is more in line with the overall 
control apoptosis levels seen throughout the rest of the experiments and for this reason all 
further experiments did not utilise frozen stored cells.  Compared to controls, at 24 hours, 
BEZ+MPA showed a high induction of apoptosis (mean values, 22% to 72% for total AV 
and 19% to 43% Δψm depolarisation).  This level of apoptosis was not significantly 
different at 48 hours (mean values 19% to 81% total AV and 16% to 58% for Δψm 
depolarisation).  These data (figure 7) therefore indicate that BEZ+MPA treatment induces 
apoptosis that peaks between 24 and 48 hours.  For subsequent experiments, a time point 
of 24 hours post treatment was chosen for analysis of apoptosis.  
3.2.4. Analysis of 28 consecutively acquired and treated CLL cells show diverse 
responses.  
Figure 8 depicts the responses to BEZ, MPA and BEZ+MPA in the presence of control L-
cells of 28 consecutively acquired CLL samples, the patient characteristic for which are 
shown in table 8.  In the case of induced apoptosis, the box plot (figure 8) indicates 
significant increases caused by both drugs when used alone.  However, the stronger 
response is the BEZ+MPA drug combination, commensurate with the plots shown in 
figures 4 and 5. 
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Figure 8.  Patients have a variable response to BEZ, MPA and BEZ+MPA  Box plots are 
shown for n=28 consecutively acquired patients cells cultured on non-CD40L expressing 
stroma in a 10:1 ratio, and treated with solvent control, 5µM MPA, 0.5mM BEZ or 
BEZ+MPA for 24 hours and analysed for the binding of AV and uptake of PI using FC.  
Line in box indicates median value; bottom line and top line of each box show 25th and 
75th centile respectively, the bottom and top whiskers correspond to 10th and 90th centile; 
circles represent outliers.  
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Factor Output Percentage 
Gender Male 57 
 Female 43 
Stage A 71 
 B 29 
LDT < 12 months 48 
 >12 months 52 
CD38 Negative 68 
 Positive 14 
 Not Analysed 18 
ZAP-70 Positive 27 
 Negative 27 
 Not Analysed 46 
Genetic analysis Normal 46 
 ATM 4 
 Trisomy 4 
 Other 7 
 Not analysed  39 
IgHV Mutated 54 
 Unmutated 17 
 Not Analysed 32 
 
Table 8.  Patient characteristics of 28 consecutively acquired samples.  The factors 
shown are for patients’ samples shown in figures 8 and 19. 
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Detailed statistics were carried out on these results by statistician Dr J Delgado.  These 
statistical tests showed that the drug effects were real and also genuinely large.  Pair-wise 
comparisons identified that BEZ, MPA and BEZ+MPA increased apoptosis compared to 
controls (P = 0.001, P = 0.002 & P < 0.001 respectively).  There was no overall difference in 
apoptosis induction either by BEZ or MPA (P = 1) but the combination was more effective 
than either drug alone (both P < 0.001).  It is important to note that within these samples 
the responses displayed by individuals showed high variability (figure 9).  Whilst some 
samples displayed responses that typified the summated response, depicted by the box 
plot, others seemed to show apparent synergy; with the individual drugs having minimal 
effects and the combination giving a large effect.  In a few samples neither the single 
drugs nor the combination had much effect on apoptosis (figure 9). 
3.2.5. Treatment of BEZ+MPA can induce caspase activation but when inhibited this 
does not prevent the cells from apoptosis.  
Induction of apoptosis is tightly regulated.  Caspases are proteolytic enzymes, involved in 
classical apoptosis.  These enzymes participate in a series of reactions that result in the 
cleavage of protein substrates, causing the disassembly of the cell.  Following the 
observations of BEZ+MPA inducing apoptosis in CLL cells, eight patient samples were 
investigated for drug induced activation of caspase cleavage.   
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Figure 9.  Based on the patient’s response to BEZ and MPA, the BEZ+MPA response can 
be divided into four categories.  Chronological plot of 17 patients cells cultured on non-
CD40L expressing stroma in a 10:1 ratio and treated with solvent control, 5µM MPA, 
0.5mM BEZ or BEZ+MPA, for 24 hours and analysed for the binding of AV and uptake of 
PI using FC.  Coloured ovals highlight variability of response into 4 categories.  
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Staurosporin, a known inducer of caspase activation (Giuliano et al., 2004), was used at 
1µM as a positive control in four of the patients analysed.  CLL cells were treated as 
described in the preceding experiments and, subsequently, stained with CaspaTag that 
utilises SR-VAD-FMK, which recognises all activated caspases intracellularly as described 
in detail in section 2.9.3.  Figure 10 shows four patients treated with solvent control, 
staurosporin or BEZ+MPA.  Each patient showed variation in both staurosporin and 
BEZ+MPA induced caspase cleavage.  In one sample, the cleaved caspase percentage was 
similar upon both staurosporin and BEZ+MPA treatment whilst in the others, 
staurosporin tended to be the stronger inducer of caspase activation.  Overall, some 
degree of BEZ+MPA induced caspase was observed in 5 out of the 8 samples (figure 10). 
In an attempt to demonstrate that the apoptosis observed as a result of BEZ+MPA 
treatment was due to caspase-dependent apoptosis, the pan-caspase inhibitor N-
benzyloxycabonyl-Val-Ala-Asp-fluoromethylketone (zVADfmk) (King et al., 1998) was 
used, at a dose of 50µM.  CLL cells were pre-treated with zVADfmk for 1 hour prior to 
treatment with BEZ, MPA or BEZ+MPA.  Total AV positivity at 24 hours (figure 11) 
identified identical levels of apoptosis between cells treated with or without the caspase 
inhibitor. 
Together, these data indicate that although caspase activation can be seen, overall the 
apoptosis induced by BEZ, MPA or BEZ+MPA may be independent of caspases.   
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Figure 10.  Treatment with BEZ+MPA induces caspase cleavage in some but not all  
patient samples.  CLL cells were cultured on non-CD40L expressing stroma in a ratio of 
10:1 in 96 well plates.  Triplicate treatments of either solvent control (left; black fill), 1µM 
staurosporin (middle; green line) or BEZ+MPA (right; purple line) were harvested and 
pooled at 24 hours and incubated with CaspaTag Pan-Caspase In Situ Assay Kit  (using 
SR-VAD-FMK), prior to being analysed by FC.  The plots shown are representative of n=8 
and show the observed variation in caspase cleavage.  
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Figure 11.  Apoptosis induced by BEZ+MPA may be caspase independent.  CLL cells 
were cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates. 
Triplicate treatments of either solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA, in 
the presence (purple fill) and absence (blue fill) of the caspase inhibitor 50µM zVADfmk  
were harvested and pooled at 24 hours and analysed for the binding of AV and uptake of 
PI using FC.  Data are the mean ± s.e.m. from n=4 patients. 
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3.2.6. BEZ+MPA pro-apoptotic effects are targeted at CLL cells. 
The data shown so far was generated using non-purified MNCs.  However, other cells 
including non-malignant B cells, T cells, myeloid cells and natural killer (NK) cells will 
have been present.  As one of the problems associated with established therapy for CLL is 
the reduction in healthy as well as malignant cells (Oscier et al., 2004) more selective 
therapies are desirable.  In order to assess the selectivity of BEZ+MPA against the 
malignant cells, the effects of BEZ+MPA against both purified CLL cells and normal B 
cells were investigated.   
First, CLL cells were positively selected for the B cell marker CD19.  These CD19+ ve CLL 
cells displayed basal levels of total AV positivity greater than in their unpurified 
counterparts (figure 12) (mean values, 52% compared to 24%).  This may have been due to 
cellular stress during the purification process.  This considered the apoptotic responses of 
CD19+ve cells to BEZ, MPA and BEZ+MPA was similar to that of non-purified cells.  In the 
combination, the percentage of total AV was increased from 52% to 83% compared to 63% 
in the non-purified.   
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Figure 12.  The effects of BEZ and MPA are recapitulated against purified CLL cells.  
Five patient samples were either unsorted or sorted for CD19 expression using indirect 
anti-CD19 IgG1 antibody and anti-IgG1 microbeads and positive selection in a 
magnetised ferrous LS column.  The cells were subsequently cultured on non-CD40L 
expressing stroma in a 10:1 ratio and treated with solvent control, 5µM MPA, 0.5mM BEZ 
or BEZ+MPA, for 24 hours and analysed for the binding of AV and uptake of PI using FC.  
Data are the mean ± s.e.m. from n=5 patients. 
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Next, the effects of BEZ, MPA and, BEZ+MPA were investigated on B cells derived from 
the blood of healthy volunteers.  The B cells from such donors express CD19, like CLL 
cells, but have low CD5.   The B cells were purified by CD19 selection and were treated 
and analysed at 24 hours for total AV positivity as shown in figure 13.  Compared to the 
levels of apoptosis seen previously in the CLL solvent controls, the background apoptosis 
seen in the normal donors was high (mean of 43%).  However, there was no induced 
apoptosis by either the single agent treatments or the combination of BEZ+MPA.   
These data on the CD19+ve purified CLL cells and peripheral blood cells from healthy 
donors together strongly suggest that the effects of BEZ, MPA and, most importantly, the 
combination are targeted towards the malignant CLL cells.   
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Figure 13.  BEZ, MPA and BEZ+MPA do not induce apoptosis of normal B cells. CD19+ve 
positive B cells were isolated from healthy donors by indirect anti-CD19 IgG1 antibody 
and anti-IgG1 microbeads and positive selection in a magnetised ferrous LS column.  The 
cells were subsequently cultured on non-CD40L expressing stroma in a 10:1 ratio and 
treated with solvent control, 5µM MPA, 0.5mM BEZ or BEZ+MPA in triplicate.  At 24 
hours the appropriate wells were harvested, pooled and analysed for binding of AV and 
uptake of PI using FC.  Data are the mean ± s.e.m from n=3 donors. 
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3.2.7. BEZ+MPA show effects similar to those of chlorambucil. 
In order to assess the potential value of BEZ+MPA as anti-CLL therapy, it is pertinent to 
compare the responses of CLL cells with those to treatments that reflect current therapies.  
One of the most common first line therapies for the treatment of CLL, particularly in the 
elderly, remains the alkylating agent chlorambucil (Oscier et al., 2004).  Therefore, the 
actions of BEZ and MPA, as assessed in this in vitro system, were compared with that of 
this agent.  Strikingly, as shown in figure 14, the pro-apoptotic actions, in the absence of 
CD40L, of BEZ or MPA alone, were similar to that of chlorambucil (P= 0.99 for both).  
Notably, apoptosis was enhanced when chlorambucil was combined with BEZ or MPA 
although this did not reach significance.  The incorporation of BEZ+MPA with 
chlorambucil did not generate significantly more apoptosis than BEZ+MPA alone, 
however, this combination was significant over chlorambucil alone (P=0.013).  The 
implications of these findings for future trials in CLL are returned to in chapter 6. 
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Figure 14.  BEZ+MPA emulate the pro-apoptotic actions of chlorambucil with the 
combination exerting still greater effects.  CLL cells were cultured on non-CD40L 
expressing stroma in a ratio of 10:1 in 96 well plates.  Triplicate treatments of either 
solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA, in the presence (purple fill) and 
absence (blue fill) of 1µM chlorambucil were harvested and pooled at 24 hours, and 
analysed for the binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. 
from n=4 patients; P values were calculated using ANOVA. 
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3.3. The assessment of BEZ and MPA on ‘PC’ CLL cells. 
3.3.1. CLL cells cultured with CD40L –L cells and IL-4 show a proliferative response.  
As described in section 3.1., the isolated MNC cells from patient blood samples were 
cultured on stroma expressing CD40L with the presence of 1ng/ml IL-4 to recapitulate the 
proliferation of CLL cells in the PCs.  Unless stated otherwise, all samples were analysed 
in parallel with non-CD40L stimulated cultures discussed in figures 4-14.  Proliferation 
was assessed using the incorporation of 3H-thymidine at 0.4µCi/well.  Cells were cultured 
for 72 hours in total, with the addition of 3H-thymidine for the final 12-16 hours.  The 
counts/min 3H-thymidine incorporated in cells cultured without CD40L ranged between 
~150 and 400 cpm, which is essentially that seen in the stroma alone.  However, in the 
majority of CLL MNC preparations cultured with CD40 L in the presence of IL-4, 
thymidine incorporation was greatly enhanced (ranging from ~1,000-16,000 cpm).  
3.3.2. In the presence of CD40L the effects of BEZ and MPA are dose dependent. 
Individually, BEZ and MPA caused a reduction in CD40L mediated proliferation of CLL 
cells that was dose dependent (figure 15).  As observed in the absence of CD40L, the 
effects of MPA effectively plateaued beyond 5µM.  BEZ continued to increase its anti-
proliferative effects beyond 0.5mM.  As shown for the absence of CD40L (figure 6), the 
doses of 5µM MPA and 0.5mM BEZ either as single agents or in combination were chosen 
for further investigation.  
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Figure 15.  BEZ and MPA reduce the CD40L proliferative response of CLL cells in a dose 
dependant manner.  CLL cells were cultured on CD40L expressing stroma in a ratio of 
10:1 in 96 well plates and were treated with solvent control and either MPA (top) or BEZ 
(bottom) in a 2-fold dose escalation (1.25µM-10 µM MPA and 0.125-1 mM BEZ) for 72 
hours.  Cells were pulsed with 3H-thymidine for the final 16 hours of culture and 3H-
thymidine incorporation was calculated, relative to control.  Data are the mean ± s.e.m. of 
n=7 patients.  
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3.3.3. Analysis of apoptosis in the presence of CD40L. 
The apoptosis data obtained from CLL cells cultured without CD40L has shown 
BEZ+MPA were effective at inducing apoptosis (figure 8).  The same analyses were 
conducted on CLL cells cultured in the presence of CD40L.  In this culture system, neither 
the individual agents of BEZ and MPA nor the combination of BEZ+MPA displayed 
induction of AV/PI positivity (figure 16).  Similarly, neither of the individual agents nor, 
most importantly, the combination was effective at inducing Δψm depolarisation (figure 
17). 
This data demonstrates that BEZ, MPA and BEZ+MPA do not induce apoptosis of CLL 
cells when CD40L is present.  This observation agrees with those of others that, in addition 
to the pro-proliferative activity of CD40L, this protein also has a protective role.  This is 
highlighted by it effectively shielding the CLL cells from BEZ and MPA mediated 
apoptotic signals.  
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Figure 16.  In the presence of CD40L, BEZ, MPA and BEZ+MPA treated CLL cells do not 
bind AV or accumulate PI.  CLL cells were cultured on CD40L expressing stroma in a 
ratio of 10:1 in 96 well plates.  Treatments of either solvent control, 0.5mM BEZ, 5µM 
MPA or BEZ+MPA were performed in triplicate for 24 hours, prior to harvesting and 
staining with AV and PI and analysis by FC.  a) plots show AV/PI positivity gated as in 
figure 4 b)analysis of FSC and SSC, gate shows viable population.  Note the difference in 
cell size compared to figure 4.  The plots shown are representative of n=15 patients and 
were set in parallel to those shown in figure 4.  
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Figure 17.  In the presence of CD40L, BEZ, MPA and BEZ+MPA do not cause Δψm 
depolarisation.  CLL cells were cultured on CD40L expressing stroma in a ratio of 10:1 in 
96 well plates.  Treatments of either solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA, 
were performed in triplicate for 24 hours, prior to harvesting and staining with JC-1 and 
analysis by FC.  Events captured in the FL-2 region (red dots) indicate ∆ψm is preserved, 
whereas those captured in the FL-1 channel (green dots) highlight aggregation of JC-1 
indicative of a loss of ∆ψm.  The plots shown are representative of n=6 patients and were 
set in parallel to those shown in figure 5.  
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3.3.4. The lack of BEZ+MPA induced apoptosis is not time dependant.  
Although BEZ, MPA and BEZ+MPA failed to induce apoptosis at 24 hours, it was 
considered that this apparent protective action of CD40L may be overcome with longer 
treatment.  The total AV positivity (figure 18a) and Δψm depolarisation (figure 18b) was  
assessed at 7, 24, 48 and 72 hours.  It is important to note that these samples are the same 
as those described in figure 6 that had previously been frozen.  As discussed in relation to 
figure 6, the control cells analysed at 7 hours by AV/PI showed a higher level of apoptosis 
than at 24 hours, which was not observed in the analysis by JC-1.  This is indicative of cell 
stress post-thawing but that is overcome overnight and then plateaus.  BEZ+MPA did not 
induce apoptosis as measured by AV/PI, JC-1 (figure 18) and a change in FSC/SSC at any 
time point analysed.  It was found that the cells could not be treated and analysed for 
longer than 72 hours because, beyond this point, the majority of samples tended to be 
over-stimulated by CD40L resulting in apoptosis of the control cells. 
3.3.5. BEZ, MPA and BEZ+MPA are effective at reducing the proliferative response of 
CLL cells to CD40L 
Thus far it has been shown that CD40L induces both CLL cell proliferation, as shown by 
others (Grdisa, 2003, Jacob et al., 1998), and protection of CLL cells from BEZ+MPA 
mediated apoptosis.  However, whilst BEZ and MPA were unable to induce apoptosis in 
the presence of CD40L, both agents substantially reduced the proliferative capability of 
CLL cells.  The reproducibility of this reduction of proliferation was investigated in a 
panel of consecutively acquired CLL cells. 
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Figure 18.  Prolonged exposure to BEZ+MPA does not induce apoptosis in the presence 
of CD40L.  CLL cells thawed from -80ºC were cultured on CD40L expressing stroma in a 
ratio of 10:1 in 96 well plates. Treatments of either solvent control or BEZ+MPA were 
performed in triplicate and were harvested at 7, 24, 48 and 72 hours and assessed for a) 
the binding of AV and uptake of PI and b) ∆ψm using JC-1 and analysis by FC.  Data are 
the mean ±s.e.m. from n=4 patients and were set in parallel to those shown in figure 6.  
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Figure 19 shows a similar box plot for the inhibition of cell proliferation of CD40L-
stimulated CLL cells from 27/28 of the same samples analysed in figure 8 (one sample 
yielded too few cells for both types of analysis).  The patient characteristics are detailed in 
table 8.  The same statistical analyses were carried out by Dr J Delgado, as described 
previously in relation to figure 8.  Despite the range in CD40L stimulated proliferation, the 
overall responses to both the individual agents and the combination was strongly 
significant.    
Pair-wise comparisons identified that proliferation following BEZ, MPA and BEZ+MPA 
treatments was significantly less than in untreated controls (P = 0.011, P=0.042 and P = 
0.003 respectively).  The anti-proliferative effect of BEZ was not statistically different from 
that of MPA (P = 0.199) but the combined treatment was significantly more anti-
proliferative than either BEZ or MPA alone (P = 0.007 and P = 0.003 respectively).  
Therefore, whilst BEZ+MPA may not be effective at inducing apoptosis in the presence of 
CD40L, the combination reduces the proliferative capabilities of CLL cells in vitro.  As a 
result, it is possible that the agents would be effective at reducing proliferation within the 
PC. 
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Figure 19.   BEZ, MPA AND BEZ+MPA arrest CD40L induced proliferation of CLL cells.  
CLL cells were cultured on CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  
Triplicate treatments of either solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA were 
incubated for 72 hours with the addition of 0.4µCi of 3H-thymidine for the final 12-16 
hours of culture.  Plot shows 3H-thymidine incorporation after 72 hours of treatment in 
n=27 patients and are the same as those shown in figure 8 without CD40L.  Each box 
shows variation in initial proliferation and its subsequent reduction. Line in box indicates 
median value; bottom line and top line of each box show 25th and 75th centile respectively, 
with the bottom and top whiskers corresponding to 10th and 90th centile, open circles 
represent outliers.  
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3.3.6.  BEZ, MPA and BEZ+MPA exert greater anti-proliferative activities against 
purified CLL cells than their normal counterparts. 
The anti-proliferative actions of BEZ+MPA were encouraging, but it was important to 
investigate the extent to which this was a targeted action.  This was assessed in two ways.  
First, the effects of BEZ, MPA and BEZ+MPA were analysed on CD19+ve cells purified 
from CLL MNCs.  Notably, the CD19+ve cells displayed a slightly reduced proliferative 
response to CD40L (figure 20).  However, as the purified cells were isolated by engagement 
of CD19 on the cells’ surface, this is to be expected.  It is known that engagement of CD19 
reduces the cells’ ability to proliferate (J Gordon, personal communication).  Despite this 
dampened CD40L proliferative response of the purified CLL cells, both BEZ and MPA 
reduced this overall proliferation (figure 20).  BEZ+MPA proved to be most significant; 
reducing cpm incorporated to background 130-252 (mean 172.4± 14.5 SEM; P =<0.0001; 
n=5).   
Second, the anti-proliferative actions of BEZ, MPA and BEZ+MPA were investigated 
againstCD19+ve B-cells from healthy donors (figure 21).  The proliferation of normal B cells 
was attenuated by BEZ and MPA, however; not to the same degree as in the CLL cells.  
Therefore, some proliferation was maintained even in the presence of both drugs (figure 
21).  This data indicates that, whilst BEZ+MPA may reduce the proliferative capacity of 
normal B cells, some normal proliferation of these cells would be maintained in vivo. 
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Figure 20.  The anti-proliferative effects of BEZ and MPA are targeted against the CLL 
cells.  Five patient samples were either unsorted or sorted for CD19 cells using indirect 
anti-CD19 IgG1 antibody and anti-IgG1 microbeads and positive selection in a 
magnetised ferrous LS column.  The cells were subsequently cultured on CD40L 
expressing stroma in a 10:1 ratio, and treated with solvent control, 5µM MPA, 0.5mM BEZ 
or BEZ+MPA for 72 hours.  Cells were pulsed with 3H-thymidine for the final 16 hours of 
culture and 3H-thymidine incorporation was calculated.  Data are the mean ± s.e.m. from 
n=5 patients. 
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Figure 21.  BEZ and MPA exert milder anti-proliferative effects against normal B cells.  
CD19 positive B cells were isolated from healthy donors by indirect anti-CD19 IgG1 
antibody and anti-IgG1 microbeads and positive selection in a magnetised ferrous LS 
column.  The cells were subsequently cultured on CD40L expressing stroma in a 10:1 ratio, 
and treated with carrier control, 5µM MPA, 0.5mM BEZ or BEZ+MPA in triplicate.  Cells 
were pulsed with 3H-thymidine for the final 16 hours of culture and 3H-thymidine 
incorporation was calculated.  Data are the mean ± s.e.m. from n=3 donors. 
CO
NT BE
Z
M
PA
BE
Z+
M
PA
3 H
-t
h
y
m
id
in
e 
in
co
rp
o
ra
te
d
(c
p
m
 x
 1
00
0)
0
5000
10000
15000
20000
25000
Chapter Three - Effects of BEZ & MPA on Peripheral and ‘PC’ CLL Cells 
 
 105 
 
 
3.3.7. Activity of BEZ and MPA in combination with chlorambucil in the presence of 
CD40L. 
Following the encouraging results from the combination of BEZ+MPA with chlorambucil 
in the absence of CD40L (figure 14), the effects of this combination in this culture system 
were investigated.   
Chlorambucil treatment was markedly anti-proliferative against CD40L-stimulated CLL 
cells alone (figure 22a).  The addition of BEZ, MPA or BEZ+MPA further reduced the 
proliferation significantly (P= <0.001 for all).  As chlorambucil is used therapeutically, it 
was anticipated that this strong reduction in thymidine incorporation in chlorambucil 
alone treatment would be associated with cell death and that BEZ+MPA may enhance the 
level of apoptosis observed.  However, treatment of CLL cells with chlorambucil did not 
induce apoptosis (figure 22b) and the addition of BEZ+MPA did not potentiate this.  
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Figure 22.  Together BEZ+MPA and chlorambucil cause greater growth arrest in the 
presence of CD40L than by chlorambucil alone.  CLL cells were cultured on CD40L 
expressing stroma in a ratio of 10:1 in 96 well plates.  Triplicate treatments of either 
solvent control, 5mM BEZ, 5µM MPA or BEZ+MPA, in the presence (purple) and absence 
(blue) of 1µM chlorambucil were harvested at a) 72 hours after the addition of 0.4µCi of 
3H-thymidine for the final 12-16 hours of culture and b) at 48 hours analysed for the 
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binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. from n=4  patients; P 
values calculated using ANOVA.  
3.4. Discussion. 
This chapter has demonstrated that the lipid lowering agent BEZ and the contraceptive 
MPA induced significant apoptosis of CLL cells cultured in the absence of CD40L and that 
the combination induced greater apoptosis than either drug alone.  Data using caspase 
inhibitors indicated that this apoptosis may be caspase independent.  This is not 
surprising given that caspase independent apoptosis has been previously described in 
CLL (Mone et al., 2006) and other cell types (Igney and Krammer, 2002).  
 
BEZ and MPA each inhibited the CD40L driven proliferation of CLL cells with the 
combination of BEZ+MPA having more activity than either drug alone.  Additionally, the 
drugs had little effect on normal CD19+ve peripheral blood B-cells, indicating that these 
agents have a tumour cell specific effect. 
Although not normally considered as anti-cancer therapy, BEZ+MPA was as potent in 
vitro as the established CLL agent chlorambucil.  This, combined with the relatively low 
toxicity profiles of BEZ and MPA, renders it plausible to consider their use in the 
treatment of CLL patients.  As the combination shows effects in both the absence of CD40L 
(by the induction of apoptosis) and in presence of CD40L (by the reduction in 
proliferation), this combination could be considered for the use indolent disease.  
However, reducing the proliferative capacity of the PC alone may not be sufficient and 
thus resistant cells in the PCs may be problematic and the addition of additional agent(s) 
may be necessary to target this disease as a whole.  
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4.1. Introduction. 
In the previous chapter it was demonstrated that BEZ, MPA and BEZ+MPA successfully 
reduce the proliferation and selectively induce apoptosis of non-CD40L protected CLL 
cells.  Following these findings, the mechanisms by which these agents elicited their 
effects were investigated. 
As discussed in section 1.13., BEZ and MPA have been investigated for their use in a 
parallel AML study.  There it was demonstrated that BEZ+MPA are effective in inducing 
differentiation and apoptosis of AML cells (Khanim et al., 2009).  Studies from this group, 
have shown that AML cells have high levels of AKR1C3 (Birtwistle et al., 2009), which 
exhibits PGD2 ketoreductase activity.  Khanim et al (2009) further demonstrated that this 
activity is inhibited by MPA, thereby increasing the level of PGD2 and its bioactive 
dehydration product 15d∆12,14PGJ2.   
BEZ is one of the only members of the fibrate family to have been shown to have pan-
PPAR activity (Tenenbaum et al., 2005).  In 2000, PPARγ was shown to be expressed by 
B cells (Padilla et al., 2000b) and in 2003 it was demonstrated that the use of PPARγ 
agonists in B lineage cells can induce apoptosis (Padilla et al., 2002).  Work by Kleiwer et al 
in 2000 showed that 15d∆12,14PGJ2, is a PPARγ ligand and studies by Padilla et al and Ray et 
al have shown that the treatment of B cells with 15d∆12,14PGJ2  induces apoptosis (Padilla et 
al., 2002, Ray et al., 2006).  However, this was demonstrated to be PPARγ independent.   
An alternative action of BEZ is to induce elevated ROS which, in turn, leads to induction 
of oxidative stress (Scatena et al., 2004, Scatena et al., 2003).  As presented in chapter 1, 
oxidative stress can lead to cellular damage, including to membrane lipids.  In turn this 
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has been shown to induce LP, a component of which is the production of PGs from the 
IoPP (Gao et al., 2003). 
The use of specific ELISAs demonstrated that both BEZ and MPA increased PGD2 levels 
in AML cell lines and that the increase was  even greater when the agents were combined. 
The combined activity against AML cells exerted by BEZ+MPA was, therefore, attributed 
to the increases in PGD2 caused by the inhibition of AKR1C3 by MPA and IoPP PGD2 
synthesis following BEZ treatment.  The increased PGD2 allowed the subsequent 
accumulation of PGD2’s metabolite 15d∆12,14PGJ2, which was responsible for the cellular 
responses.  
This chapter investigates whether the activity of BEZ, MPA and BEZ+MPA against CLL 
cells is similar to that described for AML cells.  
Much of the work presented in this chapter was published in 2009 by Macmillan 
Publishers Ltd.  The full details of this manuscript can be found in Appendix A2. 
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4.2. The actions of MPA against CLL cells. 
4.2.1.  Only AKR1C3 of the AKR1C family is readily detected in CLL cells. 
Analysis of AKR1C1, 2, 3 and 4 expression was carried out by QRT-PCR.  Western blot 
was also used to determine protein levels of AKR1C3.  The myeloid cell line K562, has 
been demonstrated to have moderate expression levels of AKR1C3 (Birtwistle et al., 2009).  
This was, therefore, used as a positive control.  AKR1C1 and 2 were observed (figure 23) 
in very few samples and overall were not present.  AKR1C4 could not be detected owing 
to it being liver specific (data not shown).  AKR1C3 was readily detected in all 18 samples 
(figure 23).  Expression was variable but overall levels were largely in line with those 
observed in K562.  Western blot analysis (figure 24) of AKR1C3 also showed that protein 
levels of AKR1C3 were similar to those seen in K562.  Thus, these data were consistent 
with a model that MPA may act against CLL cells by virtue of inhibiting AKR1C3.  
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Figure 23.  CLL cells express AKR1C3 almost exclusively and to varying levels. 
Uncultured CLL cells from 18 patients were analysed by quantitative real-time PCR for 
the expression of AKR1C1, AKR1C2 and AKR1C3 and the message detected displayed 
relative to K562, used as a positive control.  
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Figure 24.  Protein levels of AKR1C3 in CLL cells are variable. 
Western blot was carried out on 40µg of protein extracted from 5x106 cells from the same 
18 samples shown in figure 21,  for the expression of AKR1C3.  The protein β-actin was 
used as a loading control.  
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4.2.2.  Investigation into the ability of BEZ and MPA to induce the production of PGD2 
in CLL cells. 
An ELISA was employed to measure the levels of PGD2 within 5 x106 CLL cells and 1ml of 
their supernatant following treatment with and without MPA, BEZ and combined 
BEZ+MPA.  Three patient samples were studied in triplicate (figure 25). As there was 
inter-patient variability in PGD2 levels, each patient was plotted separately.  In the control 
cells of both CD40L deprived (figure 25 top) and CD40L stimulated (figure 25 bottom), the 
levels of PGD2 varied between 10 – 200 pg/ml.  In every patient and in both stromal 
culture systems, BEZ caused PGD2 accumulation, with patient three showing the highest 
accumulation (200pg/ml to 950pg/ml without CD40L and 10pg/ml to 600pg/ml with 
CD40L).  
Overall, there was a lack of enhanced PGD2 accumulation when MPA was used alone or 
when added to BEZ.  In the non-CD40L CLL cells, only patient two showed enhanced 
PGD2 accumulation in BEZ+MPA over that seen in BEZ alone.  In patients one and three, 
the overall level of PGD2 was reduced in BEZ+MPA when compared to BEZ alone, 
although it should be noted that this was only a significant decrease in patient three.  
When CD40L was present, BEZ+MPA induced an increase in PGD2 accumulation over that 
of BEZ alone in patients one and three but it was observed to only reach significance in 
patient three.  
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Figure 25.  Treatment of CLL cells with BEZ and BEZ+MPA causes the production of 
PGD2 in both the absence and presence of CD40L.  CLL cells from three patients were 
cultured in the absence (top) and presence (bottom) of CD40L in a ratio of 10:1 in 6 well 
plates and treated with solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA for 6 hours 
prior to harvesting of the cells, together with 1ml of supernatant, extracting the 
prostanoids and analysis by ELISA.  Data are shown for the three individual patients, 
analysed in triplicate and shown as mean  ±  s.e.m. 
Chapter Four - Investigating the Mechanisms of BEZ & MPA 
 
 116 
 
 
The above data demonstrate that, as in AML cells, BEZ induces an increase of PGD2. in 
CLL cells.  Conversely, it was conclusive that MPA did not cause an increase in PGD2. To 
investigate this disparity further it was investigated whether CLL cells exert 11β-
PGD2 ketoreductase activity.  Birtwistle et al (2009) have shown that the exogenously 
added 3H-PD2 and both its enzymatic and non-enzymatic metabolites should be detected 
in the supernatant of K562 cells post-incubation.  Using the K562 line as a positive control, 
cells were cultured with 0.2µCi 3H-PGD2 for 16 hours and the prostanoids in the 
supernatant extracted and analysed by TLC.  For these experiments, CLL cells were 
cultured without stromal support to avoid any metabolism of PGD2 by these cells.   
The representative trace of K562 cells (figure 26) clearly shows 3 peaks, corresponding to 
remaining (unconverted) PGD2, non-enzymatically produced 15dΔ12,14PGJ2  and AKR1C3 
synthesised 11-epi-PGF2α.  Surprisingly, when the traces from CLL cells (figure 26) were 
obtained, no 11-epi-PGF2α could be detected 
4.2.3.  CLL cells do not appear to take up PGD2. 
The above observation was generated from analyses of the cell supernatants.  Further 
analysis of the prostanoids extracted from the cells was carried out.  Following incubation 
of CLL cells with 3H-PGD2, prostanoids were extracted and compared to extracts from the 
myeloid cell line KG1a that has been shown to have high levels of AKR1C3 (Birtwistle et 
al., 2009).  Figure 27 shows traces from the extracts from 3 CLL samples, compared to a 
trace obtained from KG1a.  In this trace, the KG1a cells no longer had any PGD2 
detectable.  This would be expected owing to the incubation time and the high level of 
AKR1C3 expressed by these cells.   
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Figure 26.  CLL cells do not appear to have 11β-PGD2 ketoreductase activity. 5x106 CLL 
or K562 cells were exposed to 3H-PGD2 in PBS for 18 hours and the prostanoids extracted, 
and analysed by TLC.  Top trace is representative of samples analysed from 8 patients, 
(each in duplicate) with K652 (bottom trace) used as a positive control each time. The 
migration of cold standard PGD2, PGF2α and 15d 14,12PGJ2 were revealed by incubation in 
iodine vapour.  
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Figure 27.  When cellular extracts from the myeloid cell line KG1a are compared to CLL 
cells, PGs cannot be detected in CLL.  2x107 CLL cells or the cell line KG1a were exposed 
to 3H-PGD2 in PBS for 18 hours.  Prostanoids were extracted from the and were analysed 
by TLC.  Top trace, of KG1a, shows two peaks, probably of the J series prostanoids.  
Traces 2-4 are samples from three CLL patients.   Note the differences in scale of counts 
for KG1a and the CLL samples.   
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Additionally, there was only a very small detectable PGF2α peak in the KG1a cells.  This is 
not surprising, as it has been shown that PGF2α is exported by this cell line and readily 
detected in the supernatant (as shown in figure 26).  Despite the lack of these 2 
prostanoids, there was a readily detected peak relating to 15dΔ12,14PGJ2.. 
The observation of this 3H-labelled peak serves to prove that the exogenously added PGD2 
had entered the myeloid cells either by diffusion or active uptake and been converted 
non-enzymatically to 15dΔ12,14PGJ2 (some of which is remaining in the cell) and 
enzymatically to PGF2α (which is then secreted).  In contrast, the CLL cells show none of 
these prostanoid related peaks (figure 27).  Indeed, the traces contained no clearly 
determinable peaks and the CPM detected was essentially background.  Taken together, 
these data would indicate that CLL cells are unable to take up PGD2.  Alternatively, PGD2 
may be taken up by the cell but then be rapidly exported, thus protecting the cell from 
any exogenous PGD2.  
4.2.4.  Analysis of steroid dehydrogenase activity of CLL cells. 
The above data indicate that PGD2 is not a likely substrate of AKR1C3 in CLL cells.  
AKR1C3 also has steroid dehydrogenase activity.  As CLL cells have been shown in figure 
23 to only typically express AKR1C3 and not the other AKR1Cs, it was hypothesised that 
MPA was exerting its effects by inhibition of this activity.  This was investigated using the 
steroid substrate 5α-DHT and looking for its product of 3α-ASD.  K652 cells were used as 
a positive control. 
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Figure 28.  Comparison of CLL cells to K562 indicates that CLL cells do not have steroid 
dehydrogenase activity.  5x106 of cell line K562 (top) or CLL cells (middle and bottom) were 
treated with solvent control (left panel) or 5µM MPA (right panel) overnight prior to 
incubation with 5α-DHT in supplemented media for 24 hours.  Sterols were extracted 
from the supernatant and analysed by TLC.  5α-DHT and 3α –ASD peaks were identified 
following co-migration of cold standard and incubation in iodine vapour.  
Chapter Four - Investigating the Mechanisms of BEZ & MPA 
 
 121 
 
 
Traces from K562 cells (figure 28) clearly showed 2 peaks: 5α-DHT and 3α-ASD.  
Furthermore, in the absence of MPA the product was greater than the substrate, whereas 
in the presence of MPA metabolism was very much diminished.  Conversely, the traces 
from CLL cells (figure 28), only display a large 5α-DHT peak.  No detectable 3α-ASD peak 
was observed in one patient and only a very small peak in the other.  This small 3α-ASD 
peak was not commensurate with that seen in the K562 sample and, given the 18 hour 
incubation time, is exceptionally small.  The fact that 3α-ASD is either undetected or only 
moderately detected in these samples could be explained by the findings of Birtwistle et al 
(2009) who demonstrated that cellular steroid dehydrogenase activity is mainly 
attributable to AKR1C2.  Therefore, as CLL cells have very little of this enzyme (as shown 
in figure 23), the inability of these cells to convert 5 α-DHT to 3α –ASD would be 
consistent with this model.  Consequently, this negates the possibility of MPA working 
via inhibition of this activity.  
4.3. Investigation of MPA exerting effects via known receptors. 
The above data indicate that MPA may not exert its affect against CLL cells via the well-
known activities of AKR1C3.  Therefore, additional experiments were performed to 
consider other possible activities of MPA that might explain its actions against CLL cells.  
It is known (and was discussed in section 1.15.) that besides being a ligand of PR,  MPA 
also binds to GR and MR (Schindler et al., 2003, Schindler et al., 2008) but it is not thought 
to have any AR activity (Schindler et al., 2003, Schindler et al., 2008).  It was therefore 
hypothesised that MPA could be working in CLL by exerting agonistic or antagonistic 
affects on one or several steroid receptors.  
Chapter Four - Investigating the Mechanisms of BEZ & MPA 
 
 122 
 
4.3.1. Comparison of MPA with mifepristone. 
The effects of MPA were first compared with mifepristone (MFE), a corticosteroid, 
predominantly used as a PR antagonist.  It is also known as RU146 and is most commonly 
used in combination with PGF2α during pregnancy terminations or to induce labour 
(Gottlieb and Bygdeman, 1991).  At a dose of 100µM, MFE was seen to exert a small pro-
apoptotic effect against CLL cells, similar to that seen by MPA (figure 29).  When 
combined with BEZ+MPA (figure 29), MFE did not increase the apoptosis seen by 
BEZ+MPA.  Together, these observations suggest that MPA and MFE could be exerting 
their effects via the same target.  However, at high enough doses, MFE also has GR 
antagonist effects and if MFE were affecting CLL via the PR, a much lower dose than 
100µM would be expected to induce the effects described for figure 29.  At the lower 
doses of 100ng - 1µM, MFE did not exert any activity against CLL (data not shown).  
Therefore, if MPA and MFE were acting via a common mechanism it was possible that it 
was GR rather than PR.   
4.3.2. The non-methylated GR agonist, prednisolone, exerts no effect against CLL cells 
whilst its methylated form is commensurate with MPA. 
To further investigate the possible role of GR, PRD, a GR agonist that notably has been 
used in the treatment CLL (Hamblin, 2001) was used.  ML-PRD, has a methyl group at the 
6α position (see section 2.7; table 6.), was developed in the 1950s and has taken preference, 
clinically, over PRD.   
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Figure 29.  MFE induces a similar level of apoptosis to MPA.  CLL cells were cultured on 
non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  Triplicate treatments of 
either solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA in the presence (purple) and 
absence (blue) of 100µM MFE were harvested and pooled at 24 hours and analysed for the 
binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. from n=4 patients.  
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ML-PRD has increased potency, first postulated to be due to an increased half life but 
now thought attributable to improved interaction with the cellular membrane via the 
methyl group (Waddell et al., 1977).  HD ML-PRD combined with Rituximab has also 
been advocated for the treatment of CLL in patients with the 17p deletion (Bowen et al., 
2007).   
A dose titration of PRD (figure 30a) against CLL cells showed that PRD exerted no pro-
apoptotic activity and that, when combined with MPA, there was no additive or reductive 
effect on that observed with MPA alone (figure 30a).  However, in a dose titration of ML-
PRD (figure 30b) a pro-apoptotic effect was observed at a concentration of 20µM and this 
effect was commensurate with that seen exerted by MPA alone.  Further, the combination 
of 20µM ML-PRD and MPA was not additive to that of either agent used alone.  
Following these data, further experimental analysis of 20µM ML-PRD was conducted.   
When compared to BEZ+MPA, BEZ+20µM ML-PRD showed similar apoptotic effects 
against CLL (figure 31).  Once again 20µM ML-PRD+BEZ+MPA had no additive apoptosis 
to BEZ+MPA alone.  Together these data indicate that the similar levels of apoptosis 
induced by ML-PRD and MPA could be via the same target.  If this target were the GR 
then it seemed plausible that a more specific GR agonist should also exert similar 
outcomes and that a GR antagonist would reduce the pro-apoptotic effects exerted by ML-
PRD and MPA. 
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Figure 30.  ML-PRD but not PRD recapitulates but does not potentiate the actions of 
MPA.  CLL cells were cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 
well plates.  Triplicate treatments of solvent control, 1µM, 5µM and a) 20µM PRD or 
b) ML-PRD, either in the presence (purple) or absence (blue) of 5µM MPA were harvested 
and pooled at 24 hours and analysed for the binding of AV and uptake of PI using FC.  
Data are the mean ± s.e.m. from n=4 patients.  
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Figure 31.  Combining ML-PRD with BEZ recapitulates the apoptotic effects of 
BEZ+MPA but all 3 agents combined are not additive.  CLL cells were cultured on non-
CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  Triplicate treatments of 
solvent control, 5µM MPA, 20µM ML-PRD and ML-PRD+MPA, either in the presence 
(purple) or absence (blue) of 0.5mM BEZ, were harvested and pooled at 24 hours and 
analysed for the binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. 
from n=4 patients.  
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Dexamethasone (DEX) was selected as a highly specific GR agonist.  The effects of 1µM 
DEX on CLL cells in the absence of CD40L were compared with the level of apoptosis 
induced by MPA and ML-PRD (figure 32).  As previously discussed in section 4.3.1, MFE 
is a GR antagonist and this was therefore combined with MPA, ML-PRD or DEX in an 
attempt to antagonise any apoptosis observed.  DEX induced very little apoptosis 
compared to that exerted by MPA and ML-PRD.  Furthermore, whereas the effects of 
MPA and ML-PRD have been shown to be variable between samples the small, lesser 
effect of DEX was consistent.  In addition, MFE was unsuccessful at inhibiting the MPA or 
ML-PRD effects and the small effect by DEX (figure 32).  Taken together these data would 
suggest that, while MPA and ML-PRD may share a common target, it is not likely to be 
GR.  
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Figure 32.  The effects exerted by MPA and ML-PRD are not via GR. CLL cells were 
cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  Triplicate 
treatments of 5µM MPA, 20µM ML-PRD and 1µM DEX, either in the presence (purple) or 
absence (blue) of 1µM MFE, were harvested and pooled at 24 hours and analysed for the 
binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. from n=3 patients.  
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4.3.3.  Mineralocorticoid investigations reveal that HD antagonists emulate the MPA 
apoptotic effect. 
Whereas DEX is a highly specific GR agonist, PRD has been shown to also have relatively 
high affinity for the MR (Juruena et al., 2006).  PRD has been shown to have similar 
binding affinity for the MR as its natural ligand, cortisol, whilst DEX has a 70% lower 
binding affinity  (Lan et al., 1981).  It is almost certain, that as ML-PRD is only different to 
PRD by its methyl group, the binding efficiencies of these agents will be the same.   
Therefore, as ML-PRD induced apoptosis to a similar level to MPA (and DEX induced 
none), it is possible that this is via the MR.  Thus, it was hypothesised that an MR 
antagonist may inhibit MPA and ML-PRD induced apoptosis.  A dose titration of the MR 
antagonist spironolactone (SPN) alone (figure 33) indicated that at the active inhibitor 
dose of 100nM, the agent had no pro-apoptotic activity.  However, at the10-fold higher 
dose of 1µM, SPN induced apoptosis to a similar level of that of MPA observed in 
previous experiments.  Following these results, HD (1µM) and LD (100nM) SPN were 
investigated, in the presence and absence of BEZ and MPA.  
When compared to the pro-apoptotic effects of MPA and BEZ, HD SPN induced similar 
levels of apoptosis to both of these agents (figure 34a).  Moreover, HD SPN when 
combined with BEZ+MPA did not potentiate the BEZ+MPA alone response (figure 34a).   
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Figure 33.  HD SPN exerts pro-apoptotic effects.  CLL cells were cultured on non-CD40L 
expressing stroma in a ratio of 10:1 in 96 well plates.  Cells were treated in triplicate with 
the doses shown of SPN.  After 24 hours, triplicate wells were harvested, pooled and 
analysed for the binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. 
from n=4 patients.  
 
 
 
Chapter Four - Investigating the Mechanisms of BEZ & MPA 
 
 131 
 
CO
NT BE
Z
MP
A
BE
Z+M
PA
T
o
ta
l 
A
n
n
ex
in
 V
 p
o
si
ti
v
e 
(%
)
0
20
40
60
80
100
- HD SPN 
+ HD SPN 
P=0.0032
P=0.952
P=0.263
P=0.453
CO
NT BE
Z
MP
A
BE
Z+M
PAT
o
ta
l 
A
n
n
ex
in
 V
 p
o
si
ti
v
e 
(%
)
0
20
40
60
80
100
-SPN 
+SPN 
P=0.936
P=0.082
P=0.343
- LD SPN
+LD SPN
a
b
 
Figure 34.  HD SPN exerts similar effects to both MPA and BEZ without potentiating 
BEZ+MPA, whilst LD SPN does not antagonise their effects. CLL cells were cultured on 
non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  Triplicate treatments of 
solvent control, 5µM MPA, 0.5mM BEZ, BEZ+MPA either in the presence (purple) or 
absence (blue) of a) 1µM SPN or b) 0.125µM SPN were harvested and pooled at 24 hours 
and analysed for the binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. 
from n=5 patients.  
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As LD SPN did not yield apoptosis when used alone, it is possible that when combined 
with MPA it would antagonise the MPA effect.  When used in combination with 
BEZ+MPA, a mild reduction in apoptosis could be seen but this did not reach significance.  
These data tend to suggest that the effect of MPA against CLL cells is not as an MR 
agonist.  This statement was supported by the fact that hydrocortisone (a synthetic 
corticosteroid that, reciprocally to  ML- PRD, can bind both the MR and the GR) showed 
no effect on CLL cells (figure 35). 
Overall, this body of data, using corticosteroids as agonists and antagonists of the PR, GR 
and MR showed that 20µM ML-PRD and 1µM SPN induce similar levels of apoptosis to 
MPA when used alone.  Additionally, combining these agents with BEZ+MPA did not 
result in additive apoptosis.  It therefore remains possible that all three agents are 
effective against a common target.  However, it is unlikely that any of these agents, 
including MPA, are exerting their activities by their known receptors.  Additionally, the 
target is unlikely to be AKR1C3; whilst MPA has been shown to inhibit AKR1C3, neither 
ML-PRD nor SPN are able to do so at the concentrations tested here (Dr Nick Davies, 
personal communication).     
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Figure 35.  Hydrocortisone does not induce apoptosis of CLL cells.  CLL cells were 
cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  Cells were 
treated in triplicate with a 2-fold titration of hydrocortisone (from 1mM to 62.5µM).  After 
24 hours triplicate wells were harvested, pooled and analysed for the binding of AV and 
uptake of PI using FC.  Data are the mean ± s.e.m. from n=5 patients.  
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4.3.4. AKR1C3 inhibitors other than MPA do not induce apoptosis of CLL cells. 
The data so far have shown that MPA is unlikely to be working via its known steroid 
targets, or indeed MR.  Additionally, MPA cannot be affecting 11β-PGD2 ketoreductase 
activity as CLL cells do not appear to be able to perform this activity. However, it 
remained possible that MPA is effecting an alternative mechanism of AKR1C3.  Other 
known inhibitors of AKR1C3 were used to address this.  Lovering et al (2004) showed that 
the anti-inflammatory agents flufenamic acid (FLA) and IMN bind the active sites of 
AKR1C3 at doses of around 20µM.  Similarly, this group have demonstrated that the 
plant derived hormone MeJ inhibits cellular AKR1C3 activity (Davies et al., 2009).  It was 
hypothesised, therefore, that if AKR1C3 was the target of MPA then FLA, IMN and MeJ 
should have similar effects on CLL cells to that observed by MPA.  However, comparing 
each of these agents against MPA and ML-PRD showed that none of the agents caused 
apoptosis of CLL cells (figure 36).   
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Figure 36.  Alternative inhibitors of AKR1C3 do not induce apoptosis of CLL cells.  CLL 
cells were cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  
Triplicate treatments of solvent control, 5µM MPA, 20µM ML-PRD, 20µM FLA, 20µM 
IDM and 1mM MeJ were harvested and pooled at 24 hours and analysed for the binding 
of AV and uptake of PI using FC.  Data are the mean ± s.e.m. from n=4 patients.  
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4.3.5. The potential use of ALL cell lines to investigate the importance of AKR1C3 for 
MPA activity.  
In order to definitively establish or refute AKR1C3 as the target of MPA interfering RNA 
experiments should be undertaken.  Disappointingly, CLL cells are difficult to manipulate 
and attempts at Sh RNA experiments failed to yield a high enough efficiency for this to be 
possible.  CLL cell lines are rare as it has been shown that the normal method of 
generating a cell line, i.e. transfection with Epstein Barr virus (EBV), does not induce the 
cells into cell cycle, nor prolong their lifespan in culture (Crawford and Catovsky, 1993).  
Therefore, it was investigated whether cell lines from an alternative B-cell malignancy 
could be used as a model to study the role of AKR1C3 in lymphoid malignancy.   
There are many ALL cell lines both from T cell and B cell lineages.  Gene expression of 
AKR1C1, 2 and 3 was analysed in a panel of these lines using QRT-PCR, as well as protein 
levels of AKR1C3, as determined by western blot.  Additionally, the 11β-PGD2 
ketoreductase activity of these lines was analysed.  From this, two cells lines, Nalm6 and 
REH, were chosen to investigate further.  The reasoning behind this was two-fold; first 
because both lines are of pre-B cell origin and, second, because they differed in expression 
of AKR1C3 and 11β-PGD2 ketoreductase activity.  REH expressed high levels of AKR1C3 
(ranging from 800 to 1552% relative to K562) (figure 37) and displayed 11β-PGD2 
ketoreductase activity that was inhibited by MPA (figure 38).  In contrast, Nalm6 had no, 
or very little, expression of the enzyme (ranging from 0.06 to 1.6%, relative to K562) 
(figure 37) and, as would be anticipated, did not have 11β-PGD2 ketoreductase activity.   
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Figure 37.  Analysis of expression of AKR1, 2 and 3 of the ALL cell lines REH and 
Nalm6.  a)  QRT-PCR for AKR1C1, AKR1C2 and AKR1C3 was performed on cDNA from 
100ng RNA extracted from 2x106 REH (blue) and Nalm6 (purple).  Message levels are 
plotted as percentage relative to K562 shown as mean ± s.e.m from n=3. b)  Western blot 
analysis was performed on 40µg protein extracted from 5x106 cells.  K562 is displayed as a 
positive control.  
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Figure 38.  REH display 11β-PGD2 ketoreductase activity.  2x107 cells were treated with 
solvent control or 5µM MPA overnight, prior to incubation with 3H-PGD2 in PBS for a 
further 18 hours.  Prostanoids were extracted from the cells’ supernatant using methanol 
and chloroform and analysed by TLC.  Conversion of PGD2 to PGF2a was calculated using 
the equation (product/(product + substrate))x100.  Graph shown is mean ± s.e.m from n=3.  
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Importantly, like the majority of CLL samples tested, neither of these lines displayed 
expression of AKR1C1 and only Nalm6  had a very small (around 0.5%, relative to K562) 
of AKR1C2 (figure 37).  Using all these data and, in particular, the disparate levels of 
AKR1C3 it was proposed that these two cell lines could provide evidence as to whether 
AKR1C3 is likely to be the target of MPA in B cell malignancies.  
4.3.6.  The AKR1C3-ve ALL cell line, Nalm6, is most sensitive to MPA and BEZ+MPA. 
REH and Nalm6 were treated with MPA, BEZ and BEZ+MPA, and the effects analysed by 
calculation of cellular activity or ‘cellularity’ by cell titre blue and total AV positivity.   
Although REH was demonstrated to have high levels of AKR1C3, which MPA was able to 
inhibit, MPA alone did not induce any apoptosis (figure 39a).  Whilst BEZ alone exerted a 
moderate amount of total AV, the combination of BEZ+MPA proved to be most effective, 
with the two agents showing apparent synergy.  This result was also observed in the 
cellularity assay, cell titre blue (figure 39b), with MPA having no effect on cell number 
and BEZ+MPA being the most effective treatment.   
Interestingly, Nalm6 that was demonstrated to have only traces or no AKR1C3, showed a 
significant level of apoptosis to MPA alone (figure 40a).  BEZ alone was also able to 
induce apoptosis.  Most striking was the additive level of cell death induced by 
BEZ+MPA.  The total mean AV measured was 79% compared to 15% observed in the 
controls.  This level of apoptosis was far greater than seen in any CLL sample and was 
much higher than the BEZ+MPA effect observed in REH.   
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Figure 39.  MPA exerts little activity against REH cells.  Triplicate wells of 5x104 REH 
cells were treated with solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA for 5 days, 
prior to  a) harvesting, pooling and analysis for the binding of AV and uptake of PI using 
FC; or  b) incubating with cell titre blue and determining cellular activity by analysing OD 
at 530/565.  Plots shown are mean ± s.e.m. from n=5 experiments.    
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Figure 40.  MPA and BEZ+MPA are significantly pro-apoptotic against the AKR1C3 
negative ALL cell line Nalm6.  Triplicate wells of 5x104  Nalm6 cells were treated with 
solvent control, 0.5mM BEZ, 5µM MPA or BEZ+MPA for 5 days, prior to  a) harvesting, 
pooling and analysis for the binding of AV and uptake of PI using FC or b) incubating 
with cell titre blue and determining cellular activity by analysing OD at 530/565.  Plots 
shown are mean ± s.e.m.from n=5 experiments.    
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When the effects of the agents were observed in the cellularity assay of cell titre blue, both 
MPA and BEZ reduced the cellularity to a similar amount (figure 40b).  The combination 
proved to reduce the cellularity the most; yet the combinatorial effect was less striking 
than by the AV/PI assay (figure 40b), though it was still significantly additive.  
Overall, these data on ALL cell lines, with contrasting levels of AKR1C3 expression, 
serves to suggest that the ability of MPA to promote the apoptosis of malignant B-cells is 
not exerted via AKR1C3 either by inhibition of the 11β-PGD2 ketoreductase activity or by 
another described or undescribed activity of this enzyme.   
4.3.7.   15d∆12,14PGJ2 and PGD2 induce apoptosis of CLL. 
Although the above experiments collectively refute a role for AKR1C3 as either the target 
of MPA in CLL cells or in mediating PGD2, the observation that BEZ treatment does 
elevate PGD2 remained (figure 25).  Therefore, to investigate the possible actions of BEZ, 
CLL cells were treated with exogenously added PGD2 and its dehydration product, 
15d∆12,14PGJ2 and tested for the recapitulation of the effects seen by BEZ, either alone or in 
combination with MPA.  Two-fold dose titrations of PGD2 and 15d∆12,14PGJ2 from 50µM to 
6.25µM were conducted.  In the case of PGD2 (figure 41a), a 50µM dose induced apoptosis 
at levels similar to those exerted by BEZ+MPA.  Lower doses had minimal effects.  
15d∆12,14PGJ2 exerted powerful pro-apoptotic effects at 50µM and induced around 50% 
apoptosis at the-fold lower doses of 25µM (figure 41b).  Therefore, for further studies, 
doses of 50 µM PGD2 and 35 µM 15d∆12,14PGJ2 were selected.  
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Figure 41.  PGD2 and 15d∆12,14PGJ2 induce apoptosis in the absence of CD40L.  CLL cells 
were cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  
Triplicate treatments of either solvent control, or a dose titration of a) PGD2 or b) 
15d∆12,14PGJ2 (from 50 µM to 6.25 µM).  At 24 hours, triplicate wells were harvested, 
pooled and analysed for the binding of AV and uptake of PI using FC.  Plots shown are 
the mean ± s.e.m. from n=4 patients.  
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However, it should be noted that these doses are much higher than those seen to exert 
activity in other B cells (Padilla et al., 2000a, Padilla et al., 2000b) and in the AML study 
(Khanim et al., 2009). 
4.3.8. PGD2 effects against CLL cells are not DP1 receptor mediated or 
PPARγ dependent. 
Many PGD2 effects are mediated via cell surface PGD2 receptors (DP1/DP2).  In this study, 
it is unlikely that PGD2 is working via the DP2 receptor due to it being T cell specific.  
Therefore, only the DP1 receptor mediated effects were assessed.  The quiescent and 
proliferating CLL cells were treated with BEZ, MPA, BEZ+MPA or PGD2 with and 
without the DP1 receptor antagonist BW 868C.  In the absence of CD40L (figure 42a), the 
antagonist exerted no effect alone and was not successful in antagonising the effects of 
PGD2.  Similarly, BW 868C did not remove the pro-apoptotic activities of BEZ, MPA or 
BEZ+MPA.  Equally, BW 868C did not reinstate proliferation of CD40L cells after 
treatment with PGD2 or BEZ, MPA or BEZ+MPA (figure 42b).  Consequently, it is unlikely 
that the effects of PGD2 or BEZ are mediated via this receptor.  
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Figure 42.  The activities of BEZ and MPA against CLL cells are not mediated via PGD2 
DP1 receptor.   CLL cells were pre-incubated for 1 hour with solvent control or the PGD2 
receptor antagonist BW868C in the a) absence or b) presence of CD40L prior to treatment 
with solvent control, 0.5mM BEZ, 5 µM MPA, BEZ+MPA or 50 µM PGD2, with (purple) or 
without (blue) BW868C.  a) Cells cultured on the non-CD40L-expressing stroma were 
analysed for total AV positivity by FC after 24 hours treatment.  b) CLL cells on CD40L-
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expressing stroma were treated for 72 hours with the addition of 0.4µCi 3H-thymidine for 
the final 16 hours of culture.  Data shown are the mean ± s.e.m from n=3 patients. 
A second indirect form of PGD2 signalling is via its non-enzymatic dehydration to the 
PPARγ ligand, 15dΔ12,14PGJ2.  Therefore, BEZ, MPA, BEZ+MPA and 15d∆12,14PGJ2 
treatments were combined with the PPARγ antagonist GW 9662.  Again, this antagonist 
did not affect the induction of apoptosis of non-CD40L-stimulated CLL cells by 
15d∆12,14PGJ2 or BEZ, MPA or BEZ+MPA (Figure 43a). The CD40L-stimulated proliferation 
was slightly promoted by GW 9662 and this effect was also reflected in the treatment 
groups (figure 43b).  Nevertheless, this pro-proliferative effect of GW 9662 did not reach 
significance.  
Collectively these data imply that the activities of BEZ and MPA against CLL cells are not 
significantly mediated via either PGD2 DP1 receptor or PPARγ. 
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Figure 43.  The activities of BEZ and MPA against CLL cells are not mediated via 
PPARγ.   CLL cells cultured in the a) absence or b) presence of CD40L and treated with 
solvent control, 0.5mM BEZ, 5 µM MPA, BEZ+MPA or 50 µM PGD2, with (purple) or 
without (blue) GW 9662.  a) Cells cultured on the non-CD40L-expressing stroma were 
analysed for total AV positivity by FC after 24 hours treatment.  b) CLL cells on CD40L-
expressing stroma were treated for 72 hours with the addition of 0.4µCi 3H-thymidine for 
the final 16 hours of culture.  Data are the mean ± s.e.m from n=3 patients.  
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4.3.9. The activities of BEZ and MPA against CLL cells are associated with the 
generation of ROS. 
In 2006, Ray et al demonstrated that 15dΔ12,14PGJ2 induces apoptosis in Ramos, the B-cell 
lymphoma cell line, via PPARγ-independent mechanisms (Ray et al., 2006).  Furthermore, 
they demonstrated that 15dΔ12,14PGJ2 induced Ramos cell apoptosis was associated with 
induction of ROS and MSO.  However, they did not investigate whether PGD2 was also 
effective.  As shown, and discussed for figure 41, PGD2 and 15dΔ12,14PGJ2 exerted similar 
effects on CLL cells as those demonstrated for BEZ, MPA and BEZ+MPA.  In light of these 
findings, and as an attempt to establish a mechanism for these agents and their use as a 
combination, ROS generation was analysed following treatment both in the presence and 
absence of CD40L.  The agent H2DCFDA recognises all ROS.  Incubation with this, 
following treatment, showed that BEZ, MPA and BEZ+MPA induced ROS both in the 
absence and presence of CD40L (figure 44).  In the absence of CD40L the percentage of ROS 
produced was extremely variable between patient samples, especially in regard to MPA 
treatment.  Overall, without CD40L, BEZ induced the production of more ROS than MPA 
and the combination of BEZ+MPA was not substantially more than with BEZ alone.  
Nevertheless, the average ROS produced in the presence of CD40L was more with 
BEZ+MPA than with either agent alone.   
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Figure 44.  BEZ, MPA and BEZ+MPA induce ROS in both the absence and presence of 
CD40L   a) Cells were cultured in the absence (left) and presence (right) of CD40L and 
treated in triplicate with solvent control (black fill), 0.5mM BEZ (pink line), 5µM MPA (blue 
line) or BEZ+MPA (purple line) for 24 hours prior to harvesting, pooling and incubating 
with H2DCFDA for 40 minutes, and analysis by FC.  b) Data are the mean ± s.e.m. from 
n=3 patients, in the presence (purple) and absence (blue) of CD40L.  
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Figure 45.  BEZ, MPA and BEZ+MPA induce MSO only in the absence of CD40L. 
 a) Cells were cultured in the absence (left) and presence (right) of CD40L and treated with 
solvent control (black fill), 0.5mM BEZ (pink line), 0.5µM MPA (blue line) or BEZ+MPA 
(purple line) for 24 hours prior to harvesting, pooling and incubating with MitoSOX Red 
for 10 minutes and analysis by FC. b) Data are the mean ± s.e.m. from  n=3 patients, in the 
presence (purple) and absence (blue) of CD40L.  
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4.3.10. Treatment with BEZ+MPA induces MSO only in the absence of CD40L. 
MitoSOX Red was used to detect the production of MSO following treatment.  In the 
absence of CD40L (figure 45) BEZ and MPA, as individual agents, both induced MSO 
production to similar levels.  Nevertheless, as with many CLL cell apoptotic responses, 
the combination of BEZ+MPA was additive.  More strikingly, though, was the lack of 
MSO produced by BEZ, MPA or BEZ+MPA when CD40L was present (figure 45a right plot 
and b purple fill).  When treated with PGD2 or 15dΔ12,14PGJ2  (figure 46) ROS was produced 
to a similar level as that seen by BEZ+MPA in the absence of CD40L.  Notably, 
15dΔ12,14PGJ2 and PGD2 also generated some increased MSO in CD40L-stimulated cells, 
possibly indicating an alternative mechanism of action to those exhibited by BEZ+MPA.  
Nonetheless, the percentage of MSO produced was minor, in comparison to non CD40L-
stimulated cells.  Overall the data suggests that BEZ elicits similar cellular effects on CLL 
cells to 15dΔ12,14PGJ2 and PGD2 and that this action is not interfered with by MPA.  It 
could, therefore, be postulated that the ROS and MSO generation in response to BEZ and 
BEZ+MPA, in the absence of CD40L, may be the consequence of PGD2 and thus 
15dΔ12,14PGJ2 elevation.  This is likely to be the case for BEZ but, in light of the data 
previously shown, MPA is not causing the same induction of prostanoids.   
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Figure 46.  PGD2 and 15d∆12,14PGJ2 induce ROS and MSO to a comparable level to 
BEZ+MPA.  Cells were cultured in the absence (left) and presence (right) of CD40L and 
treated with solvent control (black fill), 50µM PGD2 (green line) or 35µM 15d∆12,14PGJ2 (red 
line) for 24 hours prior to harvesting, pooling and incubating with  a) H2DCFDA for 40 
minutes or b) MitoSox Red for 10 minutes and analysis by FC.  Plots are representative of 
n=3 experiments.  
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4.3.11.  Chlorambucil does not induce the production of MSO. 
In chapter 3, the effects of BEZ+MPA and BEZ+MPA+chlorambucil were compared to the 
in vitro levels of apoptosis induced by chlorambucil alone.  It was shown that BEZ+MPA 
induced apoptosis, in the absence of CD40L, to similar levels as chlorambucil and that 
chlorambucil, like BEZ+MPA, did not induce apoptosis in the CD40L-stimulated CLL cells.  
This led to the analysis of MSO produced following chlorambucil treatment, compared to 
BEZ+MPA and BEZ+MPA+ chlorambucil.  It was surprising to note that chlorambucil did 
not induce MSO without CD40L stimulation (figure 47).  However, the lack of MSO by 
chlorambucil, in the presence of CD40L, was less surprising in light of the result that, like 
BEZ+MPA, chlorambucil also did not induce apoptosis of CD40L-stimulated CLL cells.  As 
might be expected, these data indicate that the mechanisms of action of BEZ+MPA and 
chlorambucil are different and may explain why more apoptosis was observed in the 
combination of chlorambucil with BEZ+MPA.  The differential targets of three agents 
combined may lead to a better in vivo response than the use of these regimens 
individually. 
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Figure 47.  Unlike BEZ+MPA, chlorambucil treatment does not induce MSO.  CLL cells 
were cultured on non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  
Triplicate treatments of either solvent control (left; black fill), 1mM chlorambucil (middle; 
grey line) or BEZ+MPA (right; purple line) were harvested and pooled at 24 hours and 
incubated with MitoSOX Red for 10 minutes, prior to analysis by FC.  Plots shown show 
are representative of variability of response observed from n=4 patients.  
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4.4. Discussion  
Unlike in the parallel study of MPA treatment of AML cells, the 11β-PGD2-ketoreductase-
activity of AKR1C3 could not be detected in CLL cells and no strong evidence was 
obtained that AKR1C3 represents the CLL target of MPA.  Investigations into the 
alternative activities of MPA revealed that ML-PRD and SPN exerted similar effects to 
those of MPA, but these were not associated with their known receptors or other receptors 
of the corticosteroid family.  However, it remains possible that these agents are exerting 
their effects via an unknown, common target.  
BEZ was able to induce and increase in PGD2 and when added exogenously, PGD2 and 
15dΔ12,14PGJ2 were able to induce apoptosis in a dose dependent manner, recapitulating 
the effects of BEZ and BEZ+MPA.  
It has previously been reported that 15Δ12,14PGJ2 is associated with the generation of ROS 
and MSO.  Additionally BEZ has been associated with oxidative stress.  In the absence of 
CD40L, BEZ, MPA and moreover the combination induced ROS and MSO.  A proposed 
mechanism for the induction of ROS and/or MSO by BEZ and thus the induction of 
apoptosis in this setting is shown in figure 62 at the end of chapter 6.   
Conversely, in the presence of CD40L, only the presence of ROS was observed.  These data 
imply that CD40-ligation protects CLL cells against drug induced MSO production and 
that this generation of MSO within the PC may be the key to causing apoptosis in this 
protected niche. 
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5.1. Introduction. 
For a therapy to be successful in CLL, the tumour load, both in the  PC as well as in the 
periphery, needs to be eradicated.   Chapter 3 demonstrated that BEZ+MPA were effective 
at inducing apoptosis of the quiescent peripheral CLL cells and reducing the proliferation 
of the CD40L stimulated cells.  Conversely, like most therapies tested in vitro, they were 
unsuccessful at causing death of cells cultured in the presence of CD40L.  This regimen 
would be beneficial to patients as it would reduce or stop the production of the malignant 
cells from the PCs.  Whilst this would potentially improve a patient’s life and reduce the 
tumour burden, once the therapy is ceased it is probable that, without a suppressive 
signal, the PCs would be re-established and the patient relapse.   
Chapter 4 showed that whilst BEZ+MPA induced the production of MSO and ROS in the 
absence of CD40L, only ROS was produced in the presence of CD40L.  Therefore, CD40L is 
likely to be protecting against MSO production and thus, potentially, preventing cell 
death.  It is apparent, therefore, that this protective signal needs to be overcome in order 
to induce cell death within the PCs.  Targeting mitochondria within tumour cells has 
recently been cited as a potential way to overcome apoptotic blocks (Goldin et al., 2007).  
In this chapter it is proposed that, in the PC CLL setting, this could be executed by 
inducing a high enough level of MSO that CD40L cannot counteract, or by a third 
mechanism, different to that of BEZ+MPA, that leads to the diminution of this protection.  
Hallaert  et al (2008) reported that the protective effects of CD40L could be overcome by 
the use of the c-Abl kinase inhibitor DSN.  It was demonstrated that this was due to a 
reduction in anti-apoptotic proteins such as BimEL and Mcl-1.  However, the CD40L signal 
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was removed for 24-48 hours prior to analysis of the patient samples.  Therefore, it cannot 
be concluded that DSN can overcome CD40L when the signal is continually present.   
In this chapter, several agents were investigated for the potential of inducing apoptosis in 
this system and any successful agents compared to the effectiveness of DSN.  These 
compounds are different to BEZ and MPA in that they are not currently available drugs.  
Each of them is a novel compound that could be developed as a therapeutic agent if 
effective.   
Parts of sections 5.2 and 5.3.1 were published in 2008/9 by Elsevier and AACR Journals 
respectively.  Full details of these manuscripts can be found in Appendix A2.  
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5.2. Use of an intercalating DNA agent. 
A tetracationic supramolecular cylinder, [Fe2L3]4 (Fe cylinder), was developed in 2001 
(Hannon et al., 2001) and has since been proven to intercalate in the major groove and 
affect DNA coiling (Khalid et al., 2006).  It has been suggested that this agent could be 
used as an alternative to chemotherapeutics such as cisplatin.  Collaborative studies led to 
the investigation of the cellular effects of this agent and were first tested in AML.  The 
ability of Fe cylinder to induce apoptosis and inhibit proliferation in the AML cell line 
HL-60 was analysed.   
At a dose of 10µM Fe cylinder, inhibition of cell cycle was seen with an accumulation of 
G1/G0 at 24 hours (figure 48a).  The percentage of events in G1/G0 in the controls was 
observed at 40.0% ± 3.5% compared to 64.7% ± 4.5% in treated cultures.  Additionally, a 
reduction in the percentage of cells in S phase (22.8% ± 6% compared to 43.8% ± 7%) was 
seen.  The higher dose of 25 µM did not induce the same G1/G0 arrest but the reduction in 
S phase was maintained (figure 48b; left panel).  Additionally, at this dose, sub-G1 events 
were higher compared to the controls.  This is indicative of cell death and, as cell counts of 
the cultures revealed 50% less cell in those treated (data not shown) compared to controls, 
it was hypothesised that Fe cylinder was inducing apoptosis.  This was investigated 
further using the AV/PI analysis used for the CLL experiments.  At 24 hours, very little 
AV binding or PI accumulation could be detected (figure 48b).  This was slightly 
enhanced to 17% at 48 hours but was not sufficient enough to account for the reduction in 
cell number.  Further, analysis of the cell cycle profile also revealed a reduction in the PI 
signal in Fe cylinder treated cultures. 
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Sub G1 G1/G0 S G2/M  Total AV
positive (%)
Control 2.3±0.3 43.3±1.9 38.5±0.7 15.5±0.4 1.8±0.1
24h 21.4±1.6 39.6±1.8 22.7±2.3 14.4±1.9 7.1±1.0
48h 23.4±4.1 42.9±5.7 20.6±3.0 11.8±1.1 17.1±1.2
c
Sub-G1
G0/G1
G2M
S
 
 
 
Figure 48.  Fe cylinder causes cell cycle arrest, reduces the fluorescence intensity of PI 
and induces apoptosis in HL-60 cells.  HL-60 cells were seeded at a density of 2.5x105/ml 
and treated with Fe cylinder.  a) Induction of G1 cell-cycle arrest at 24 hours, following 
treatment of 10 µM as assessed by PI staining of DNA and FC analysis.  Plots are 
representative of n=3 experiments.  b)  Induction of apoptosis following 25µM treatment 
as assessed by (left panel) PI staining and FC and (right panel) binding of AV and uptake of 
PI and FC at 0 hours (top) 24 hours (middle) and 48 hours (bottom).  c) The associated table 
shows the percentage of events in each stage of the cell cycle and the percentage of total 
AV positive cells ± s.d. from n=3 experiments.   
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Compared to the untreated controls this indicated that the PI used to stain DNA, was 
unable to bind with the same efficiency.  As it has been previously shown that Fe cylinder 
can displace ethidium bromide from calf thymus DNA (Hannon et al., 2001), it was 
thought that Fe cylinder treatment could lead to PI having to compete to be able to bind to 
DNA.  Indeed, this was proven to be the case by other members of the laboratory (Hotze 
et al., 2008).  As this was not seen in the lower dose, it is possible that the amount of DNA 
binding is attributable to the amount of cell death seen.  It is probable that Fe cylinder 
induces cell cycle arrest, rendering the cells in senescence and, upon DNA intercalation, 
induces some cell death.   
Using the above data it was hypothesised that combining BEZ+MPA with Fe cylinder 
may be more effective at reducing cell proliferation of the CD40L stimulated CLL cells.  If 
the cells were to become cytostatic it was hypothesised that BEZ+MPA could induce 
apoptosis of the CLL cells.  A dose titration of Fe cylinder with BEZ+MPA revealed that 
no doses of this combination exerted pro-apoptotic effects (figure 49).   
Therefore, whilst Fe cylinder may be worth further investigation in AML, it is unlikely to 
be of benefit in CLL. 
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Figure 49.  Fe Cylinder does not potentiate BEZ+MPA to induce apoptosis in the 
presence of CD40L.  CLL cells were cultured on CD40L expressing stroma in a ratio of 10:1 
in 96 well plates.  Cells were treated in triplicate with a BEZ+MPA in the absence (blue) 
and presence  (purple) of a 2-fold titration Fe Cylinder (from 50µM to 6.25µM).  After 72 
hours, triplicate wells were harvested, pooled and analysed for the binding of AV and 
uptake of PI using FC.  Data are the mean ± s.e.m. from n=6 patients.  
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5.3. Use of plant derived compounds 
5.3.1. Jasmonates 
Jasmonates are fatty acid–derived cyclopentanones and have been investigated for their 
potential use as cancer therapy (Heyfets and Flescher, 2007, Flescher, 2007, Flescher, 2005).  
They have also been reported to have mitochondrial effects, most notably in CLL cells 
(Rotem et al., 2005).  JA and MeJ have structural similarity to PGD2 and this led  this group 
to study these compounds in relation to their ability to inhibit AKR1C3 in AML cells.  In 
addition, the cellular effects of JA and MeJ on cell viability, cell differentiation and the 
production of both ROS and MSO were investigated. 
Using KG1a, both JA and MeJ reduced cellularity in a dose dependant manner (figure 50).  
In JA treatment only 4mM proved to be lethal to the whole culture with around 50% 
cellular activity at doses of 2 and 1mM.  Conversely, MeJ was far more potent, reducing 
cellularity to almost 0 at a dose of 0.5mM.  Comparing JA and MeJ at 0.5mM on Δψm 
showed that JA had no effect on the Δψm (figure 51a), whereas MeJ significantly reduced 
Δψm.  Analysis of MSO production demonstrated that JA did not induce MSO generation 
at doses lower than 4mM (figure 51b) and that very little MSO was detected at 4mM.  
Conversely, MeJ was far more effective at inducing MSO, with 0.5 to 4mM showing dose 
dependent increases in MSO produced.  Following the CLL data in chapter 4 (section 
4.3.10.), this supports the proposed importance of the induction MSO in order to induce 
cell death.   
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Figure 50.  Jasmonates reduce cellularity of myeloid KG1a cells.  KG1a cells were seeded 
at a density of 2.5x105/ml and cultured for 5 days in the presence of a 2-fold titration of JA 
(blue) and MeJ (purple) before analysis of cellularity by cell titre blue.  Data are the mean ± 
s.e.m. from n=3 experiments. 
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Figure  51.  Jasmonates adversely affect mitochondria and induce MSO in KG1a cells.  
KG1a cells were seeded at a density of 2.5x105/ml and treated with solvent control, 0.5mM 
JA or 0.5mM MeJ and a) cultured for 5 days prior to analysis of ∆ψm; (top) representative 
FC plots are shown; (bottom) mean percentage of apoptotic cells ± s.e.m. from  n=3 
experiments; b) cultured for 24 hours in the presence of a 2-fold titration of JA (blue) and 
MeJ (purple) before analysis of MSO generation by MitoSOX Red and FC.  Data are the 
mean ± s.e.m. from n=3 experiments.  
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Although Jasmonates have been researched for their use in CLL, this was on quiescent 
cells only (Rotem et al., 2005).  Following the data of MeJ inducing MSO in AML cells, it 
was hypothesised that MeJ may also be effective at inducing MSO in the presence of 
CD40L and that, when combined with BEZ+MPA, could lead to apoptosis of the 
proliferating CLL cells.  A dose titration of MeJ without BEZ+MPA (figure 52) revealed 
that MeJ alone did not induce any apoptosis of CD40L protected CLL cells.  When 
BEZ+MPA was combined with MeJ (figure 52) the level of apoptosis was increased but 
even at 1mM only reached around 32%.  In the absence of BEZ+MPA, MeJ was 
additionally unable to induce MSO (figure 53). Upon the addition of BEZ+MPA only 1mM 
produced any significant level of MSO.  This data correlates with cell death only being 
significantly detected in BEZ+MPA+1mM MeJ.  Following Rotem’s studies (2005), it was 
surprising that low doses of MeJ could not potentiate BEZ+MPA.  Whilst 1mM MeJ could 
potentially be combined with BEZ+MPA to treat CLL, this dose is high and the levels of 
apoptosis seen in vitro are not substantial enough for this to be likely to be successful 
clinically.  Nonetheless, the data did contribute to the data presented thus far; that CD40L-
mediated protection can be overcome and apoptosis instigated together with the 
generation on MSO.  It also highlighted the potential of naturally derived compounds to 
exert these activities.  
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Figure 52.  HD MeJ potentiates BEZ+MPA to induce apoptosis in the presence of 
CD40L. CLL cells were cultured on CD40L expressing stroma in a ratio of 10:1 in 96 well 
plates.  Cells were treated in triplicate with a 2-fold titration (1mM to 0.125mM) of MeJ in 
the absence (blue) and presence (purple) of BEZ+MPA.  After 72 hours, triplicate wells 
were harvested, pooled and analysed for the binding of AV and uptake of PI using FC.  
Data are the mean ± s.e.m. from n=4 patients.  
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Figure 53.  HD MeJ potentiates BEZ+MPA to produce MSO in the presence of CD40L.   
CLL cells were cultured on CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  
Cells were treated in triplicate with a 2-fold titration (1mM to 0.125mM) of MeJ in the 
absence (blue) and presence (purple) of BEZ+MPA.  After 48 hours triplicate wells were 
harvested, pooled and analysed for MSO positivity using MitoSOX Red and FC.  Data are 
the mean ± s.e.m. from n=4 patients.  
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5.4. Lycorine. 
Lycorine is one of many alkaloids found in the plant family Amaryllidaceae.  Several 
Amaryllidaceae alkaloids have been found to have anti-cancer properties and lycorine in 
particular has been investigated for its use in AML (McNulty et al., 2009) and ALL (Liu et 
al., 2007).  Its potential use as a therapeutic has recently led to studies into synthetic 
production of the compound (Jones et al., 2009).  The anti-apoptotic protein MCL-1 is 
known to be upregulated in CLL cells exposed to CD40L.  Studies to date have shown that 
lycorine causes the down regulation of this protein (Liu et al., 2009), as well as inducing 
cell cycle arrest and mitochondrial damage (Liu et al., 2004).  These three documented 
effects, led to the hypothesis that lycorine may be able to overcome the protection of 
CD40L and induce apoptosis either alone or in combination with BEZ+MPA.   
5.4.1.  Lycorine has little pro-apoptotic effect when used alone but the combination of 
BEZ+MPA+lycorine is potent. 
Surprisingly, lycorine alone was found to have very little pro-apoptotic effect on CD40L-
stimulated CLL cells (figure 54).  However, doses of 5µM induced higher apoptosis than 
was seen previously with either 1mM MeJ or 50µM Fe cylinder- alone.  This result was 
encouraging and thus, the effects of combining this agent with BEZ+MPA were analysed.  
When combined with BEZ+MPA the results showed a dose-dependent additive effect of 
BEZ+MPA to lycorine (figure 54).  Even at the lowest dose tested, of 0.6µM, the BEZ+MPA 
pro-apoptotic effect was potentiated to give apoptosis of around 36%, compared to 17% in 
the controls.  This apparent synergistic action of lycorine on BEZ+MPA, effectively 
plateaued beyond 2.5µM (figure 54).   
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Figure 54.  Lycorine potentiates BEZ+MPA to induce apoptosis in the presence of 
CD40L in a dose dependent manner.  CLL cells were cultured on CD40L expressing 
stroma in a ratio of 10:1 in 96 well plates.  Cells were treated in triplicate with a 2-fold 
titration (10µM to 0.06µM) of lycorine in the absence (blue) and presence (purple) of 
BEZ+MPA.  After 72 hours triplicate wells were harvested, pooled and analysed for the 
binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. from n=6 patients.  
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Figure 55.  Lycorine potentiates BEZ+MPA to produce MSO in the presence of CD40L, in 
a dose dependent manner.   CLL cells were cultured on CD40L expressing stroma in a 
ratio of 10:1 in 96 well plates.  Cells were treated in triplicate with a 2-fold titration (10µM 
to 0.06µM) of lycorine in the absence (blue) and presence (purple) of BEZ+MPA.  After 48 
hours triplicate wells were harvested, pooled and analysed for MSO positivity using 
MitoSOX Red and FC.  Data are the mean ± s.e.m. from n=6 patients.  
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As a result of the lack of cell death induced by lycorine alone, it was predicted that this 
agent on its own would not induce MSO production.  This indeed was the case (figure 55), 
with only 10µM able to cause detectable MSO.  Even at this dose the amount produced 
was the same as that produced by BEZ+MPA alone.  The combination of 
BEZ+MPA+lycorine induced far more MSO.  This generation correlated with the level of 
total AV seen, with 0.6 to 1.25µM inducing a significant level of MSO, and doses higher 
than 2.5µM levelling out.  Additionally, when cells were observed for viability, as 
measured by FSC and SSC, the number of viable events was reduced in 
BEZ+MPA+lycorine dose dependently (figure 56a).  Further, correlation analysis of total 
MSO produced against viable events (figure 56a; right panel) and total AV (figure 56b; 
right panel) demonstrated that an increase in MSO correlated with loss of viability and 
apoptosis.  Together, these data strongly suggest that the apoptosis caused by the 
combination of BEZ+MPA+ lycorine is due to the reinstated accumulation of MSO by the 
treated cells. 
5.4.2.  Low dose lycorine+BEZ+MPA is targeted against malignant B cells. 
Following the observation that lycorine could be combined with BEZ+MPA to induce 
apoptosis of the PC CLL cells, the effect on normal cells was investigated.  Using MNCs 
isolated from normal donors, two doses of lycorine with and without BEZ+MPA were 
analysed on both CD40L stimulated cells and non-CD40L stimulated.  The lower dose of 
1.25µM lycorine did not induce apoptosis of either the CD40L protected cells (figure 57a) 
or MNCs without CD40L (figure 57b).  However, lycorine used at the higher dose of 10µM, 
however, did cause some apoptosis of the normal cells.  This apoptotic response was 
further potentiated by the addition of BEZ+MPA. 
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Figure 56.  Cell viability and total AV correlates with MSO production.  CLL cells were 
cultured in a 10:1 ratio on stromal cells expressing CD40L and were treated with solvent 
control or BEZ+MPA with a 2-fold dose titration of lycorine.  a) At 72 hours cells were 
analysed for cell viability by FSC and SSC by FC and the viable events gated as shown 
(left panel), as well as for the binding of AV and exclusion of PI.  b) At 48 hours cells were 
analysed for the generation of MSO.  Graph a) shows total % MSO plotted against % 
viable cells and graph b) shows total % MSO plotted against total AV for each lycorine 
concentration.  Data are the mean ± s.e.m. from n=6 patients. 
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Figure 57.  LD lycorine+BEZ+MPA exerts minimal effects against normal cells.  MNCs 
from normal donors were cultured on a) CD40L expressing stroma or b) non-CD40L 
expressing stroma in a ratio of 10:1 in 96 well plates.  Cells were treated in triplicate with 
1.25µM or 10µM lycorine in the absence (blue) and presence (purple) of BEZ+MPA.  After 
72 hours, triplicate wells were harvested, pooled and analysed for the binding of AV and 
uptake of PI using FC.  Data are the mean ± s.e.m. from n=6 patients.  
Chapter Five - Targeting the PC 
 
 175 
 
Together with the dose titration, this indicates that, for CLL cells to be sufficiently 
targeted with low effects on normal haemopoietic cells, that the best combination to use 
as a treatment would be BEZ+MPA+1.25µM lycorine.   
5.4.3.  The Mitochondrial specific antioxidant, MitoQ, is unable to rescue the cells from 
MSO production.  
The anti-oxidant MitoQ, a ubiquinone derivative, was developed in 2001 to specifically 
locate to the mitochondria (Kelso et al., 2001).  Subsequent studies have shown that MitoQ 
can successfully reduce myocardial ischemia (Neuzil et al., 2007), which has been linked 
with mitochondrial damage (Rodriguez-Cuenca et al., 2009).  To date, no studies have 
been published using MitoQ to counteract mitochondrial damage exerted by exogenously 
added therapies.  Nevertheless, it was hypothesised that MitoQ may be able to inhibit 
MSO production by cells treated with BEZ+MPA+2.5µMlycorine.  A dose titration of 
MitoQ against CLL cells showed a mild dose dependent increase in MSO when MitoQ 
was used alone (figure 58).  At the doses of 0.2 µM, very little MSO was induced alone but 
this dose was unable to counteract the MSO produced by BEZ+MPA+lycorine (figure 58).  
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Figure 58.  MitoQ is unable to reduce the levels of MSO produced by 
BEZ+MPA+lycorine.  CLL cells were cultured on CD40L expressing stroma in a ratio of 
10:1 in 96 well plates.  Cells were treated in triplicate with a 2-fold titration (1µM to 
0.2µM) of mitoQ in the absence (blue) and presence (purple) of BEZ+MPA+2.5µMlycorine.  
After 48 hours triplicate wells were harvested, pooled and analysed for MSO positivity 
using MitoSOX Red and FC.  Data are the mean ± s.e.m from n=4 patients.  
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5.4.4.  When the CD40L is removed BEZ+MPA is as good at inducing apoptosis as the 
published study of dasatinib + fludaribine. 
As described in chapter 1, sections 1.10.1 and 1.21, in 2008 Hallaert et al published the 
potential use of the DSN to sensitise CLL cells to F-ara-A.  Owing to the way the 
experiments had been carried out, attempts were made to recapitulate them, together 
with BEZ+MPA.  Following Hallaert’s protocol of removing the CD40L signal and 
culturing the cells with treatments for a further 24 hours prior to analysis, DSN did not 
induce apoptosis alone, but the combination of DSN and F-ara-A did (figure 59).  This 
confirmed the observation of Hallaert et al.  Nevertheless, BEZ+MPA was equally as good 
at inducing apoptosis in this setting.  Additionally, DSN did not have any additive effect 
on BEZ+MPA (figure 59).   
5.4.5.  When the protective CD40L is maintained, unlike lycorine, DSN+F-ara-A no 
longer induce apoptosis. 
Whilst the above experiment serves to prove that DSN+F-ara-A could induce apoptosis of 
circulating B-CLL cells on release from the PC, it does not serve to prove that this 
combination would be effective at targeting cells within the PC.  Indeed, as the 
combination was only effective as BEZ+MPA, it was hypothesised that in the same way as 
BEZ+MPA is unable to, the Hallaert combination would not be effective at inducing 
apoptosis within the PC.  To investigate this, the treatments were repeated without the 
removal of CD40L thereby mimicking the PC, as already shown in this chapter.   
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Figure 59.  DSN, BEZ+MPA and DSN+BEZ+MPA sensitise previously, CD40L 
stimulated CLL cells to F-ara-A 24 hours after the signal is removed.  CLL cells were 
cultured on CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  Cells were 
treated in triplicate with solvent control, 30µM DSN, 5mM F-ara-A, DSN+F-ara-A, 
BEZ+MPA or BEZ+MPA+DSN.  After 48 hours the cells were harvested from the stroma, 
washed and re-cultured with the appropriate treatments for a further 24 hours, as 
described in Hallaert et al.  Triplicate wells were harvested, pooled and analysed for the 
binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. from n=3 patients.  
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Figure 60.  If the CD40L is not removed DSN does not sensitise CLL cells to F-ara-A.  
CLL cells were cultured on CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  
Cells were treated in triplicate with solvent control, 1.25µM lycorine, 30µM DSN, 5µM F-
ara-A , BEZ+MPA, BEZ+MPA+1.25µM lycorine, DSN+F-ara-A, or BEZ+MPA+DSN.  After 
72 hours, the cells were harvested, pooled and analysed for the binding of AV and uptake 
of PI using FC.  Data are the mean ± s.e.m. from n=3 patients.  
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After 72 hours treatment, BEZ+MPA predictably did not induce any apoptosis of the 
CD40L stimulated CLL cells (figure 60).  Additionally, and again as expected, DSN did not 
sensitise the CD40L protected cells to BEZ+MPA.  As already shown, the combination of 
BEZ+MPA+1.25µM lycorine did successfully induce apoptosis of the cells.  The lack of 
apoptosis caused by DSN+F-ara-A (figure 60) was particularly interesting.  Consequently, 
the combination studied by Hallaert et al can only induce apoptosis of non-CD40L 
protected cells, in the same was as BEZ+MPA alone.  However, BEZ+MPA+1.25µM 
lycorine consistently causes apoptosis of these cells.  
5.4.6.  DSN+F-ara-A are not specifically targeted to CLL cells. 
Whilst DSN+F-ara-A did not cause apoptosis of CLL cells in vitro when the CD40L is 
maintained, it could be therapeutically useful to treat CLL cells that are in the periphery.  
The level of apoptosis induced by DSN+F-ara-A on the removal of CD40L was similar to 
that of BEZ+MPA alone.  In a chapter 3, figures 12, 13 and 20, it was shown that 
BEZ+MPA had minimal effects on normal B cells.  Therefore, the effects of DSN+F-ara-A 
against normal cells were investigated.   
Both in the presence (figure 61a) and the absence (figure 61b) of CD40L DSN induced 
apoptosis of normal MNCs.  It is well documented that F-ara-A is non-targeted and will 
induce death in many cell types, not only the malignant cells.  Therefore, the level of 
apoptosis induced by F-ara-A in both the CD40L protected cells and the cells cultured 
without CD40L was to be expected (figure 61).  This non-discriminatory induction of 
apoptosis seen in DSN or F-ara-A alone was increased when both agents were used 
together (figure 61).  This was the same for the presence (figure 61a) and absence (figure 
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61b) of CD40L, with the total AV positivity of the combination reaching around 60% in 
both culture conditions 
This data suggests that, while DSN+F-ara-A induce apoptosis of CLL cells, it is 
untargeted.  The level of cell death of CLL cells using this published combination is no 
better than that of BEZ+MPA.  As BEZ+MPA exert little effect on non-malignant cells the 
combination of BEZ+MPA would seem to be more beneficial than that of DSN+F-ara-A.  
Further, the combination of BEZ+MPA+1.25µM lycorine in vitro is able to target the PC 
whilst leaving the normal cells intact.  
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Figure 61.  DSN alone induces apoptosis of normal cells, which is potentiated by 
F-ara-A.  MNCs from normal donors were cultured on a) CD40L expressing stroma or b) 
non-CD40L expressing stroma in a ratio of 10:1 in 96 well plates.  Cells were treated in 
triplicate with solvent control or 30µM DSN in the absence (blue) and presence (purple) of 
5µM F-ara-A.  After 72 hours, triplicate wells were harvested, pooled and analysed for the 
binding of AV and uptake of PI using FC.  Data are the mean ± s.e.m. from n=3 patients.  
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5.5. Discussion. 
Targeting the PCs in CLL in vivo remains a challenge.  In chapter 3, it was shown that 
BEZ+MPA induced apoptosis in the absence of CD40L, but not in its presence. 
Investigations into the use of novel compounds has revealed that whilst agents such as 
the DNA intercalator Fe cylinder can reduce proliferation of the AML cell line HL-60, it is 
unlikely to be of therapeutic use in CLL.   
Plant compounds and their use in cancer, are a current area of research.  The use of 
jasmonates have been investigated in leukaemia including CLL by other research groups 
(Rotem et al., 2005) and have been shown to cause mitochondrial damage.  Here we have 
shown in the AML cell line KG1a that, MeJ causes Δψm depolarisation, and induces 
apoptosis with MSO dose dependently.  However, on investigation in CLL, MeJ alone 
exerted very little effects and in combination with BEZ+MPA only the highest dose tested 
(of 1mM) was able to induce apoptosis and MSO.  
The experiments shown here, using lycorine and BEZ+MPA, highlight that as a proof of 
principle, apoptosis can be induced when CD40L is continually present.  This is 
significantly different to other studies on DSN+F-ara-A, where apoptosis is dependent on 
the removal of the protective signal.  Additionally, normal cells remain relatively 
unaffected by the combination of BEZ+MPA+1.25µM lycorine, whereas DSN and F-ara-A 
cause significant apoptosis of normal cells.  
The data presented here, strongly suggests that the apoptosis caused by the combination 
BEZ+MPA+1.25µM lycorine is most likely to be due to the production of MSO by the 
treated cells.   
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6.1. The case for rational drug redeployment in CLL. 
To date CLL remains a disease that requires new therapies that aim to improve response 
rates, progression free survival and OS.  Whilst research into new drugs should provide 
improvements, the time from concept to clinic is likely to be lengthy.  Therefore, it is 
pertinent to consider the redeployment of existing drugs, either alone or in combination 
with other therapies for the treatment of this disease.  Such strategies in haematological 
malignancies have demonstrated the substantial impact that existing agents can exert.  
Examples include the use of retinoic acid (RA) (Fenaux et al., 2007) and arsenic trioxide 
(Chen et al., 2007) in APL and thalidomide in multiple myeloma (MM) (Prince et al., 
2007).  These paradigms illustrate that drugs, not originally considered as cancer 
therapeutics, can provide genuine benefit.  Screening ‘old’ therapies in CLL in vitro has 
already proven to be beneficial in relation to bendamustine.  The in vitro studies of this 
agent alone against CLL cells (without CD40L) identified that at 72 hours this agent was 
able to induce a median apoptosis of around 40% (Schwanen et al., 2002).  Such studies 
have led to the use of this agent in clinical trials, which have shown around a 30% CR 
(Kath et al., 2001, Knauf et al., 2009). 
Other studies from our group have highlighted the potential of BEZ and MPA in AML 
and BL (Fenton et al., 2003, Khanim et al., 2009, Murray et al.).  Here the potential for 
redeployment of the same drugs in CLL was investigated. 
6.1.1. Is the redeployment of MPA and BEZ feasible? 
MPA, best known as the contraceptive Provera,  has been successfully used to treat breast 
(Davila et al., 1988) and endometrial (von Minckwitz et al., 2002) cancers.  The doses used 
in these settings (up to a 1000mg/day) achieve plasma levels up to 15µM 
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(Ohtsu et al., 1998).  The dose titration of MPA against CLL shown in figures 6 and 15 
indicates that the doses of 5µM MPA that were subsequently selected for further study, 
were sub-optimal in the generation of apoptosis or the arrest of cell division. However, 
this dose of 5µM is commensurate with that achievable in patients.  Notably, with BEZ the 
standard dose used to treat hyperlipidemia is 400 mg of Bezalip Mono, taken once a day.  
This dose is associated with a plasma level of 25µM.  Although the in vitro dose of 0.5mM 
used here to exert the pro-apoptotic (figure 6) and anti-proliferative actions (figure 15) of 
BEZ exceed this by twenty fold, investigations of overdose in humans and exposure in 
rhesus monkeys indicates that thirty times the standard daily dose is tolerated without ill 
effect, for up to a year (Yoshikuni et al., 1988). It seems likely, therefore, that the drug dose 
used herein can be achieved and tolerated in patients. 
Following the parallel laboratory study of the actions of BEZ and MPA in AML (Khanim 
et al., 2009), a pilot phase I/II study has been undertaken in 20 elderly or relapsed AML 
patients (Murray et al.).  This study aimed at investigating the safety of combining BEZ 
and MPA in vivo and was restricted to using only those maximal doses that had been 
previously administered to patients. Despite the known shortfall in the drug doses 
achieved, compared to those used both in the in vitro studies of AML and this study of 
CLL, strong indications of potential clinical benefit were observed.  This included one 
patient who, although classified as a PR, had reduced blast count and was both platelet 
and red cell-transfusion independent for over 201 weeks and is currently fit and well 
(Murray et al; 2009 in press).  These benefits observed following BEZ+MPA therapy were 
associated with very little toxicity.  Despite the positive outcomes observed, the 
investigation was stopped due to the fact that little or no toxicity was observed and owing 
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to the concomitant laboratory studies that, as discussed here, achieved better responses at 
higher does.  Murray et al (2010) therefore proposed the use of six 400mg tablets twice 
daily.  This dose has been demonstrated to give peak bezafibrate plasma concentration of 
264µM, without significant toxicity (Abshagen, et al 1980, Dollery 1999).   Therefore, if 
trialled in CLL, the doses of Provera and Bezalip Mono should be 1000mg and 3600mg per 
day respectively.  
6.2. The potential of the combination of BEZ+MPA and its use in combination with 
chlorambucil.  
The in vitro studies shown here demonstrated that while the overall response rate of CLL 
cells to BEZ and MPA was high, the combination of BEZ+MPA proved to be most 
effective at inducing apoptosis and reducing proliferation in the absence and presence of 
CD40L respectively.  Nonetheless, there was some underlying heterogeneity in responses, 
especially in the absence of CD40L.   Extensive statistics revealed that this heterogeneity 
did not correlate with acknowledged prognostic indicators namely of Binet stage, LDT, 
CD38 expression, ZAP-70 positivity, chromosomal abnormalities or IgVH mutations.  
Considering chromosomal alterations, in particular the TP53 deletion, the finding that 
BEZ+MPA response does not correlate with any investigated deletion could be 
encouraging.  This indicates that BEZ+MPA, unlike most common therapies (Pepper, 
2008) (except flavopridol and antibody therapies), is unlikely to be dependent on the P53- 
apoptosis pathway.  Nevertheless, as yet, the cellular and/or molecular basis of the 
heterogeneous response to BEZ+MPA remains unknown.  As with all current CLL 
therapy, it is likely that if BEZ+MPA became an established form of treatment some 
patients would benefit from this therapy more than others.  Forthcoming publications on 
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risk and prognosis in CLL could elucidate this.  For example, new risk variants in CLL, 
following SNPs analysis, such as 2q37.3, 8q24.21, 15q21.3 and 16q24.1 (Crowther-
Swanepoel et al.) and/or the newly modified prognostic indicator glomular filtration rate 
(GFR) adjusted B2M (GFR-B2M) (Delgado et al., 2009b) were not assessed here.  Such 
comparisons, theoretically, may identify patients likely to respond to therapy.  However, 
such methods, especially SNPs analyses are expensive, therefore, it would be less costly, 
and interesting to consider whether in vitro responses to BEZ+MPA were to reflect in vivo 
responses.  In this regard, if a clinical trial on refractory and relapsed patients were to be 
undertaken, patients’ pre-treatment samples should first be subjected to BEZ+MPA in 
vitro  and analysed by the assays used here such as MitoSOX.  This will determine 
whether these in vitro analyses will, in future, be able to  identify patients likely to benefit.   
Despite the ability of BEZ+MPA to successfully induce apoptosis, in most patient samples 
tested, in the absence of CD40L, and reduce proliferation in its presence, it is likely that to 
proceed with a phase I/II trial, ethically, additional chemotherapeutics may have to be co-
administered.  Whilst F-ara-A is the most commonly used agent, this was not assessed 
here.   There is also some clinical debate over the advantage of F-ara-A over chlorambucil, 
especially in elderly patients (Jaksic and Brugiatelli, 1988, Jaksic et al., 1997).  Additionally 
bendamustine was compared clinically against chlorambucil rather than F-ara-A (Knauf 
et al., 2009).  Therefore the studies here only utilised chlorambucil, in comparison and as 
adjunctive treatment with BEZ, MPA and BEZ+MPA.  Whilst chlorambucil was effective 
alone, its addition to BEZ+MPA generated the most apoptosis and the highest reduction 
in proliferation.  This additive or perhaps synergistic effect is likely to be due to different 
mechanisms of the agents.  In this regard, BEZ+MPA successfully induced MSO in the 
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absence of CD40L whereas chlorambucil did not.  It has previously been suggested that 
inducing oxidative stress within cells, sensitises them to chlorambucil (Boldogh et al., 
2003).  BEZ, MPA and BEZ+MPA all increased ROS in both the presence and absence of 
CD40L.  Therefore, it is possible that the combination of BEZ+MPA+chlorambucil is 
effective due to the elevation of ROS by BEZ+MPA and, thereby, the sensitisation of CLL 
cells to chlorambucil.  To make the combination of BEZ+MPA more attractive to clinicians 
further studies should investigates its combinatorial effects with the more commonly used 
F-ara-A. 
6.2.1. The proliferative and protective properties of CD40L render the effects of 
BEZ+MPA different to those observed in the absence of CD40L. 
Whilst BEZ+MPA induced apoptosis in culture conditions used to represent CLL cells in 
the periphery, apoptosis was not observed where CD40L was used to mimic the PC niche.  
It is possible that apoptosis was not observed, owing to its delay by the protective action 
of CD40L rather than its prevention.  A time course revealed that whilst apoptosis in the 
absence of CD40L peaked between 24 and 48 hours, even at 72 hours no apoptosis could be 
seen in the presence of CD40L.  It was not possible to extend this time course due to the 
culture system being over stimulated and apoptosis occurring in the controls.  This 
culture exhaustion was not surprising as studies have alluded to the peaking of gene 
expression at 72 hours (Gricks et al., 2004) and thymidine incorporation has been 
demonstrated to peak at 72 hours and rapidly decline after one week in culture (Crawford 
and Catovsky, 1993).   
This study was able to recapitulate the observations of others that co-culture of CLL cells 
with stromally delivered CD40L and IL-4 (Willimott et al., 2007a, Willimott et al., 2007b, 
Willimott et al., 2007c, Hallaert et al., 2008, Vogler et al., 2009) induced cell proliferation.  
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The level of proliferation was extremely variable.  However, one of the first studies on the 
in vitro use of anti-CD40 antibodies and IL-4 additionally showed patient to patient 
variability.  Such increased proliferation could be postulated to be due to variation in 
CD38 level or CD38 induction owing to the increasing evidence of a CD38 role in the 
microenvironment (Calissano et al., 2009, Patten et al., 2008, Pepper et al., 2007).  
However, studies by Willimot et al have shown that this is unlikely to be the case 
(Willimott et al., 2007a).  The proliferation of CLL cells when engaged by CD40L and aided 
by IL4 was reduced by both BEZ and MPA but most significantly the combination of the 
agents (figure 19).  Once again, this was not associated with any of the known prognostic 
indicators and, notably, there was less heterogeneity in this response between individuals 
compared with their apoptotic response.  Previous studies have calculated the clonal 
expansion within PCs to be around 109 to 1012 cells per day.  Therefore, despite the lack of 
apoptosis induced by BEZ+MPA in the presence of CD40L they could have significant 
impact on reducing the CLL clone, in turn affecting the number of CLL cells entering the 
circulation.  
In addition to the increase in proliferation afforded by CD40L and IL-4, there have been 
reports that the CD40L provides CLL cells with chemoresistance (Kater et al., 2004, Kitada 
et al., 1999) and in 2009, Vogler et al demonstrated that CLL cells exposed to CD40L have 
1000-fold resistance to the novel therapeutic ABT-737 (Vogler et al., 2009).  Microarray 
studies have shown that CLL cells exposed to CD40L upregulate many genes encoding for 
anti-apoptotic proteins (Gricks et al., 2004) which is likely to contribute to the lack of 
apoptosis observed in this environment.  A recent suggestion is that circulating CLL cells 
are able to migrate to and re-engage with PCs within the LN.  The LN provides these CLL 
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cells with survival signals from CD40L, causing the development of pro-survival niches 
that are widely believed to be the source of relapse and therapy resistance (Hallaert et al., 
2008, Hartmann et al., 2009).  The lack of apoptosis induced by BEZ+MPA in the presence 
of CD40L fits with this theory.   
6.3. The possible mechanism of BEZ activity against CLL cells. 
The actions of BEZ when used alone or in combination with MPA were associated with 
marked elevations of PGD2 compared to the untreated controls.  The actions of MPA were 
not associated with the elevation of PGD2, nor did MPA enhance its elevation by BEZ.  
The argument that BEZ exhibits anti-leukaemic actions against CLL cells via PGD2 is 
supported by the observations that exogenously added PGD2, or its dehydration product 
15dΔ12,14PGJ2, induced CLL cell apoptosis (in the absence of CD40L) in the micromolar 
range.  Similar pro-apoptotic and anti-neoplastic actions of 15dΔ12,14PGJ2 have been 
demonstrated against multiple myeloma cells, non-Hodgkin lymphomas, including BL 
(Eucker et al., 2004, Eucker et al., 2006, Higashiyama et al., 1996, Padilla et al., 2000b, Ray 
et al., 2006, Ray et al., 2004) and a number of non-haemato-lymphoid cancers, including 
neuronal (Kondo et al., 2002), oral sarcoma (Nikitakis et al., 2002), hepatoma (Date et al., 
2003), breast cancer (Liu et al., 2003), anaplastic thyroid carcinoma (Hayashi et al., 2004), 
glioblastoma (Morosetti et al., 2004) and colorectal cancer (Lin et al., 2007).  However, it 
should be noted that these effects were seen at lower doses than those used here.   
Previously, BEZ has been reported to induce oxidative stress (Qu et al., 2001).  This has 
been further demonstrated here, with BEZ and BEZ+MPA inducing ROS within CLL cells.  
Oxidative stress has been strongly linked to LP (Montuschi et al., 2007, Montuschi et al., 
2004), which in turn has been linked with the formation of IoP-PGs via the COX 
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independent LLP (Morrow et al., 1992a, Morrow et al., 1992b).   Therefore, the elevated 
levels of PGD2 following BEZ and likewise, the BEZ component of BEZ+MPA treatment 
are most likely due to this pathway.   
Collectively this study and those of others indicate that drugs leading to the accumulation 
of 15dΔ12,14PGJ2 by tumour cells may have widespread clinical benefit.  In pursuit of this, a 
recent study identified that a novel cycloanthranilylproline derivative, Fuligocandin B 
(FCB) increased 15dΔ12,14PGJ2 levels in adult T cell leukaemia cells and thereby increased 
their apoptotic response to TNK–related apoptosis-inducing ligand (TRAIL) (Hasegawa et 
al., 2007).  However, the data shown here and this group’s studies in AML, indicate that 
similar elevation of 15dΔ12,14PGJ2 can be achieved using a drug that is already available.  
On a cautionary note, it has been demonstrated that elevated LpL is a poor risk factor in 
CLL (Heintel et al., 2005), that the LpL-inhibitor orlistat induces apoptosis of CLL cells in 
vitro (Pallasch et al., 2008) and that BEZ elevated LpL in hypertriglyceridemic patients 
during BEZ administration (Totsuka et al., 2000).  The effects of BEZ against LpL should 
be investigated further. 
6.4. The possible mechanism of MPA activity against CLL cells.  
The anti-leukaemic actions of MPA against AML cells has been shown to include the 
inhibition of the PGD2 ketoreductase activity of AKR1C3 (Khanim et al., 2009). However, 
whilst AKR1C3 was readily detected in CLL cells, PGD2 ketoreductase activity could not 
be detected; an observation consistent with the fact that MPA alone or in combination 
with BEZ did not generate an increase in PGD2 levels.  Investigations using other known 
AKR1C3 inhibitors also revealed that none tested were able to recapitulate the effects of 
MPA alone or when combined with BEZ.  These observations indicate that AKR1C3 is 
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unlikely to be the target of MPA in mediating its activity against CLL cells and indicates 
the likelihood of an alternative and PGD2 ketoreductase independent target. The presence 
of a non AKR1C3 target for MPA in B-cell malignancies was further supported by 
observations that the AKR1C3 negative line Nalm6 was sensitive to both MPA and 
BEZ+MPA treatment.   
Other known targets of MPA include GR and PRs (Bentel et al., 1999, Kawaguchi et al., 
2006, Poulin et al., 1989).  Experiments using ligands and antagonists of these receptors 
demonstrated that ML-PRD mimics the effects of MPA alone and in combination with 
BEZ.  The apparent synergy of ML-PRD with BEZ is complementary to a recent clinical 
trial in CLL in which high dose ML-PRD was shown to increase patient response to 
rituximab, with low associated toxicity (Castro et al., 2009).   However, investigations 
demonstrated that the actions of MPA and ML-PRD, although similar, are unlikely to be 
mediated by PR or GR, as investigations using PR antagonists and GR agonists and 
antagonists were unable to recapitulate or reduce their effects.  Despite this it should be 
noted that the GR agonist DEX and the PR agonist PRD have been used as CLL therapy.  
HD SPN, a MR antagonist, also exerted similar levels of apoptosis to MPA but again the 
experiments shown here were unable to demonstrate that this activity is mediated via the 
MR.  Whilst the effects of ML-PRD and SPN are small it should be noted that the level of 
apoptosis generated by either agent is in line with the average response seen to MPA.  
Furthermore, combining either ML-PRD or SPN with MPA or BEZ+MPA, failed to 
abrogate or add to the effect of MPA on CLL cells.  Therefore, it is plausible that all three 
of these agents share an undocumented common target.  However, owing to the 
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differences in doses required to exert their effects (5µM MPA, 20µM ML-PRD and 1µM 
SPN) it is probable that SPN and MPA have higher affinities for this target than ML-PRD.  
Others have identified that MPA enhances anthracyclin uptake by CLL cells and increases 
apoptosis of cultured CLL cells exposed to the anthracyclin idarubicin (Florio et al., 2003, 
Pagnini et al., 2000). These observations are possibly explained by the chemosensitising 
actions of MPA acting as an inhibitor of the ATP-binding cassette (ABC) drug resistance 
transporter p-glycoprotein (PgP; MDR1) (Zibera et al., 1995). 
Further studies could investigate whether MPA is aiding the uptake of BEZ.  However, 
this is unlikely to explain the MPA alone response.   
The data demonstrating that MPA effects were not mediated via enhanced PGD2 
synthesis were unexpected.  Nevertheless, MPA did contribute to ROS and MSO 
generation in CLL cells and exerted both pro-apoptotic and anti-proliferative effects 
independently of BEZ.  However the mechanism of the generation of ROS without an 
accumulation of isoprostane-PGD2 is uncertain.   
6.4.1. Dissecting the variability in response 
As previously discussed, the heterogeneity in response did not correlate with any known 
factors.  The patient responses, in the absence of CD40L, could be categorised into non-
responder, single agent responder, apparent synergistic responder or additive responder 
(figure 9).  It would be of clinical and scientific relevance to elucidate the variance in drug 
response.  Such studies could be investigated in one of the many CLL mouse models 
(Michie et al., 2007), such as NZB mice.  However, in light of the hepato-toxicity of BEZ in 
mice this would be problematical.  An alternative would be the use of metabolomic 
analyses which are gaining interest in CLL (Macintyre et al.).  Similar profiling has been 
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employed in AML following BEZ+MPA treatments AML (Tiziani et al., 2009) and such 
profiling may give indications to the mechanism of action of MPA. 
6.5. The relative importance of induction of ROS and MSO for BEZ and BEZ+MPA 
induced CLL cell apoptosis 
ROS has been shown to be increased in cells that have acquired mtDNA mutations 
following chemotherapy (Carew et al., 2003), thereby indicating an increased ROS to be 
advantageous to survival of the malignant clone.  As increased ROS was also seen in CLL 
cells exposed to CD40L it is likely that ROS alone is not the mechanism of cell death.  
Therefore, as well as the generation of ROS, BEZ and BEZ+MPA were investigated for the 
production of MSO.   BEZ has been reported to cause mitochondrial damage and 
mitochondria specific ROS in rodent hepatocytes (Qu et al., 2001).  Therefore it was not 
surprising that BEZ alone and, most potently in combination with MPA, induced MSO.  
However, this was only the case in the absence of CD40L.  Whilst ROS was generated in 
both culture conditions, MSO was only detected in the non-CD40L cultured cells.  These 
data indicated that CD40-ligation protects CLL cells against BEZ+MPA induced MSO 
production and reciprocally that the induction of MSO is essential to achieve BEZ+MPA 
apoptosis.  That BEZ+MPA induced apoptosis is particularly associated with an MSO 
mediated mechanism is supported by the observation that chlorambucil successfully 
induced apoptosis in the absence of CD40L without generating significant increases in 
MSO (chapter 3 figure 47).  However, it should be noted that this observation is based on 
a small sample of CLL cells (n=4) amongst whom apoptosis responses were not as strong 
as the overall responses across the whole study.  Consequently, it may remain a 
possibility that a strong chlorambucil response also requires high MSO production. 
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6.6. Targeting the T cell-B cell interaction. 
Whilst BEZ+MPA may have therapeutic benefit in CLL by reducing the circulating CLL 
cells, the lack of cell death in the presence of CD40L limits the potential of the approach.   
For the best treatment outcomes it would be desirable to maintain the reduction in cell 
expansion by BEZ+MPA, whilst also reinstating the pro-apoptotic effects afforded by 
BEZ+MPA, observed when CD40L is present.  Theoretically, in a clinical setting this could 
lead to reduced disease and ultimately CR with MRD negativity.  It was hypothesised that 
the introduction of a third novel agent with a mechanism of action distinct but 
complementary to BEZ+MPA may achieve this. 
Investigations into identifying this compound first led to the use of Fe cylinder, which has 
been suggested to be a possible alternative to cisplatin.  Initial studies used this 
compound against the AML cell line HL-60 and showed that moderate apoptosis was 
induced, with cell cycle arrest (figure 48).  Whilst this agent exerted no determinable effect 
against CLL cells, it should not be ruled out of the leukaemic arena completely.  It could 
be exploited as combination therapy in AML and its interchealating DNA properties and 
potential induction of cellular senescence could make it a useful agent against malignant 
cells with a high proliferative index such as BL.  Although on a cautionary note this 
would be expensive to develop and administer. 
Previous studies have demonstrated that transcription of MSO antioxidant mnSOD is 
upregulated in cells exposed to TNF-α.  As CD40 and its ligand are members of the TNF 
super-family, it is possible that CLL cells exposed to CD40L also upregulate mnSOD to 
levels sufficient to overcome the pro-apoptotic effects of BEZ+MPA induced MSO.  Thus a 
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desired characteristic of an agent to be used alongside, or indeed in place of, BEZ +MPA, 
would be the induction of MSO despite the presence of CD40L. 
Investigations into the plant hormones JA and MeJ against the AML cell line K562 
revealed that, except at high doses, JA exerts little effects whilst MeJ causes Δψm 
depolarisation, and induces apoptosis with MSO dose dependently (figures 50 and 51).  
This was postulated to be due to the methyl group aiding cellular uptake.  Indeed, 
investigations into this proved this to be the case (Davies et al., 2009).  Owing to its PGD2 
like structure and its ability to inhibit AKR1C3 (Davies et al., 2009), MeJ could be 
considered to be exploited as anti-AML therapy.  It is most likely that this would be best 
used in combination with other agents, in order to reduce the concentrations required to 
generate the required effects.  However, despite its reported interference on the 
mitochondrial membrane bound enzyme hexokinase (Goldin et al., 2008), on investigation 
in CLL, MeJ alone exerted very little effects and, in combination with BEZ+MPA, only the 
highest dose tested (of 1mM) was able to induce moderate apoptosis (figure 52) and MSO 
(figure 53).  Additionally, whilst MeJ has been shown to be exerting activities against 
AKR1C3 in AML this was not the case here.  Together with the current lack of FDA 
approval for the use of this agent, collectively these data preclude this agent as a viable 
option for further investigation for the targeting the PC in CLL.   
 Recapitulation of the work by Hallaert et al, using DSN to sensitise CLL cells to F-ara-A, 
demonstrated that this synergy only occurred upon the removal of CD40L (figures 59 and 
60).  This, in effect, correlates with Amrein et al (Amrein et al., 2008) who concluded that 
DSN sensitises CLL cells to chemotherapeutics in the absence of CD40L.  Additionally it is 
worth considering that in the experiments shown here, the combination of F-ara-A+DSN 
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was only as good as BEZ+MPA at inducing apoptosis.  Additionally, DSN did not 
sensitise CLL cells to BEZ+MPA in the continual presence of CD40L.  Therefore, it is 
unlikely that combination therapy utilising DSN would target cells within the PC. 
Lycorine has previously been shown to induce apoptosis of APL cells (Liu et al., 2004, Liu 
et al., 2007) and has been shown to exert its effects via mitochondria (Del Giudice et al., 
2005) making it of interest to this study.  It was observed that, whilst neither lycorine nor 
BEZ+MPA alone induced apoptosis in CD40L protected CLL cells, the combination of all 
three agents produced profound apoptosis (figure 54), which was associated with the 
reinstated generation of MSO (figure 55).  The level of apoptosis observed was dose 
dependent and was tightly correlated with MSO (figure 56).  These data strongly indicate 
that a mechanism that is able to generate cell death in the presence of CD40L is likely to 
sufficiently increase the level of MSO to that which the cell cannot overcome.   
More elderly CLL patients are commonly excluded from clinical trials due to their 
susceptibility to the development of treatment-related cytopenia and infections.  Thus in 
these patients in particular more targeted therapies that spare non-tumour cells are 
urgently required.  Studies on normal donor cells indicated that BEZ+MPA had little 
effect on CD19+ve cells (figures 13 and 21).  Additionally, MNCs isolated from normal 
donors remained relatively unaffected by the combination of BEZ+MPA+ lycorine (figure 
57).  However, the combination of DSN and F-ara-A caused significant apoptosis (figure 
61).  This further indicates that therapy utilising BEZ+MPA and lycorine has better 
potential for the treatment of CLL.    
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6.7. Conclusion.  
New drug discovery is time consuming, expensive and has low success rates.  
Increasingly, there is an interest in utilising existing drugs to target different diseases 
(Keiser et al., 2009, Chong and Sullivan, 2007) and a call for a better ‘off-label’ FDA 
approved prescribing system (Tabarrok, 2009).  Currently, the cure rate for CLL is low 
and many patients are not treated as a first line of therapy.  Many patients are unable to 
tolerate intensive treatments because of advanced age or a poor performance status.  The 
use of low-cost, low-toxicity, therapy could be advantageous both clinically and 
financially.  The in vitro data acquired here demonstrates the powerful effects of 
BEZ+MPA by apoptosis in the absence of CD40L and reducing the proliferative capacity in 
the presence of CD40L.  In vivo BEZ+MPA, with or without chemotherapy, are likely to 
exert these effects on the peripheral and PC compartments respectively with little side 
effect (as demonstrated in the AML phase I/II trial) and should be considered for a phase 
I/II clinical trial.  Considering the possible transition of MBL to CLL, BEZ+MPA could also 
be considered in these patients, as a cost-effective attempt to cease the progression.   
In order to fully target the PCs and gain a MRD negative state, further investigation into 
the addition of lycorine to BEZ+MPA should be considered.  Currently, many plant 
compounds are being investigated with the intention of gaining FDA approval for their 
use therapeutically.  Recently, the prescription drug, Reminyl was released for the 
treatment of Alzheimer’s disease.  The active ingredient of this compound is 
galanthamine, another Amaryllidaceae alkaloid (McNulty et al., 2009, Houghton et al., 
2006).  Therefore, a precedent has been set for the use of this family of agents in the 
treatment of diseases.  Thus, the concept of lycorine gaining FDA approval for therapeutic 
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use is a real possibility.   Nonetheless, the time scale and cost of developing new drugs is 
limiting and, in addition, the in vivo toxicity of lycorine is as yet unknown and will have 
to be determined prior to possible trials in combination with BEZ+MPA. However, the 
data shown here indicate that only a relatively low dose of lycorine of 1-2µM would be 
required to be effective. 
Whilst it is certain that CD40L and IL-4 play a role in the PC, there are likely to be other 
environmental factors that offer CLL cells protection.  Until these are elucidated further, 
the targeting of the CD40L protective niche is a positive starting point.  As proof of 
principle, lycorine serves to show that the anti-apoptotic signal afforded by CD40L can be 
overcome by the generation of MSO.  Such targeting of the cell-cell interaction in vitro, 
mimicking that of the B cell-T cell interaction in vivo reinstates the pro-apoptotic actions 
of BEZ+MPA seen in the absence of CD40L.  Utilising the concept, further proven here, 
that already existing drugs can be beneficial in new settings, it is likely that an agent that is 
already available can target this cell-cell interaction, in the same way as lycorine.  With the 
importance of MSO generation highlighted here, drug screening together with BEZ+MPA 
should be undertaken with MSO as the readout in an attempt to find a suitable candidate.
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Figure 62.  A proposed schematic of the pro-apoptotic mechanism of BEZ against CLL 
cells cultured in the absence of CD40L.  BEZ induces the production of ROS, as measured 
by H2DCFDA staining and FC.  We propose that, like in our AML studies, ROS attacks 
membrane lipids, inducing lipid peroxidation and the production of PGD2, most likely via 
the isoprostane pathway.  PGD2 was found to be elevated in extracts of CLL cells with 
their supernatants.  If not exported the PGD2, will spontaneously convert to 15dΔ12,14 PGJ2 
which causes damage to mitochondrial membranes and thus the production and leaking 
of MSO as detected by MitoSox Red and FC.  A high level of MSO could inhibit 
mitochondrial metabolism and ultimately cause cell death.  Note that in CLL both BEZ 
and MPA induce the production of MSO, that is increased in the combination of 
BEZ+MPA. 
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2.1.2.  MACS buffer 
PBS with the addition of 2mM EDTA (filtered to sterilise and degas) and 1% (v/v) FBS.  
Keep at 4ºC.  
2.2.  Freezing mix  
FBS supplemented with 5% (v/v) DMSO to be made fresh each time  
2.4.2.  FACS Fix 
PBS with the addition of 1%(v/v) formaldehyde and 2% (v/v)FBS.  Keep at 4ºC. 
2.8.3.  Cell Cycle Buffer 
30µg PI, 0.1mM NaCl2, 1% (w/v) sodium citrate, 0.1% Triton X100 in ddH2O 
2.11.4.  10x TBE 
108g Tris base, 55g Boric acid, 9.3g EDTA made up to 1L in ddH2O.  Dilute to 1 x before 
use. 
2.14.1.  RIPA buffer  
1% (v/v) NP40, 0.5% (w/v) sodium deoxycholate, 0.1% (w/v) SDS in distilled water.  Keep 
at 4ºC.  Add protease inhibitor prior to use. 
2.14.2.  4x SDS gel loading buffer  
62.5mM Tris HCl pH6.8, 25% ( v/v) glycerol, 2% (v/v) SDS, 5% (v/v) 2-β-ME, Bromophenol 
Blue, in distilled water.  Store at RT. 
2.14.2.  10% Resolving gel 
 
30% Bis/Acrylamide (Geneflow)     3.3ml 
1.5M Tris HCl pH8.8        2.5ml   
10% (v/v) SDS                         0.1ml   
 Distilled water       4.1ml   
10% Ammonium persulphate ((w/v)APS; Sigma)   60µl   
TEMED (VWR international)      4.5µl  
Appendix A1 -Buffers and Recipes 
 
A- 2 - 
 
2.14.2.  Stacking gel  
30 % Bis/Acrylamide        440µl 
0.5M Tris HCl pH6.8         830µl 
10% (w/v)SDS             33µl 
distilled water                    2.03ml 
10% (w/v)APS                    16.7µl 
TEMED          1.7µl 
2.14.2.  1x SDS gel running buffer 
25mM Tris, 192mM glycine, 3.5mM SDS in distilled water 
2.14.3.  Towbin’s transfer buffer  
25mM Tris, 192mM glycine, 20% (v/v) methanol in distilled water 
2.14.4.  TBS-T  
137mM NaCl, 20mM Tris HCl pH 7.6, 0.2% (v/v) Tween20 in distilled water 
2.14.4.  5% blocking solution 
5% (w/v) milk powder (Marvel) in TBS-T 
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